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More than 10 million people died from cancer in 2020 [89], which
makes cancer the second leading cause of death globally [214].
This complex group of diseases arises from a cascade of genetic
aberrations, which transform normal cells into tumor cells [74, 75,
102]. Normal cells are controlled in size and quantity by a process
called homeostasis, where a renewal and a destruction process are
sustained. The renewal process is led by cell growth and division
and is called proliferation. The destruction process leads to cell
death, which is called apoptosis or necrosis. In contrast to normal
cells, tumor cells resist the cell death mechanisms and sustain cell
proliferation, and therefore grow abnormally [74, 75].
The complexity of cancer lies within the genetic changes, which,
among others, arise from genetic predisposition and environmen-
tal influences. These aberrations are mostly affecting not only
one single molecular target, i. e. gene mutation or an enzyme
activity, but often have multi-factorial causality [90]. This makes
cancer one of the most challenging diseases to treat. Today’s
most common treatments of cancer are surgery, radiation therapy,
targeted therapy, and chemotherapy. The focus of this thesis finds
its application in the latter two: In a targeted therapy specific
molecules are targeted that are known to be involved in growth,
progression, and spread of cancer [146]. Chemotherapy is often
used as an auxiliary treatment of cancer after surgery. Its aim
is to stop the growth of remaining cancer cells. This is usually
done by either stopping the cellular proliferation process or by
driving cells into cell death [145]. As chemotherapy targets certain
biological processes, these processes are also blocked in normal
cells, which can cause side-effects, such as fatigue, loss of hair,
and nausea [145]. An additional challenge arises when cancerous
cells develop drug resistance to a single treatment, which they are
known to acquire quickly [96, 178].
2 Chapter 1. Introduction
While the above mentioned therapies have become highly
specific over the recent years, their effect is limited given the
arising challenges. To circumvent these problems, one uses a
combination of drug therapies. The main motivation behind
applying such combinations is (i) to increase the effectiveness of a
therapy, (ii) to reduce toxicity, i. e. side effects, and (iii) to delay
the development of drug resistance. If a combination of drugs
fulfills either of these three criteria one speaks of synergy or a
synergistic effect between the compounds.
While herbal combination therapies have been used for over
1, 000 years in Chinese Herbal Medicine to treat various ill-
nesses [234], it was only in 2014 that the first combination treat-
ment for cancer therapy was approved by the US Food and Drug
Administration (FDA) [171]. This particular combination therapy
targets melanoma that originate from a specific genetic mutation
in the patients’ DNA. It has the advantage of increasing the time
of successful treatment before drug resistance would be developed.
Additionally, side effects of the individual drugs could be reduced
when applied in this combination [48].1 Since the approval of
this first combination treatment for cancer, there was a notable
increase of registered commercial products of drug combinations
that were granted by the FDA [38]. Today, combination therapies
have found their application also in many other complex diseases,
such as cardiovascular and respiratory diseases, HIV infections,
and type II diabetes [179].
Finding compound combinations with a synergistic effect is
challenging, but also a promising task due to the complexity of
the diseases. Phenotypic screens with millions of compounds have
been feasible for a decade now, see [55, 68] for an example screening
for anti-malarial compounds. However, such screens will not scale
1We would like to point out here that there are two reasons for the reduc-
tion of side effects: by administering lower concentration of each compound
in combination, side effects of individual compounds can be reduced. This
is a rather natural consequence of a combination treatment. In the above
mentioned example, the cause of a side effects was linked to a particular
genetic pathway. By the application of the mentioned combination, this
particular side effect could be reduced.
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to blindly testing all binary combinations, let alone higher-order
combinations. Thus, the selection process of promising candidates
needs to be more informed.
This is done by making predictions about the interaction of
compounds based on the information on the individual drugs
alone. The rise of powerful machine learning techniques over
the recent years offers new ways to combine various sources of
information for such predictions. But the lack of understanding
of how synergistic events occur still creates an obstacle to further
improve predictions.
Academic interest in synergy models has its beginning in the
early 20th century [9, 124]. From the start, there has been an
ongoing debate on how to define synergy and how to apply the
methodology to a given set of measurements [7, 30, 58]. The
definition of what synergistic effects might be is very context
dependent [199]. Still today, methodologies of defining synergy
from about a century ago are re-used and redefined for different
contexts [28–30, 43, 58, 76, 183].
Over the past few years, there has been a remarkable increase
in interest into the field of synergy. Many review papers were
published in order to shed light on the different definitions and
to resolve confusion about the definition of synergy [7, 20, 58, 66,
83, 119, 160, 182, 209, 211, 224, 234]. In addition, many different
methods for the detection of synergy were introduced [14, 16, 24,
32, 57, 66, 189, 193, 208, 218, 227, 230]. Crowd-sourcing scientific
challenges have taken place which aimed to predict synergistic
effects between compounds of which only the individual effects
are known [4, 134]. More than 200 teams from some 30 countries
across all five continents participated in these so-called DREAM
challenges (Dialogue on Reverse Engineering Assessment and
Methods) [190]. This strong participation underlines the interest
in the research field.
The proposed solutions are very diverse, which reflects the
lack of standardization in the field [4]. The research area in
detecting and/or predicting interactive effects between compound
combinations offers therefore a very complex, yet very promising
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research landscape that is worth exploring.
In this thesis, we investigate the concept of synergy in greater
detail. As we make use of several biological datasets, we pro-
vide basic background information on biological processes and
measurements upfront. Subsequently, for a better understand-
ing of the concept of synergy, we introduce the most important
methodologies of synergy, which we find back later in greater
detail.
1.1 Some Basics in Molecular Biology
A cell responds to environmental changes by signaling, adapting
its metabolism, or by synthesizing proteins. The reactions of a cell
to external signals are very diverse and can result inter alia in cell
proliferation or cell death. For these phenotype responses to take
place, there are many underlying processes that happen within the
cells beforehand. These processes can be observed by evaluating
the dynamics on the gene, protein, or metabolite profiles [20]. In
this thesis, we investigate the modes of action (MoA) of a drug or
drug combinations by focusing on the molecular and phenotype
response of a cell. Here, we provide some short background
information on the most important biological processes that play
a role in the subsequent chapters. As we only work with cell-lines
and tissues from humans, the following information is tailored to
the human organism and does not necessarily hold true for other
organisms. We would like to stress that the provided information
is very simplified, while the complete biological picture can be
more complex.
The interaction of a cell to its environment is governed by its
protein production which takes place on the genome. The genome
is the complete DNA which is encoded into 23 chromosome pairs
and serves as the genetic blueprint of the organism. While it
depends on the cell type which proteins are produced, the full
DNA is contained in almost every cell.









Figure 1.1: Gene expression. TFs bind to motifs, which
then regulate gene expression. The DNA sequences from the
gene are transcribed and translated into proteins.
The human DNA sequence consists of four nucleobases bound
to each other: adenine (A), guanine (G), cytosine (C) and thymine
(T). The genetic information of the organism is written into the
DNA, where the order of these four nucleobases encodes the in-
formation content. Small parts of the DNA, so-called genes, are
transcribed into mRNA and then translated into proteins. RNA
molecules, that are transcribed from DNA sequences, but not
translated into proteins, are called functional RNA. The end prod-
ucts can be enzymes, which accelerate chemical reactions, or can
catalyze the synthesis of other proteins or other macromolecules,
such as DNA and RNA [123, Chapter 1.1]. This process of syn-
thesizing information from a gene to a functional gene product
is called gene expression. All in all, only 1−2% of human DNA
is coding, i. e. codes for proteins, while the rest is non-coding
DNA [91].
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As it was only in the beginning of the 21st century that the
entire human genome sequence was published [35, 91], the under-
standing of a gene is under regular revision. The interested reader
obtains an overview over the evolution of the understanding of a
gene in Gerstein et al. [62].
When cells react to external signals or changes in the external
conditions, they do so by expressing specific genes. As a result they
adapt their protein repertoire to their current needs. The gene
expression process of a specific gene is activated or repressed by
proteins that bind to sequence specific patterns in the regulatory
region of the gene. These proteins are called transcription factors
(TFs) and the specific binding patterns are called motifs. TFs
therefore act as switches for the gene transcription process. A
rough sketch of this genetic regulatory process is visualized in
Fig. 1.1.
1.2 Defining Synergy
The main idea behind the combination of two or more compounds
is to create an effect that is greater than the expected additive
effect of the individual compounds. One then speaks of a syner-
gistic effect. If the effect of a combination is reduced, one speaks
of an antagonistic effect. If a combination of compounds exhibits
no interaction effect, one speaks of additivity or non-interaction.
A prerequisite for measuring whether a combination exhibits
an interaction effect is to define the expected response of the
combination in case of no interaction effect. This expected non-
interactive response is called null response.
Many methodologies that focus on a definition of such a null
response were introduced over the past century. Many arguments
were made for and against these models. The interested reader
is referred to the following review papers for more information:
Berenbaum [7], Foucquier and Guedj [52], Geary [58], and Greco,
Bravo, and Parsons [66].
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Today, only two of the early methodologies have survived the
critics: Loewe Additivity [124] and Bliss Independence [9]. As
these two methodologies will be used throughout this thesis, we
shortly outline their core concepts here. More theoretical and
technical details are given in Chapter 2 and Chapter 3.
1.2.1 Loewe Additivity
Loewe Additivity is based on the idea that the two compounds
combined have a similar mode of action, i. e. one can replace one
compound by the other to achieve the same effect. With this idea,
Loewe Additivity is based on two principles: (i) sham combination
and (ii) dose equivalence [124]. The essence of a sham combination
is to expect no interaction effect if a compound is combined with
itself. This is a very logical assumption and Loewe Additivity
is one of the very few methodologies to fulfill this requirement.
Dose equivalence, on the other hand, specifies that any effect
that is reached by one drug can be reached by the other drug.
The doses resulting in that same effect are said to be equivalent.
Several mathematical formulations for Loewe Additivity have
been introduced on the basis of these two principles [7, 29, 58, 76].
In Chapter 2 we explain the mathematical formulations in great
detail and elaborate on the restrictions of the model that are made
implicitly. It is due to the principle of Loewe Additivity that non-
interactive effects are often called additive in the literature. To
forestall confusion with other null reference models, we will refer
to combinations without an interaction effect as non-interactive.
1.2.2 Bliss Independence
The other important concept of synergy is the so-called Bliss
Independence, which follows an idea that is opposite to Loewe
Additivity. Instead of assuming that two compounds act similarly
and can be interchanged with each other, it assumes the two com-
pounds to act independently [9]. Hence, one cannot replace the
effect of one drug with the other. This stands in contrast to the
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Loewe Additivity. And, more importantly, an interaction effect
is expected when combining a drug with itself. This violation of
the principle of sham combination is the main argument for the
research community to mostly prefer Loewe Additivity over Bliss
Independence. But Bliss Independence has a few advantages over
Loewe Additivity for which it remains quite popular: (i) it makes
no assumptions about the behavior of the individual compounds,
the so-called conditional response. We will explain these condi-
tional responses in detail in Chapter 2. (ii) It follows a simple
mathematical formulation which allows for an easy computation.
This is in contrast to Loewe Additivity. (iii) Bliss Independence
can easily be extended to measure synergistic effects between
more than two compounds, whereas this is mathematically more
complex for the Loewe Additivity principle [97, 235].
1.3 Measuring Synergy
The effect of a drug or a drug combination can be measured and
investigated in many ways. On the one hand, one can look at the
direct effect of a treatment on a cell by measuring its viability
before and after the treatment. This is the so-called phenotype
response. It finds its application when validating the efficacy of
chemotherapy: the number of cancerous cells before a treatment
is compared to the number of cancerous cells after a treatment.
A chemotherapeutic drug is considered to be effective when cell
viability decreases after the cells have been exposed to the drug.
In other settings, e. g. when investigating the resistance against
antibiotics, the cell’s ability to reproduce, i. e. cell growth, is
determined before and after treatment.
On the other hand, the underlying effect of a treatment can
be looked at by following the changes of a cell at the molecular
level: one can investigate which genes are expressed or blocked
from expression, what kind of molecules are produced, which
signals emitted or silenced, and relate the molecules’ presence and
activity to the cells’ state. There is an abundance of signals in the
1.4. Thesis Outline 9
cell on the molecular level and many of them can be measured
nowadays. One key measurement in molecular biology is the gene
expression, which indicates and quantifies the parts of the DNA
that are expressed and is explained above. The final products of
gene expression serve as blueprints for proteins or other molecular
machineries which can have all sorts of functionality, such as
activating new gene expression processes, start cell proliferation,
and many more. The investigation of these molecular signals help
to identify the MoAs, and draw conclusions from the causal chain
of action that was caused by a perturbation.
1.4 Thesis Outline
The thesis is structured in three major parts: In the first part,
which comprises Chapter 2 and Chapter 3, we focus on the phe-
notype response to drugs, i. e. cell survival or cell growth. We
dive into the mathematical definitions of synergy that arose over
the past century and show their applicability to two real-world
datasets. In Chapter 2 we focus on the definition of null models.
We investigate in detail the Loewe Additivity principle and the
so-called Loewe Additivity Consistency Condition (LACC). We
derive explicit and implicit null reference models and show that
they are equivalent if the LACC holds. Of these two formula-
tions, the implicit formulation is the well-known General Isobole
Equation [124], whereas the explicit one is novel. We compare
the measurements of the non-interactive cases of both datasets
to the theoretical null reference models. We demonstrate that
the explicit formulation of the null reference model leads to a
better quality of fit than the implicit one and is also much faster
to compute.
In Chapter 3, we continue with the computation of synergy.
We use the same two datasets as in Chapter 2 and compare two
different methods for the computation of synergy on the basis of six
null reference models, including formulations from Chapter 2 and
Bliss Independence. We demonstrate that the most promising way
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to compute a synergy score is based on determining the volume of
the area spanned between the expected and measured response.
In the second part of the thesis, Chapter 4, we take a step
away from compound combinations and phenotype measurements.
Instead, we dive into the area of molecular biology to dig deeper
into the molecular biological processes within the cells and inves-
tigate the mechanisms that drive gene expression. We investigate
gene regulatory networks, where we explore modeling methods to
model motif influence on gene expression profiles. We compare
the effect of loosening mathematical assumptions of samples being
independent and allow for correlation instead. While there is an
apparent improvement of the more flexible model on simulated
data, we show that the gain is negligible when applied to real
world data.
In the last part, Chapter 5, we combine our understanding of
synergy models and biological processes on the molecular level
from Chapter 2, Chapter 3 and Chapter 4. We outline a novel
study of drug combinations to derive causal effects from gene
regulatory changes to the phenotype response. This creates a
somewhat complete picture of the effect of a compound combina-
tion - from gene expression to phenotype.
The printed version of the thesis does not contain any supple-
ment. A link to the supplement is provided in the Supplement
section.
1.5 Contribution
All of the four subsequent chapters are a result of collaborative
work. For each chapter presented, I conducted the formal analyses
and drafted the manuscripts. All authors named were actively
involved in the development of the methodology and the final
review and editing processes. For Chapter 5, I additionally con-
ceived the research and established the collaborative process with
the BROAD institute.
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2 Additive Dose-Response Models:
Explicit Formulation and the
Loewe Additivity Consistency
Condition
When combining a substance with other substances, one is gener-
ally interested in interaction effects. The combined effect can be
much larger than the individual effect. Such interaction effects
are usually described as synergistic or antagonistic, dependent
on whether the interaction is positive, resulting in greater effects
than expected, or negative, resulting in smaller effects than ex-
pected. This has applications in many areas such as chemotherapy,
pharmacology, toxicology, or antibiotic resistance.
The basic understanding of synergy is any effect greater than
the expected effect assuming no interaction. This expected effect
without interaction is specified with a so-called null reference
model. Therefore, synergy depends highly on such a reference
model of a non-interactive scenario. In this chapter, we will focus
on the definition and application of such null reference models.
The central problem of defining such null reference models is the
prediction of a response surface from the individual responses, i. e.
the responses to the individual drugs. Throughout this thesis, we
will refer to these individual responses as “individual” or “condi-
tional”. The latter term originates from the statistical take on
the combination experiment, where the individual responses are
conditional on the concentration of the other compound being
zero.
1This chapter is based on Simone Lederer, Tjeerd MH Dijkstra, and Tom
Heskes. “Additive dose response models: explicit formulation and the Loewe
Additivity Consistency Condition”. In Frontiers in Pharmacology, 9 (2018).
DOI: fphar.2018.00031.
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Over the last century, many principles of non-interaction and
methods to measure the deviance from these have been proposed.
An extensive overview is given by Greco, Bravo, and Parsons
[66] and recent reviews are given by Foucquier and Guedj [52],
Geary [58], and Vakil and Trappe [211]. Two main principles for
non-interactivity have survived the critics: Loewe Additivity [124]
and Bliss Independence [9]. The popularity of Loewe Additivity
is based on its principle of sham combination which assumes no
interaction when a compound is combined with itself. Other null
reference models do not hold that assumption. An alternative
is Bliss Independence, which assumes (statistical) independence
between the combined compounds.
In the following two chapters, we focus on the null-reference
(Chapter 2) and synergy models (Chapter 3) that build on the
Loewe Additivity. One of the main motivation to focus on Loewe
Additivity is the wide reputation the principle enjoys because
of its principle of sham combination. In this chapter, we focus
uniquely on the definition of null-reference models and provide
all necessary theoretical background. In Chapter 3, we extend
these null-reference models to synergy models and investigate
their performance in greater detail.
Loewe Additivity is a phenomenological description, not a
mechanistic one that is aiming to explain underlying mechanisms.
This has its advantages in clinical trials, as a measure of success,
such as synergy, does not need to be updated with biological
advances [51]. A way to root Loewe Additivity in such mechanistic
terms is undertaken by Baeder et al. [2]. Further, we do not
take temporal effects into consideration (see Geva-Zatorsky et al.
[63] for a study on temporal effects), but work uniquely in the
concentration (or dose) space. While temporal considerations are
important, in most high-throughput studies the effect is measured
after a fixed period when transient responses have died out, but
before effects like cell division set in.
As the first experiments for the assessment of synergy were
conducted in vivo, one used to administer varying doses of com-
pounds, that is, the unit of compound per kilogram of biological
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system under investigation. In cell-based assays, one administers
concentrations of compounds, i. e. the unit of volume. However,
it can also be an agent of a different type for example a dose
of radiation as used in modern combination therapies for can-
cer [162]. Throughout this thesis, we will use the term “dose” and
“concentration” interchangeably.
The response can be measured among others in growth rate,
survival, or death. It is usually referred to as the “measured” or
“phenotype effect” or as “cell survival” or “cell growth”. Throughout
this thesis, we refer to the response as plotted on the y-axis of a
dose-response curve as “response” or “effect”. One of our examples
on data are inhibitory, where the response consists of cell survival.
The other response is measured in cell growth. Throughout this
thesis, we transform all phenotype data to be of inhibitory nature.
Thus a larger dose leads to less cells and hence a smaller response.
We use effect to denote the inverse of response. Thus, for dose
zero we have maximal response and minimal effect and for infinite
dose we have minimal response and maximal effect.
Measurements taken for only one compound, here referred to as
the “conditional responses” or “individual dose-response”, are also
called “mono-therapeutic” [41] or “single compound”, but we prefer
a more statistical terminology. We refer to the measurements
of one cell line exposed to combinations of two compounds as
a “record”, but in other literature it is referred to as “response
matrix” [116, 227].
As the research area of synergy evolved from different dis-
ciplines, different terminologies are in common use. Whilst in
pharmacology, one refers to the Loewe Additivity as the “Loewe
model”, in toxicology, the same principle is called “concentration
addition”.
We speak of synergy when referring to a general interaction
effect, be it synergistic or antagonistic. In the detailed analysis
where the direction of interaction is of importance, we clearly
differentiate between a synergistic or antagonistic effect.
We start with a short introduction to conditional dose-response
curves in Section 2.1, to then describe the most common null
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reference principle, Loewe Additivity. We study Loewe Additiv-
ity’s consistency condition and its consequences in Section 2.1.1.
Further, in Section 2.1.2 we introduce an explicit mathematical
formulation of the null reference model which is derived from the
Loewe Additivity principle. This explicit formulation describes
the same null reference model as the General Isobole Equation,
which is the standard mathematical formulation of Loewe Addi-
tivity and written implicitly, when the so-called Loewe Additivity
consistency condition is met, which we mathematically formulate
in this chapter. As this consistency condition is often violated by
experimental data [58, 198] we investigate the consequences of
these violations to the null reference models visually at the end
of Section 2.1.2, and evaluate them statistically in Section 2.2.
2.1 Methods and Material
To quantify the degree of synergy between two compounds, the
typical approach is to somehow compare their measured com-
bination effect to a so-called null reference model, which is the
expected response assuming no interaction between the two com-
pounds. The larger the deviance to such a null reference model,
the larger the interaction effect. Writing xj for the dose of com-
pound j ∈ {1, 2}, a null reference model specifies the response
f(x1, x2) for a combination of doses x1 and x2. In the next few
sections, we will first review the ideas leading to a specific null
reference model, the so-called General Isobole Equation, which is
based on the principle of Loewe Additivity. Our own contribution
starts with Section 2.1.1, in which we write down the precise
assumption underlying this principle and discuss its consequences.
Conditional or Individual Dose-Response Curves
As we will see, null reference models are usually built on top of
the dose-response curves for the individual compounds. That is,
the null reference model extrapolates individual dose-response
curves, i.e., f1(x1) ≡ f(x1, 0) and f2(x2) ≡ f(0, x2), to a response
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Figure 2.1: Conditional dose-response curves as Hill
curves. For the exemplary responses of 0.3 and 0.9 the dif-
ferent doses x1 and x2 reaching that effect are shown (dashed
lines). The dose-response curves differ only in EC50 with
e1 = 2 and e2 = 1. Values of the other parameters are y0 = 1,
y∞ = 0 and s = 2. To highlight the sigmoidal shape of a
Hill curve in log-space, the logarithmic concentration space is
depicted.
f(x1, x2) for any combination of doses (x1, x2). A popular model
for individual dose-response curves fj(xj) with j ∈ {1, 2} is the
Hill curve [81], also referred to as the sigmoid function. The Hill
model is, due to its good fit to many sources of data, the most
widely applied model for fitting compound responses [65]. It has a
sigmoidal shape with little change in response for small doses, but
a rapid decline once a certain threshold is met. For even larger
doses the response asymptotes to a constant, which corresponds
to the maximal effect. Two exemplary Hill curves are depicted in
Fig. 2.1.
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There are several parameterizations of the Hill curve. Through-
out this thesis, we work with the so-called four-parameter log-
logistic model, which is implemented in the drc package [170] in
the R environment [166]:






where y0 is the response at zero dose (f (0) = y0) and y∞ the
maximal effect of the cells to the compound (limx→∞ f (x) = y∞),
e the dose concentration reaching half of the maximal effect, also
referred to as EC50, and s the sigmoidicity of the curve, where a
positive s leads to a monotonically decreasing curve.
We use the Hill curves to illustrate our theory and methods
and to fit individual dose-response curves to real-world data in
Section 2.2, Chapter 3, and Chapter 5. Our theoretical analysis
and the resulting methods are not restricted to the use of Hill
curves as model for individual dose-response curves, but apply
more generally to any type of dose-response model, as long as it
is monotonically decreasing or increasing and twice continuously
differentiable.
Loewe Additivity
Throughout the extensive research that was conducted in the field
of synergy over the last century, several null reference principles
were introduced, but only two survived the critics [66]: Loewe
Additivity [124] and Bliss Independence [9]. Loewe Additivity
assumes that one compound can be substituted for another, which
makes sense when the two compounds have the same MoA. In
Bliss Independence, on the other hand, the underlying assumption
is that the two compounds have a different MoA, leading to an
addition of the individual responses. In this chapter, we will
exclusively focus on Loewe Additivity, which tends to lead to
better predictions of synergy than Bliss Independence [32]. We
introduce Bliss Independence in Chapter 3.
2.1. Methods and Material 17
Figure 2.2: Response surface with linear and paral-
lel isoboles. Contour lines of the response surface from
Eq. 2.3, 3.5 or 3.6 with x1 on the x-axis and x2 on the y-axis
at linear concentrations.
Loewe argued that, if two individual doses x∗1 and x∗2 give
rise to the same response, say y, then, in case of no interaction
between the compounds, all dose combinations on the straight






= 1 , (2.2)
should yield the exact same response y. Intuitively and visually,
this idea is very appealing. We illustrate this concept in two
figures: (i) Fig. 2.1, where different doses of both compounds
(both drawn on the x-axis) yield the same response y, which
is drawn on the y-axis, and (ii) Fig. 2.2, where we depict the
straight lines running between (x∗1, 0) on the x-axis and (0, x∗2) on
the y-axis.
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In Fig. 2.1, the lower dashed horizontal line corresponds to the
response y = 0.3, e.g., representing the survival of 30% of the cell
culture. The individual doses, x∗1 and x∗2, that yield this response
follow from the intersection of this horizontal line with the red and
the blue individual response curves, respectively. These individual
doses are indicated by the two vertical dashed lines. To visualize
the response surface for arbitrary combinations of doses x1 and
x2, we make use of a contour plot in a two-dimensional coordinate
system, as in Fig. 2.2, with the dose x1 along the x-axis and the
dose x2 along the y-axis. Contour lines correspond to so-called
isoboles or iso-effect curves: combinations of doses (x1, x2) that
yield the exact same response. For y = 0.3, we already know two
points on this isobole: (x∗1, 0) and (0, x∗2). Loewe Additivity now
says that the isobole in case of no interaction should be linear,
that is, following Eq. 2.2.
The straight line matches the assumption that the two com-
pounds “act similarly, presumably at the same site of action,
differing only in potency” [66, p.344]. It suggests that doses for
the two compounds are exchangeable, more specifically that a dose
x1 which is d% of dose x∗1 needed to reach the response y by just
the first compound, has the same effect as a dose x2 which is the
same d% of the dose x∗2 needed to reach the response y by just the
second compound. This argumentation, in combination with the
principle of a sham combination (two doses of the same compound
must have the same effect as a single compound with the sum of
the doses), directly leads to Eq. 2.2. In Section 2.1.1 we will get
back to this argumentation and discuss in detail the properties
that individual (conditional) dose-response curves should have for
this argumentation to stand.
General Isobole Equation
In the above, we showed, following Loewe, how to find dose
combinations (x1, x2) that yield the same response y as the two
equivalent doses x∗1 and x∗2 that individually reach this response
y. Applying the same procedure for different values of y, we get
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the contour lines in Fig. 2.2 and can construct a response surface
for any combination of doses (x1, x2).
The corresponding null reference model is called the General
Isobole Equation [7, 124, p.179]. It is defined as fGI (x1, x2) = y






= 1 , (2.3)
which corresponds to Eq. 2.2 with substitutions x∗1 = f
−1
1 (y)
and x∗2 = f
−1
2 (y). The General Isobole Equation defines the
response curve implicitly and for most types of individual dose-
response curves, including Hill curves, numerical computations are
needed to derive fGI (x1, x2). This can be considered a practical
disadvantage, in particular when applied to high-throughput data.
More details on how to solve Eq. 2.3 numerically are presented in
Supplement B.1.
2.1.1 Theory
Above we derived the General Isobole Equation, an implicitly
defined null reference model based on the principle of Loewe
Additivity. The argumentation leading to the straight isoboles,
although appealing, was rather informal, as it was in Loewe’s
original work [124] and in most of the literature that followed. In
this section we will formalize the argumentation to arrive at the
conclusion that strictly adhering to the Loewe Additivity principle
puts very serious constraints on the (relationship between the)
individual dose-response curves of the two compounds.
Loewe Additivity Consistency Condition
Loewe Additivity says that we can exchange one compound for
another to reach the same effect. We define the effect equivalent
dose xequiv1 (x2) as the dose of compound 1 that yields the same
response as dose x2 of compound 2, and vice versa for xequiv2 (x1).
Given individual dose-response curves f1(x1) and f2(x2), these
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effect equivalent doses obey
xequiv1 (x2) = f
−1
1 (f2(x2)) (2.4)
xequiv2 (x1) = f
−1
2 (f1(x1)) . (2.5)
The construction of response equivalent doses is illustrated in
Fig. 2.1 with dashed lines for the response levels y = 0.9 and
y = 0.3.
With these equivalent doses one can construct two response
surfaces. To do so, we add to the concentration x1 of compound
1 its equivalent dose xequiv1 (x2) and the same mutatis mutandis
for x2 and compute the response:
f2→1(x1, x2) = f1(x1 + f
−1
1 (f2(x2))) (2.6)
f1→2(x1, x2) = f2(f
−1
2 (f1(x1)) + x2) . (2.7)
We can use both response curves as null reference models: just
like the General Isobole Equation they specify the expected re-
sponse for any combination of doses under the assumption of no
interaction between the two compounds. If the individual dose-
response curves are analytically invertible, as for the Hill curves
that we use throughout this thesis, these null reference models are
explicit and do not require complicated numerical computations.
It so happens that for our running example in Fig. 2.1, the two
response curves f2→1(x1, x2) and f1→2(x1, x2) coincide with each
other and with fGI (x1, x2), leading to the exact same contour
plot in Fig. 2.2. We will see in the next paragraph (“Conditions
for the LACC to hold”) why.
Taking the principle of Loewe Additivity seriously, it should
not matter whether we exchange the dose for compound 1 with
the equivalent dose for compound 2 or, vice versa, exchange the
dose for compound 2 with the equivalent dose for compound 1.
We formalize this in the Loewe Additivity Consistency Condition,
further referred to as LACC:
f2→1(x1, x2) = f1→2(x1, x2) ∀x1, x2∈R≥0 . (2.8)
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To the best of our knowledge, we are the first to explicitly state
this consistency condition in a general mathematical form.
Conditions for the LACC to Hold
Perhaps surprisingly and in contrast with suggestions elsewhere
(e.g. Yadav et al. [227], Greco, Bravo, and Parsons [66]), the Loewe
Additivity Consistency Condition is easily violated and poses
strong restrictions on the relationship between the two individual
dose-response curves. Specifically, we have the following theorem.
Theorem 1. The Loewe Additivity Consistency Condition in
Eq. 2.8 holds, if and only if a dose and its equivalent are propor-
tional to each other, i.e.,
xequiv1 (x2) = f
−1
1 (f2 (x2)) = cx2, (2.9)
xequiv2 (x1) = f
−1




for a constant c > 0.
The proof of this theorem can be found in Supplement A.1.
Both Tallarida [198] and Geary [58] recently commented on the
connection between the consistency condition in Eq. 2.8 and the
proportionality between a dose and its equivalent, but did not
provide a theoretical proof. Note that in the proof and in the
following discussion of the LACC, we make the implicit assumption
that both response curves start off at the same response for zero
dose and yield the same maximal effects, i.e., converge to the
same asymptotes when the dose goes to infinity. If this is not
the case, there exist doses for one compound that do not have an
equivalent dose for the other. In Section 2.1.2 we discuss how to
adapt the null reference models if this condition is not met.





= log (c) + log (x2) , (2.11)
i.e., the LACC holds if and only if the dose-response curves are
shifted copies of each other on the logarithmic dose axis. If the
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individual dose-response curves for the two compounds are Hill
curves, this implies that only the dose concentration reaching
half of the maximal effect (e in Eq. 2.1) can differ: both Hill
curves should have the same responses at zero dose (y0), the same
maximal effect (y∞), and the same slopes (s) for the LACC to
hold (see Supplement A.3). Since the two Hill curves in Fig. 2.1
are indeed shifted horizontally relative to each other with the
same y0, y∞, and s, yet different e, the LACC indeed holds in this
case. The implicit General Isobole Equation from Eq. 2.3 and the
explicit null reference models from Eq. 3.5 and Eq. 3.6 all yield
the same response surface and all isoboles in Fig. 2.2 are linear
and parallel to each other.
This equivalence and the parallel linear isoboles are not a coin-
cidence, as can be seen from the following corollary to Theorem 1:
Corollary 1. If the Loewe Additivity Consistency Condition in
Eq. 2.8 holds, (1) fGI (x1, x2) = f2→1(x1, x2) = f1→2(x1, x2) and
(2) the isoboles corresponding to these models are parallel.
The proof of this corollary can be found in Supplement A.2.
2.1.2 Methods
Our running example in Fig. 2.1 and 2.2 represents the exception
rather than the rule. As we have seen, the LACC requires a
very specific interplay between the two individual dose-response
curves, which is likely often violated in practice. This sheds
doubts on the value of an implicit formulation of a response
surface as the one provided by the General Isobole Equation
for real-world applications. If the LACC does hold, fGI (x1, x2)
is equivalent to explicit formulations such as f2→1(x1, x2) and
f1→2(x1, x2) that are much easier to compute. If the LACC does
not hold, we may still for aesthetic reasons prefer linear isoboles
over nonlinear ones (explained at the end of this section), but the
precise argumentation that leads to these linear isoboles breaks
down.
So, apart from aesthetic and perhaps historical reasons, the
relevant question is whether an implicit formulation as General
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Isobole Equation leads in practice, when the LACC is violated, to
better fitting response surfaces than similar explicit formulations.
This will be investigated in Section 2.2. Here, we will derive a
symmetric explicit null reference model that, for mild violations
of the LACC, still gives close to linear isoboles. We will adapt
the different null reference models to handle cases in which the
two dose-response curves have different maximal effects and will
then illustrate their response surfaces.
Explicit Mean Equation
Unlike the General Isobole Equation, the two explicit models
f2→1(x1, x2) and f1→2(x1, x2) are asymmetric, that is, the two
compounds cannot be interchanged without leading to different
results when the LACC does not hold. A simple remedy is to
consider a weighted combination of both, as in
(2.12)fmean (x1, x2) = β (x1, x2) f2→1 (x1, x2)
+ [1− β (x1, x2)] f1→2 (x1, x2) ,
with β(x1, x2) ∈ [0, 1] and β(x1, x2) = 1 − β(x2, x1) to enforce
symmetry. Obviously, when the LACC holds, we still have
fmean (x1, x2) = fGI (x1, x2). We aim for a choice of β(x1, x2)
such that under mild violations of the LACC, the explicit for-
mulation is still close to the implicit one, i.e., fmean (x1, x2) ≈
fGI (x1, x2), which then also will result in isoboles that are still
close to linear.
In Supplement A.4, we prove that a simple arithmetic mean,
fmean (x1, x2) =
1
2
[f2→1 (x1, x2) + f1→2 (x1, x2)] , (2.13)
does the best job: for mild violations of the LACC it stays close
to the General Isobole Equation and hence may be an alternative
worth investigating. In the following, we will refer to Eq. 2.13
as the Explicit Mean Equation. A geometric mean instead of a
simple arithmetic mean also closely matches the General Isobole
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Figure 2.3: Pairs of conditional response curves that
violate the LACC. Dose-response curves (red and blue)
with different parameter settings that all violate the LACC:
s1 6= s2 (left) with s1 = 1 and s2 = 2, y∞,1 6= y∞,2 (center)
with y∞,1 = 0.3 and y∞,2 = 0, and (right) with s1 6= s2 and
y∞,1 6= y∞,2 with the same settings as above. Additionally,
all other parameters that are chosen to be equal for both Hill
curves take the values s = 1, y0 = 1, y∞ = 0 and e = 1.
Equation for mild violations of the LACC. Details can be found
in Supplement A.6.
Different Maximal Effects
In case one dose reaches an effect that cannot be reached by the
other, there is no equivalence relationship between the two doses
and therefore Loewe Additivity cannot hold. Here we discuss how
to adapt the General Isobole Equation and the Explicit Mean
Equation to this situation.
Let us first assume that dose x2 of compound 2 leads to an




This is depicted in Fig. 2.3 in the middle and right panel, where
the first compound reaches a maximal effect of y∞,1 = 0.3 and
the second one a maximal effect of y∞,2 = 0. For the General
Isobole Equation, Di Veroli et al. [41] suggests that one would
need an infinite dose of x1 to yield a response as close as possible
to f1(x1), and hence proposes to set the first term in Eq. 2.3 to
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zero to arrive at
x2
f−12 (y)
= 1 , (2.15)
with the obvious solution fGI (x1, x2) = f2(x2). The other way
around, we set fGI (x1, x2) = f1(x1) when f1(x1) < minx2 f2(x2).
Following a similar line of reasoning as in [41], we propose
















for the case f2(x2) < minx1 f1(x1), where the second step follows
since xequiv1 (x2) dominates x1. Note that in this case f2→1(x1, x2)
still follows from its original definition in Eq. 3.5. Similarly,
when f1(x1) < minx2 f2(x2), we set f1→2(x1, x2) = f1(x1) and
leave f2→1(x1, x2) unchanged. In both cases, the Explicit Mean
Equation still equals the average of f2→1(x1, x2) and f1→2(x1, x2),
which, in case of f2 (x2) < minx1 f1 (x1):




f2 (x2) + f2
(
f−12 (f1 (x1)) + x2
)]
. (2.17)
Note that this is different to the General Isobole Equation, which
takes the form fGI (x1, x2) = f2 (x2).
Illustrations of Violations of LACC
As mentioned before and commented by Tallarida [198] and Geary
[58], the conditional response curves of experimental data are
often not proportional and therefore, the LACC in Eq. 2.8 is often
violated. Here, we investigate what different violations of the
LACC imply for the null reference models.
In Fig. 2.3, two Hill curves are depicted in three scenarios
where the LACC is violated: either (i) two different slopes s (left),
or (ii) two different maximal effects y∞ (middle), or (iii) both
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(right). It becomes immediately clear that in all scenarios there
is no proportional relationship between the two curves. Fig. 2.4
shows the four null reference models fGI (x1, x2), f2→1 (x1, x2),
f1→2 (x1, x2) and fmean (x1, x2) with the conditional response
curves from Fig. 2.3. Fig. 2.4A depicts the fGI (x1, x2) model
while the three explicit models, f2→1(x1, x2) and f1→2(x1, x2) from
Eq. 3.5 and Eq. 3.6 and fmean (x1, x2) from Eq. 2.13, are depicted
in Fig. 2.4B, Fig. 2.4C and Fig. 2.4D, respectively. In each
column, the three cases of LACC violation (Fig. 2.3) are depicted.
The contour lines of the fmean (x1, x2) in Fig. 2.4D are depicted
in white and for reference, the contour lines of fGI (x1, x2) are
depicted in gray.
Let us first investigate in detail the first case of violation,
assuming different slope parameters for the conditional responses,
as depicted in the left column of Fig. 2.4. The fGI (x1, x2) displays
straight isoboles, which are not parallel as they are in Fig. 2.2.
The straightness is due to Berenbaum’s definition of the General
Isobole Equation and becomes obvious by inspection of Eq. 2.3,
which is symmetric in the fractional terms. This is one of the
reasons why this model has been popular. The two explicit models
f2→1(x1, x2) and f1→2(x1, x2) in the left panel of Fig. 2.4B and
Fig. 2.4C display a concave or convex curvature to the point of zero
dose concentration. The Explicit Mean Equation in Fig. 2.4D
shows nearly linear isoboles, with a slight curvature which is
concave for x1 reaching a larger effect than x2 and convex for x1
reaching a smaller effect than x2.
The scenario for different maximal effects but same slopes
is depicted in the middle panels of Fig. 2.4 for the fGI (x1, x2)
model as well as for the explicit models f2→1 (x1, x2), f1→2 (x1, x2)
and fmean (x1, x2). The models all have a smaller effect than
in the previous scenario, where the slopes differ. All explicit
models exhibit nonlinear isoboles. f2→1 (x1, x2) and f1→2 (x1, x2)
exhibit a similar concave and convex curvature behaviour as in
the scenario of differing slopes. For fGI (x1, x2), f2→1 (x1, x2)
and fmean (x1, x2), the asymptotic behaviour is depicted. For
fGI (x1, x2) and f2→1 (x1, x2), these figures display a constant
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Figure 2.4: Response surfaces if LACC is violated.
Three cases of violation of the LACC for the fGI (x1, x2) (A),
f2→1 (x1, x2) (B), f1→2 (x1, x2) (C) and fmean (x1, x2) (D)
model. Contour lines are depicted in white. In Figure (D) the
contour lines of the corresponding fGI (x1, x2) are depicted
in gray for reference. The parameter setting is the following
from left to right: (left) s1 6= s2, here depicted with s1 =
1, s2 = 2, y∞ = 0, or (middle) the maximal effect values differ,
y∞,1 6= y∞,2, here shown with s = 1, y∞,1 = 0.3, y∞,2 = 0 or
(right) both, the slopes and the maximal effects are different,
here shown with s1 = 1, s2 = 2, and (continued next page)
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Figure 2.4 (previous page): y∞,1 = 0.3, y∞,2 = 0. The
remaining two parameters of the Hill curve are set equal for
all figures to y0 = 1 and e = 1.
horizontal response for x1, only decreasing for increasing x2 doses.
The isoboles of fmean (x1, x2), which is formed by the mean of
f2→1 (x1, x2) and f1→2 (x1, x2), are convex for small doses of x1
and then become almost linear for increasing doses of x1.
For the case where both scenarios of a violation are met,
namely different slopes and different maximal effects, we depict the
response surfaces of the null models in the right column of Fig. 2.4.
Here, we see the characteristics from the two violations combined,
namely, non-linear isoboles for the explicit null reference model,
but fmean (x1, x2) exhibiting almost linear isoboles, together with
an asymptotic effect behaviour for Fig. 2.4A and Fig. 2.4B.
2.1.3 Material
Two datasets are used throughout the following two chapters: The
first dataset was created by Mathews Griner et al. [130] and is a
cancer compound synergy study. We refer to this dataset as the
Mathews Griner data. It is composed of 463 different drug-drug-
cell combinations on the cancer cell line TMD8 and was published
along with many other large drug-drug-cell combination studies
on the website https://tripod.nih.gov/matrix-client/. It
is a so-called one-to-all experiment, meaning that one compound
(in this case ibrutinib) is combined with 463 other compounds. In
this high-throughput study all 463 compound combinations are
screened in a 6× 6 matrix design and the effect of the compound
combinations is measured as cell viability. The six different con-
centrations of ibrutinib and the paired compound decrease from
2.5µM and 125µM four times with a four-fold dilution with the
sixth dose being zero [227].
In a synergy modeling study, Yadav et al. [227] categorized
each record of the Mathews Griner data into three interaction
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classes after visual inspection of its dose-response matrix: synergy,
no interaction, and antagonism. For the analysis in this chapter,
we only use the 252 dose-response matrices classified as non-
interactive. In Chapter 3, we include the interactive records as
well.
The Cokol dataset comes from a study about fungal cell growth
of the yeast S. cerevisiae (strain By4741), where Cokol et al. [32]
categorized the dataset. In this study the influence on cell growth
was measured when exposed to 33 different compounds that were
combined with one another based on promising combinations
chosen by the authors, resulting in 200 different drug-drug-cell
combinations. With an individually measured maximal effect dose
for every compound, the doses administered decrease linearly in
seven steps with the eighth dose set to zero, resulting in an 8× 8
factorial design.
Each record was given a score based on the longest arc length
of an isobole that is compared to the expected longest linear
isobole in a non-interactive scenario, where Loewe Additivity
serves as null reference model. In more detail, from the estimated
surface of a record assuming no interaction, the longest contour
line is measured in terms of its length and direction (convex or
concave). A convex contour line leads to the categorization of a
record as synergistic and the arc length of the longest contour
line determines the strength of synergy. A concave contour line
results in an antagonistic categorization with its extent being
measured again as the length of the longest isobole. Thus the
Cokol dataset not only comes with a classification but also with a
synergy score similar to α or γ, which we introduce in Chapter 3.
We consider all records to be non-interactive if their absolute value
is smaller than 0.8. This decision is based on communication with
the authors [32].
To our knowledge, these two datasets are the only high-
throughput combination datasets with a classification into the
three synergy classes: antagonistic, non-interactive and synergis-
tic. Both datasets are somewhat imbalanced because interactions
are rare [14, 50, 232]. The distribution of the classification is
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listed in Table 2.1. We received both categorizations after per-
synergistic antagonistic non-interactive
Mathews Griner 121 90 252
Cokol 50 68 82
Table 2.1: Number of records categorized as synergistic,
antagonistic or non-interactive in the two datasets Mathews
Griner and Cokol.
sonal communication with the authors [32, 227]. For the purpose
of comparing the null reference models introduced in Section 1.2
and Section 2.1.2, as well as for the comparison of the synergy
models introduced in Chapter 3, we consider these two classifi-
cations as ground truth, given that no molecular information is
available for verification.
Before proceeding with the analysis, we normalize and clean
the data from outliers. In a first step we normalize all records
to the same value, y0, the measured response at zero dose con-
centration from both compounds. Second, we discard outliers
using the deviation from a spline approximation. Third, we fit
both conditional responses of each record, namely the responses
of each compound individually, to a pair of Hill curves (Eq. 2.1,
Chapter 2). For the fitting, we make use of the drc package [170].
This gives the parameter set Θ = {y0, y∞,1, y∞,2, e1, e2, s1, s2} for
each record. More details are given in Supplement B.1. Records
with negative slopes or negative EC50 values are excluded, which
leaves us with 159 records for the Mathews Griner and 79 for the
Cokol data. The main reason for the exclusion of nearly 40% of
the records of the Mathews Griner data is the fixed dose range
applied to all compounds. Many conditional readouts show barely
any response over the entire dose range. The compounds might
therefore have no effect at all on the cell line or the dose range
is too small to cause any effect. A more detailed investigation of
such bad fits to Hill curves can be found in Supplement B.1.
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2.2 Results
With the two datasets introduced in Section 2.1.3 we confirm
Geary’s statement about the common violation of the LACC.
Furthermore, we compare the different null reference models
by considering non-interactive records of two different datasets
of compound screenings: with the fitted conditional responses
we construct two response surfaces, one for the General Isobole
Equation and one for the Explicit Mean Equation. Residuals are
calculated by subtracting the predicted responses of the General
Isobole and Explicit Mean response surfaces from each measured
response (maximally 36 values for Mathews Griner and 64 for
Cokol). We summarize the residuals for each response matrix by
their mean and standard deviation. These capture the bias and
mean-squared error, respectively.
2.2.1 Violation of the LACC
To support the statement from Section 2.1.2 about the LACC
being often violated, we apply Wilcoxon signed-rank test to the
Mathews Griner data which combines one compound with a set of
other compounds. We first test the null hypothesis that the slopes
s from the two fitted conditional responses are equal. Second,
we test for equality of the maximal effects y∞. The results of
both tests on s and y∞ are significant with ps = 6.26× 10−5 and
py∞ = 2.2× 10−16, respectively. Thus, the LACC is often violated
due to differing slopes s and maximal effects y∞.
2.2.2 Quality of Fit
We compare the General Isobole Equation fGI (x1, x2) (Eq. 2.3)
and the Explicit Mean Equation fmean (x1, x2) (Eq. 2.13) by
computing the bias and mean-squared error between the null
reference surfaces that are spanned by the null reference mod-
els and the measured response data, excluding the outliers (see


























Figure 2.5: Quality of fit: bias. Mean difference between
the responses given by the model and the measured responses.
To better qualify the differences in bias, the diagonal is de-
picted. The distribution of the models’ bias values is given in













(ŷi,j − yi,j)2 (2.19)
with ŷi,j being the estimated response and yi,j the measured
response for dose combination i and record j, and mse short for
mean-squared error.
Scatter plots of the bias of both datasets are depicted in
Fig. 2.5. For every record, the bias of fmean (x1, x2) is depicted
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on the x- and the bias of fGI (x1, x2) on the y-axis. A striking
observation from Fig. 2.5 is that the bias values of fGI (x1, x2)
are always larger than those of fmean (x1, x2). This holds for
both datasets. For positive bias values, this gives a smaller bias
for fmean (x1, x2) and for negative bias values, a smaller bias in
absolute terms for fGI (x1, x2). We look in detail into the bias,
namely the individual differences of estimated data points to the
measured ones, for each record. For all records of the Mathews
Griner and most records for the Cokol dataset, the residuals of each
data point, meaning the read-out for a given dose combination, are
larger for the fGI (x1, x2) model. We suspect this to be due to the
definition of the explicit models, as, by taking into consideration
the effect of the other compound as well, the spanned surfaces are
steeper decreasing if the LACC is violated. This becomes clear
by inspecting the right panel of Fig. 2.4D, for which the contour
lines of the fmean (x1, x2) model are depicted in white with the
contour lines of the fGI (x1, x2) model depicted in gray: due to
the white contour lines being more contracted to the origin than
the gray ones, the response surface of the explicit fmean (x1, x2)
model has a steeper decrease than the implicit fGI (x1, x2) model.
This is also in line with the negative bias values, which are larger
for the fmean (x1, x2) model in absolute terms. Thus, if the
fGI (x1, x2) model spans a surface below the measured data, the
fmean (x1, x2) model then definitely spans a surface below the
fGI (x1, x2) model and therefore below the measured data.
Additionally, we compare the mean-squared errors of the
fGI (x1, x2) model and the fmean (x1, x2) model. We do so us-
ing the Wilcoxon signed-rank test for paired samples. For the
Mathews Griner and the Cokol data, the results of the Wilcoxon
signed-rank tests are significant to reject the null hypothesis of an
equal mean for the alternative hypothesis that the mean-squared
error values of the fGI (x1, x2) model are greater. The p-value for
the mean-squared error values of both null models on the Mathews
Griner data is pMathews Griner = 9.74× 10−7 and for the Cokol data
is pCokol = 4.86 × 10−2. Further, in Fig. 2.6, the mean-squared
error values of both datasets are depicted in two scatter plots,



































Figure 2.6: Quality of fit: mean-squared error. be-
tween the measured and the expected responses of the
fmean (x1, x2) and fGI (x1, x2) model, each drawn in the ac-
cording axes. To better qualify the differences in mean-squared
error, the diagonal is depicted. The distribution of the models’
mean-squared error values is given in histograms plotted on
the axes.
the Mathews Griner data on the left and the Cokol data on the
right hand side. The mean-squared errors of the fmean (x1, x2)
model are drawn on the x-axis and the mean-squared errors of the
fGI (x1, x2) model on the y-axis. The models are considered to
perform equally well if their mean-squared error values are equal
and therefore lie on the diagonal axis. As visual aid, this diagonal
is drawn in both scatter plots. Points depicted in the lower trian-
gle of a scatter plot represent records for which the fGI (x1, x2)
model results in smaller mean-squared error values and points
in the upper triangle represent records where the fmean (x1, x2)
model performs better. There are a few outliers depicted in the
2.2. Results 35
lower triangle of the mean-squared error values of the Mathews
Griner data for records which yield a mean-squared error value
above 0.02 with the fmean (x1, x2) model. Investigating these
records reveals a huge difference in slope parameters of the con-
ditional responses. To give an example, the slope parameters
of the record that results in a mean-squared error value above
0.04 for the fmean (x1, x2) model are s1 = 1.2 and s2 = 9.6. The
f1→2 (x1, x2) model gives an almost ten times higher mean-squared
error, which is caused by the surface being strongly contracted
to the origin. The majority of mean-squared error values scat-
ter in the range of [0, 0.01] and are slightly above the diagonal.
In the scatter plot on the right-hand side of Fig. 2.6, depicting
the mean-squared error values for the Cokol dataset, there is a
tendency of records to scatter in the upper triangle, supporting
the Wilcoxon signed-rank test result of the fGI (x1, x2) model
resulting in larger mean-squared error values.
2.2.3 Computational Complexity
To further investigate the difference between the implicit and
explicit formulation derived from the Loewe Additivity principle,
we conduct a small benchmarking test. We compare the com-
putation time of the null reference models fGI (x1, x2) (Eq. 2.3)
and fmean (x1, x2) (Eq. 2.13). For this, we use the dataset from
a study conducted by Yonetani and Theorell [231] which is be-
lieved to have no synergistic or antagonistic effect [30]. The data
represents the inhibition of horse liver alcohol dehydrogenase by
two inhibitors, ADP ribose and ADP. The data was used in an
analysis of Chou and Talalay [28]. We fit the conditional pa-
rameters as described in Supplement B.1. For benchmarking,
we use the microbenchmark package [135]. It runs each calcu-
lation per default 100 times. The median time to compute the
explicit formulation of Loewe Additivity is 280 times faster than
the implicit one (comparing to fGI (x1, x2)). Both, f2→1 (x1, x2)
and f1→2 (x1, x2), have to be computed. Further results for the
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benchmark test on the null reference models are shown in Fig. A.1
in Supplement A.5.
2.3 Discussion
With the rise of high-throughput methods, there is a huge op-
portunity to investigate compound combinations for synergistic
effects. Especially with a first success in a synergy study on in
vivo mice [67], there is an urge to develop reliable methods to
screen for promising combinations. Loewe Additivity is one of the
most popular principles to investigate synergistic effects in com-
pound combination studies. With the mathematical formulation
in the first part of this study we are to our knowledge the first to
have developed the theoretical background and the consistency
condition of Loewe Additivity. Further, this mathematical deriva-
tion led to an explicit formulation of Loewe Additivity which
underlines the arbitrariness of models derived from the Loewe
Additivity principle. As commented upon before [58, 124, 198],
we showed in two datasets that the LACC is often violated. These
violations lead to differing predictions for different null reference
models. This fact is generally ignored in the literature or even
contradicted [6].
Despite the common violation of the LACC, the General
Isobole Equation is popular. Therefore, it is important to tackle
the biological question of which interaction to expect in the case
the LACC is violated. We introduced the Explicit Mean Equation
which is equivalent to the General Isobole Equation under the
LACC and spans a similar surface if the LACC is violated.
Most of the synergy analyses focus on a difference in shape of
isoboles at fixed effects, such as the EC50 effect, which, assuming
a Hill curve for conditional response curves, is the parameter e
in this research. Methods, such as the Combination Index from
Berenbaum [5] or the Median Effect Method from Chou and
Talalay [30] build upon the assumption of linear isoboles and have
found wide application [22, 27, 32, 61, 186]. We want to emphasize
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that the argument to fix the isobole to be linear by making the
effect-equivalent doses xequiv1 (x2) and x
equiv
2 (x1) from Eq. 2.4
and Eq. 2.5 to be dependent on y, and therefore loosening the
LACC in Eq. 2.8 to a local area, namely the isobole of the effect
y, leads to a circular type of reasoning and does not solve the
ambiguity of the Loewe Additivity if the LACC does not hold.
In two non-interactive high-throughput combination datasets
we found our new Explicit Mean Equation null reference model
to show smaller bias values than those of the General Isobole
Equation model. This is a consequence of the more contracted
surface of the Explicit Mean Equation to the origin if the LACC
is violated. Further, we found the Explicit Mean Equation to have
smaller mean-squared errors than the General Isobole Equation.
These findings provide for an explicit model to replace the standard
implicit model, both based on the Loewe Additivity principle.
Additionally, the explicit model speeds up the computation time
by a factor of roughly 280. In a large high-throughput experiment
with 10, 000 records this would reduce computing time from 20
hours to less than 5 minutes. We herewith provide a first step
into the direction of improving the biological and numerical issues
that follow from the Loewe Additivity principle.
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3 Additive Dose Models:
Defining Synergy
The combination of compounds can lead to interaction effects that
are greater or smaller than the expected effect. These interaction
effects are referred to as synergistic or antagonistic, respectively.
From data generated with high-throughput techniques, one is
confronted with massive compound interaction screens. From
those screens, one needs to filter for interesting candidates that
exhibit an interaction effect. To quickly scan all interactions, a
simple measure is needed. Based on such a preprocessing scan, the
filtered combination candidates can then be examined in greater
detail. In such a quick scan, one focuses uniquely on the measured
response and not on possible MoAs of each compound.
To determine whether a combination of substances exhibits an
interaction effect, it is crucial to first decide on an expected non-
interactive effect. Only when deviance from such a so-called null
reference is observed, can one speak of an interactive effect. For
a detailed introduction to null reference models, go to Chapter 2.
As mentioned in the previous chapter, there are only two main
principles of non-interactivity that have survived the critics and
are in common use: Loewe Additivity [124] and Bliss Indepen-
dence [9]. Again, the popularity of Loewe Additivity is based on
its principle of sham combination, which assumes no interaction
when a compound is combined with itself. Other null reference
models do not hold that assumption. Opposed to that model
of dose equivalence is the Bliss Independence, which assumes
(statistical) independence between the combined compounds.
1This chapter is based on Simone Lederer, Tjeerd MH Dijkstra, Tom
Heskes. “Additive dose response models: defining synergy”. In Frontiers in
Pharmacology, 10 (2019). DOI: 10.3389/fphar.2019.01384.
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Independent of the indecisive opinions about the null refer-
ence, there are multiple proposals regarding how synergy can be
measured given a null reference model. Many models are based
on the concept of isoboles [30, 39, 60, 141]. An isobole is the set
of all dose combinations of the compounds that reach the same
fixed effect, such as 50% of the maximal effect, usually known
as EC50. Some suggest to measure synergy as the difference
between an observed isobole and a reference isobole calculated
from a null-reference model. Another way to quantify synergy on
the basis of the isobole is to look at the curvature and arc-length
of the longest isobole spanned over the measured response [32].
The general problem with the isobole approaches lies in the use of
isoboles at fixed effects or dose ratios. The deviations measured
from the isoboles (and hence synergy) are therefore only measured
locally for these fixed effects or dose ratios. In order to measure
all interaction effects, this method has to be applied to many fixed
effects or dose ratios.
In this chapter we measure synergy as the deviation over the
entire response surface. One way to do so is the Combenefit
method by measuring synergy in terms of volume between the
expected and measured effect [41]. We will refer to it as a lack-
of-fit method as it quantifies the lack of fit from the measured
data to the null reference model. Another way of capturing the
global variation is by introducing a synergy parameter α into the
mathematical formulation of the response surface. This parameter
α is fitted by minimizing the error between the measured effect and
the α-dependent response surface. Such statistical definition of
synergy allows for statistical testing of significance of the synergy
parameter. Fitting a synergy parameter to the data as in the
parametric approaches tends to be computationally more complex
than computing the difference between the raw data and the null
model as in the lack-of-fit approaches.
There is an increase in theoretical approaches to synergy, such
as the recently re-discovered Hand model [76, 183], which is a
formulation of Loewe Additivity in form of a differential expression,
or new ways of defining and measuring synergy, such as the
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ZIP model [227], SynergyFinder [79], MuSyC [138] and a copula
model [109]. It would be a large effort to compare these recent
approaches with ours. An extensive comparison of the models has
recently been made in Meyer et al. [138]. Here we focus on the two
main principles, Loewe Additivity and Bliss Independence, and
compare the lack-of-fit and parametric approach for computing
synergy.
In Section 3.1.1, we revisit shortly the two null response prin-
ciples, Loewe Additivity and Bliss Independence. We explain
in detail several null reference models that build on those prin-
ciples. We introduce synergy as any effect different from an
interaction free model in Section 3.1.2. There, we also introduce
the parametrized and lack-of-fit synergy approaches. We use the
two datasets introduced in the previous chapter to compute a
synergy score for each record per model and method. Based on
the comparison of the computed and provided synergy scores, we
evaluate the models and methods in Section 5.2.
3.1 Methods and Material
3.1.1 Theory
An introduction to the conditional dose-response curves, and the
construction of additive null-reference models on the basis of
Loewe Additivity is given in Chapter 2. For completeness of this
chapter, we shortly recap the most important information on the
null reference models of Loewe Additivity here.
Null reference models are constructed from the conditional
(mono-therapeutic) dose-response curves of each of the compounds,
which we denote by fj (xj) for every compound j ∈ {1, 2}. Null
reference models extend the conditional dose-response curves to
a (null-reference) surface spanned between the two conditional
responses. We denote the surface as f (x1, x2) such that
f (x1, 0) = f1 (x1) (3.1)
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and
f (0, x2) = f2 (x2) . (3.2)
Thus, the conditional response curves are the boundary conditions
of the null reference surface. For this study, we focus on Hill curves
to model the conditional dose-responses, as described in Section 2.1
in Chapter 2.
Loewe Additivity
As discussed before, the Loewe Additivity builds on the concepts
of sham combination and dose equivalence. The first concept
is the idea that a compound does not interact with itself. The
latter concept assumes that both compounds that reach the same
effect can be interchanged. Therefore, any linear combination
of fractions of those doses which reach the effect individually
and, summed up, are equal to one, yields that exact same effect.
Mathematically speaking, if dose x∗1 from the first compound
reaches the same effect as dose x∗2 from the second compound,







holds, should yield the same effect as x∗1 and x∗2. As this idea can







where x∗1 and x∗2 are replaced with f
−1
1 (y) and f
−1
2 (y), the inverse
functions of Hill curves, respectively. For a fixed effect y, Eq. 3.4
defines an isobole, which is in mathematical terms a contour line.
Hence the name of this model: the General Isobole Equation.
It is an implicit formulation as the effect y of a dose combina-
tion (x1, x2) is implicitly given in Eq. 3.4. In the following we
use the mathematical notation for the General Isobole Equation
fGI (x1, x2) = y with y being the solution to Eq. 3.4. As shown
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in the previous Chapter 2, the principle of Loewe Additivity is
based on the Loewe Additivity Consistency Condition (LACC).
This condition states that it should not matter whether equiv-
alent doses of two compounds are expressed in terms of the first
or the second. Under the assumption of the LACC being valid,
we have shown, that a null reference model can be formulated
explicitly, by expressing the doses of one compound in terms of
the other compound:







f1→2 (x1, x2) = f2
(
f−12 (f1 (x1)) + x2
)
, (3.6)
where f−11 (f2 (x2)) is the dose x1 of compound one to reach the
same effect of compound two with dose x2 (see Fig. 2.1 in Chap-
ter 2). Summing up this dose equivalence of the first compound
with a dose of the second compound allows for the computation of
the expected effect of the compound combination. With the two
formulations above, the effect y of the dose combination (x1, x2) is
expressed as the effect of either one compound to reach that same
effect. We showed in Chapter 2 that all three models, Eq. 3.4,
Eq. 3.5 and Eq. 3.6 are equivalent under the LACC. We further
showed that, in order for the LACC to hold, conditional dose-
response curves must be proportional to each other, i. e. being
parallel shifted on the x-axis in log-space. It has been commented
by Geary [58] and we have shown in Chapter 2, that this consis-
tency condition is often violated. Geary [58] himself comments
that it cannot be determined whether a response that lies between
the two surfaces f2→1 (x1, x2) and f1→2 (x1, x2) is synergistic or
antagonistic and hence should be treated as non-interactive. We
refer to the envelope spanned between the two explicit surfaces
f2→1 (x1, x2) and f1→2 (x1, x2) in Eq. 3.5 and Eq. 3.6 as fgeary. In
contrast to that, in an effort to take advantage of the explicit
formulation and to counteract the different behavior of Eq. 3.5 and
Eq. 3.6 in case of a violated LACC, we introduced in Chapter 2
the so-called Explicit Mean Equation as mean of the two explicit
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formulations of Eq. 3.5 and Eq. 3.6:
fmean (x1, x2) = 1/2 (f2→1 (x1, x2) + f1→2 (x1, x2)) . (3.7)
Bliss Independence
Bliss Independence assumes independent sites of action of the two
compounds and was introduced by Bliss [9] a decade later than
Loewe Additivity. Note that the formulation of Bliss Independence
depends on the measurement of the effect. The best known
formulation of Bliss Independence is based on monotonically
increasing responses for increasing doses:
gbliss (x1, x2) = g1 (x1) + g2 (x2)− g1 (x1) g2 (x2) , (3.8)
where gi (xi) = 1 − fi (xi) is a conditional response curve with
increasing effect for increasing doses. In case the effect is measured
in percent, i. e. y ∈ [0, 100], the interaction term needs to be
divided by 100 to ensure the right dimensionality of the term.
Throughout this thesis, we measure the effect in terms of cell
survival or growth inhibition. Therefore the conditional response
curves are monotonically decreasing for increasing concentrations
or doses. Bliss Independence then reformulates to
fbliss (x1, x2) = f1 (x1) f2 (x2) . (3.9)
The records are normalized to the response at x1 = 0, x2 = 0,
thus f1 (0) = f2 (0) = 1. To arrive from Eq. 3.8 to Eq. 3.9, one
replaces any g by 1− f . Chou and Talalay [30] derive the Bliss
Independence from a first order Michaelis-Menten kinetic system
with mutually non-exclusive inhibitors.
While there are many mathematical variations to the general
concept of Loewe Additivity (here we introduced five null-reference
models based on this methodology), there is generally only one
way to compute Bliss Independence.
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3.1.2 Methods
The six models introduced in the previous section are null refer-
ence models in that they predict a response surface in the absence
of compound interaction. We capture synergy in a single parame-
ter to facilitate the screening process. This is different from other
approaches, such as Chou and Talalay [28], who measure synergy
as deviation from a null-reference isobole without summarizing
the deviation in a single parameter. The single parameter value
is typically referred to as synergy- or α-score [5]. As we investi-
gate two methods to quantify synergy, we introduce two synergy
parameters α and γ, which measure the extent of synergy and
are calculated with different methods (more details below). Both
synergy scores α and γ are parametrized such that α = 0 or γ = 0
denote absence of an interaction effect. In case α or γ take a value
different from zero, we speak of a interactive or synergistic effect.
A compound combination is, dependent on the sign of synergy




= 0 additive or non-interactive
< 0 antagonistic
. (3.10)
Here, we measure synergy in two different ways, namely in fit-
ting parametrized models or computing the lack-of-fit. The first
method fits null reference models that are extended with a synergy
parameter α. For these parametrized models α is computed by
minimizing the square deviation between the measured response
and the response spanned by the α-dependent model. For the
second method the difference between a computed null reference
model and the measured data is computed. For this method,
which we refer to as lack-of-fit, the synergy score γ is defined as
the volume that is spanned between the null reference model and
the measured response.
Just as the conditional responses form the boundary condition
for the null-reference surface (Eq. 3.1, Eq. 3.2), we want the
conditional responses to be the boundary condition for all values
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of α. Explicitly, assuming a synergy model dependent on α is
denoted by f (x1, x2|α), then
f (x1, 0|α) = f1 (x1)
f (0, x2|α) = f2 (x2)
}
∀α, (3.11)
with fi denoting the conditional response of compound i. We refer
to Eq. 3.11 as the Synergy Desideratum. As we will see below,
not all synergy models fulfill this property.
Parametrized Synergy
We extend the six null reference models introduced in Section 3.1.1
in Eq. 3.4 - Eq. 3.9, including the Geary model, to parametrized
synergy models. The extension of the General Isobole Equation
is the popular Combination Index introduced by Berenbaum [5]






= 1− α. (3.12)
Berenbaum originally equated the left-hand side of Eq. 3.4 to the
so-called Combination Index I. Depending on I smaller, larger,
or equal to 1, synergy, antagonism or non-interaction is indicated.
For consistency with the other synergy models, we set I = 1− α
such that α matches the outcomes as listed in Eq. 3.10. In
Section 5.2 we refer to this implicit model as fCI (x1, x2|α), where
α is the parameter that minimizes the squared error between
measured data and Eq. 3.12.
Note that this model violates the Synergy Desideratum in
Eq. 3.11 as α not zero leads to deviations from the conditional
responses. Explicitly, fCI (x1, 0|α) = f1 ((1− α)x1) 6= f1 (x1). Al-
though the Combination Index model violates the Synergy Desider-
atum, in practice it performs quite well and is in widespread use.
The explicit formulations in Eq. 3.5 and Eq. 3.6 are equivalent
to the General Isobole Equation, fGI (x1, x2), given in Eq. 3.4,
under the LACC, but different if the conditional responses are not
proportional. The two explicit equations are in fact an extension
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of the “cooperative effect synergy” proposed by Geary [58] for
compounds with qualitatively similar effects. For these explicit
formulations in Eq. 3.5 and Eq. 3.6 we propose a model that
captures the interaction based on the explicit formulations:
f2→1 (x1, x2|α) = f1
(





f1→2 (x1, x2|α) = f2
(
(1 + α) f−12 (f1 (x1)) + x2
)
. (3.14)
With this, we can extend the Explicit Mean Equation model
fmean (x1, x2) in Eq. 3.7 to a parametrized synergy model:
fmean (x1, x2|α) = 1/2 (f2→1 (x1, x2|α) + f1→2 (x1, x2|α)) ,
(3.15)
which we refer to as fmean (x1, x2|α). As f2→1 (x1, x2|α)
and f1→2 (x1, x2|α) do not fulfill the Synergy Desideratum,
fmean (x1, x2|α) does not fulfill it, either.
To investigate the difference between the two models
f2→1 (x1, x2) (Eq. 3.5) and f1→2 (x1, x2) (Eq. 3.6) we treat com-
pound 1 and compound 2 based on the difference in slopes in
the conditional responses (for more detailed information on the
different parameters in Hill curves, refer to Supplement B.1). In-
stead of speaking of the first and second compound, we speak of
the smaller and larger one, referring to the order of sigmoidicity.
Therefore, we use models Eq. 3.13 and Eq. 3.14, but categorize
the compounds based on the slope parameter of their condi-
tional response curves. This results in flarge→small (x1, x2|α)
and fsmall→large (x1, x2|α).
Analogously, we extend the Geary model fgeary (x1, x2) to a
synergy model and refer to it as fgeary (x1, x2|α). Based on a
comment of Geary [58], the two explicit models f2→1 (x1, x2) and
f1→2 (x1, x2) yield the same surface under the LACC but do rarely
in practice. Therefore, it cannot be determined whether a response
that lies between the two surfaces is synergistic or antagonistic
and hence should be treated as non-interactive. Thus, if α from
f1→2 (x1, x2|α) and α from f2→1 (x1, x2|α) are of equal sign, the
synergy score of that model is computed as the mean of those two
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parameters. In case the two synergy parameters are of opposite





(α1→2 + α2→1) if sign (α1→2) = sign (α2→1)
0 else .
(3.16)
Next, to extend the null reference model following the principle
of Bliss Independence, we extend Eq. 3.8 to
gbliss (x1, x2|α) = g1 (x1)+g2 (x2)−(1 + α) g1 (x1) g2 (x2) . (3.17)
The motivation for this model is that any interaction between
the two compounds is caught in the interaction term of the two
conditional responses. In case of no interaction, the synergy
parameter α = 0, which leads to (1 + α) = 1, and results in no
deviance from the null reference model. As we use the formulation
of Eq. 3.9 as we use response data that measures inhibited cell
survival or cell growth, we reformulate Eq. 3.17 analogously to
the reformulation from Eq. 3.8 to Eq. 3.9: by replacing gi (xi)
with 1− fi (xi). Hence, Eq. 3.17 takes the form:
fbliss (x1, x2|α) = f1 (x1) f2 (x2) + α (1− f1 (x1)) (1− f2 (x2))
(3.18)
This model satisfies the Synergy Desideratum, i. e. the requirement
of no influence of the synergy parameter on conditional doses:
fbliss (x1, 0|α) = f1 (x1) and fbliss (0, x2|α) = f2 (x2) as fi (0) = 1.
In case of synergy, the interactive effect is expected to be larger,
therefore, α being positive. If the compound combination has an
antagonistic effect, the interaction term is expected to be negative.
For extreme α, the parametric approach leads to responses outside
of the range 0 ≤ y ≤ 1, e. g. fbliss (x1, x2) → −∞ for α →
−∞. The same holds for the formulations of Loewe Additivity.
The implicit formulation becomes impossible to match and for
the explicit formulations, the dose expression within brackets
of f2→1 (x1, x2|α) becomes negative. Additionally, α > 1 is not
possible to compute for fCI (x1, x2|α), as the left-hand side of
Eq. 3.12 cannot be negative. Such behavior is also known from
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other models, e. g. for the Greco flagship model for negative
synergy scores [66, p. 365-366, and Fig. 26]. Hence, we will limit
α to the range of −1 to 1.
Despite of the Synergy Desideratum being violated for the
models that build up on the Loewe Additivity principle, there is
no further effect on the model comparison presented in Section 5.2
as conditional doses are excluded when computing the synergy
score (see Section 3.1.2).
Lack-of-Fit Synergy
The second method to measure synergy, that we investigate here,
is the computation of the lack-of-fit of the measured response of
a combination of compounds to the response of a null reference
model derived from the conditional responses. We refer to this






(ŷ (x1, x2|Θ)− y (x1, x2)) d log(x1)d log(x2),
(3.19)
with ŷ (x1, x2 |Θ) the estimated effect with parameters Θ of the
fitted conditional responses following any non-interactive model
and y the measured effect. Note that ŷ (Θ) and y are depen-
dent on the concentration combination (x1, x2). This method
was used in the AstraZeneca DREAM challenge [134] with the
General Isobole Equation as null reference model. More technical
information is provided by Di Veroli et al. [41]. Computing the
volume has the advantage of taking the experimental design into
account in contrast to simply taking the mean deviance over all
measurement points, which is independent of the relative positions
of the measurements. We also used a synergy value calculated
from the mean deviance and it clearly performed worse (data
not shown). The synergy value varies for different dose transfor-
mations. For example, the computed null-reference surface (and
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hence the synergy value) will be different for the same experiment
if a log-transformation is applied to the doses or not.
In all, we have introduced six null reference models, five of
them building up on the concept of Loewe Additivity and one
on Bliss Independence. We further have introduced two meth-
ods to compute synergy, the parametric one and the lack-of-fit
method, where both synergy parameters α and γ are positive
if the record is synergistic, and negative, if antagonistic. This
results in twelve synergy model-method combinations: the para-
metric ones, fCI (x1, x2|α) (Eq. 3.12), flarge→small (x1, x2|α) and
fsmall→large (x1, x2|α) (Eq. 3.13, Eq. 3.14, dependent on the slope
parameters) together with their mean, fmean (x1, x2|α) (Eq. 3.15),
fgeary (x1, x2|α) (computation of αgeary explained in Eq. 3.16) and
fbliss (x1, x2|α) (Eq. 3.17). For the lack-of-fit method, we take
as the null reference: fGI (x1, x2) (Eq. 3.4), flarge→small (x1, x2)
and fsmall→large (x1, x2) (Eq. 3.5, Eq. 3.6), with the Explicit
Mean Equation, fmean (x1, x2) (Eq. 3.7), fgeary (x1, x2) (analo-
gously to Eq. 3.16) and fbliss (x1, x2) (Eq. 3.9).
Fitting the Synergy Parameter
Both datasets are normalized and cleaned from outliers analo-
gously to Chapter 2. Conditional responses are also fitted the
same way. More details are given in Supplement B.1.
We apply the two different methods to calculate the synergy
parameters α and γ to each record. First, for the parametrized
synergy models, we apply a grid search for α, for α ∈ [−1, 1] with
a step size of 0.01, minimizing the sum of squared errors. This
gives the value of α for which the squared error between the ith





























Note that we exclude the conditional responses that we used to
fit the conditional response parameters Θ from the minimization.
Second, we apply the lack-of-fit method from Di Veroli et al. [41],
where synergy is measured in terms of the integral difference
in log space of measured response and surface spanned by the
non-interactive models in Section 3.1.1, as given in Eq. 3.19.
For the calculation of the integrals, we apply the trapezoidal
rule [163, Chapter 4]. To compute the synergy score γ for the
fgeary (x1, x2) model, we compute the integral over all data points
for which the difference between expected effect f2→1 (x1, x2) or
f1→2 (x1, x2) and the measured effect are of the same sign. If
they are of opposite sign, the difference is set to zero. In Fig. 3.1
we summarize the most important steps of the analysis for a
synergistic example. We show the same descriptional figure for
an antagonistic record in Supplement B.4, Fig. B.5.
3.1.3 Material
To evaluate the two methods introduced in Section 3.1.2, we apply
them to the two datasets, of which we already made use in the
previous chapter (see Section 2.1.3). Both datasets are compound
combination screening for which a categorization into the three
cases of synergy is provided.
3.2 Results
Using the two methods of computing the synergy score, the para-
metric one and the lack-of-fit one (see Section 3.1.2), we compute
synergy scores for all records of the two datasets introduced in
Section 2.1.3.
3.2.1 Kendall Rank Correlation Coefficient
Having computed the synergy scores α and γ from the two different
methods as described in Section 3.1.2, we compute the Kendall
rank correlation coefficient, which is also known as Kendall’s tau
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Figure 3.1: Defining Synergy. Description of the analysis
steps of the lack-of-fit method for the compound pair TER
and STA from the Cokol dataset. This compound pair is
categorized as synergistic according to [32]. The raw response
data of the record is depicted in panel (B): The response data
is normalized by the read at zero dose concentration (lower
left). The degree of relative cell growth is colored from high
to low values in red to blue. Step 1: compute Hill curves
for conditional responses: Fit a Hill curve to the conditional
responses, based on the raw reads of the single dose-responses
(lower and left outer edges) The fitted Hill curves are shown
with the original raw data as points in (i) (A), which is rotated
by 90 degrees, such that the vertical x-axis is parallel to the y-
axis of (B), since both axes denote the same doses of the same
compound, and in (ii) (D), which is flipped along the horizontal
x-axis. Step 2: compute the expected non-interactive response
for all six models: not shown. Step 3: compute the difference
between measured data (C) and expected data from all six null
reference models: shown in (C): The direction of difference is
shown by color (red for negative and blue for positive, green
for zero). The larger the degree of difference, the larger the
bullet, and vice versa. Step 4: compute the integral γ over all
differences: For every model, the synergy score γ is depicted
in the title of each matrix in (C).
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coefficient and was originally proposed by Kendall [98]. This
coefficient computes the rank correlation between the data as
originally categorized by Yadav et al. [227] and Cokol et al. [32]
and the computed synergy scores resulting from the two methods
introduced in Section 3.1.2. For the analysis, we rank synergistic
records highest at rank 3, followed by non-interactive at rank 2
and antagonistic lowest at rank 1. Due to the many ties in rank,
the Kendall rank correlation coefficient cannot take a value higher
than 0.75 for Mathews Griner and 0.8 for Cokol, even if a perfect
ranking was given. An overview of the Kendall rank correlation
coefficients is given in Fig. 3.2, and Table B.3 and Table B.4 in
Supplement B.3.
In Fig. 3.2, we plot the Kendall rank correlation coefficient
of the parametric method on the x-axis versus the Kendall rank
correlation coefficient of the lack-of-fit method on the y-axis.
Most of the points scatter in the upper left triangle, above
the diagonal line. This shows that the lack-of-fit method out-
performs the parametric method. This holds for all models ap-
plied to the Mathews Griner dataset and also for all models
but fgeary (x1, x2|α) and fsmall→large (x1, x2|α) applied to the
Cokol dataset. For both datasets, the highest correlation scores
result from those null reference models that are based on the
Loewe Additivity principle. The Bliss null reference model per-
forms worst for the Mathews Griner set for the lack-of-fit. For
the Cokol data it is the second worst model for both methods.
To a certain extent this can be explained due to the classifi-
cation of the Cokol dataset being based on the isobole length
relative to non-interactive isoboles, which is a Loewe Additiv-
ity type analysis. As the categorization of the Mathews Griner
dataset is based on visual inspection, we cannot explain the
bad performance of fbliss (x1, x2) for that dataset. On both
datasets, fGI (x1, x2), flarge→small (x1, x2) and fmean (x1, x2)
perform best for the lack-of-fit method. For the Mathews Griner
dataset, flarge→small (x1, x2) dominates marginally over the Gen-
eral Isobole Equation and Explicit Mean Equation model. For the
Cokol dataset, the Explicit Mean Equation dominates for both
















































Figure 3.2: Comparison of models and methods on
both datasets. Scatter plot of Kendall rank correlation co-
efficient for both datasets, Mathews Griner (left) and Cokol
(right). The Kendall rank correlation measures the rank corre-
lation between the original categorization and the computed
synergy scores. The higher the correlation, the more similar
the score ranking. The correlation values from the synergy
scores α, computed with the parametric approach, are plot-
ted on the x-axis and those from the lack-of-fit approach are
plotted on the y-axis. Each model is depicted in a different
color. To guide the eye, the diagonal is plotted. If a data
point is above the diagonal, the Kendall rank correlation coef-
ficient from the lack-of-fit method is higher than that from the
parametric method, and vice versa. Without exception, the
Kendall rank correlation coefficients are all higher for the syn-
ergy scores γ, which are computed with the lack-of-fit method,




3.2.2 Scattering of Synergy Scores
To further investigate the performance of the methods and null
reference models, we plot the synergy scores of the best performing
models based on the Kendall rank correlation coefficient analysis
(Section 3.2.1, and an ROC analysis, which we describe in detail
in Supplement B.2) for both datasets in Fig. 3.3, Fig. 3.4 and
Fig. 3.5.
In all figures, the overall Pearson correlation of the compared
data is depicted in black together with the Pearson correlation per
categorization. The coloring of the scores is based on the original
categorization as antagonistic, non-interactive or synergistic as
provided by Yadav et al. [227] and Cokol et al. [32].
In Fig. 3.3, we visualize the synergy scores computed with the
lack-of-fit in comparison to their original scores from Cokol et al.
[32]. Applying the lack-of-fit method to the Bliss Independence
model (Eq. 3.9) results in scores which are mainly above zero
(Fig. 3.3, upper left). Further, it can be seen in the density plots
along the y-axis in Fig. 3.3, upper left panel, and on the x-axis of
Fig. 3.4, both panels in the first row and left panel in the middle
row, that the synergy scores which are computed based on the
principle of Bliss Independence cannot be separated easily by
categorization, making it difficult to come up with a threshold
to categorize a record into one of the three synergy categories
(synergy, antagonism, non-interaction) given a synergy score.
For the other three models depicted in Fig. 3.3, which are
based on the principle of Loewe Additivity, the synergy scores are
more clearly separated. The computed scores of the synergistic
records distribute above zero in the upper right corner (categorized
as synergistic and computed synergy scores above zero) as well
as they scatter in the lower left corner for antagonistic cases
(categorized as antagonistic and computed synergy score below
zero). In all these three panels in Fig. 3.3 we see for the non-
interactive records that the computed scores of those three models
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Figure 3.3: Comparison to original scores. Computed
synergy scores γ of the Cokol data of the best models according
to the Kendall rank correlation coefficient in Section 3.2.1 and
the ROC analysis given in Supplement B.2 in comparison to the
original scores from [32]. The data points are colored based on
the original categorization. For all three categories, synergistic,
non-interactive and antagonistic, the Pearson correlation is
depicted between the original scores in that category and the
computed synergy scores in the respective color. Additionally,
we depict the local polynomial regression fitting of all scores
(in gray). The histograms of the scores are plotted on the
axis, separated by color based on the original categorization.
Synergy scores γ based on the Explicit Mean Equation model
show the highest correlation with the original scores.
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Figure 3.4: Mathews Griner data: model comparison.
Scatter plot of synergy scores γ of the Mathews Griner dataset.
The scores are computed with the lack-of-fit method. Dis-
played are the four best models according to the Kendall rank
correlation coefficient and ROC analysis in Section 3.2.1 and
Supplement B.2. The scores of one model are depicted on the
x-axis and the other on the y-axis. (continued next page)
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Figure 3.4 (previous page): The original categorization is
highlighted in different colors. The Pearson correlation score
between the synergy scores are depicted by color for every
categorization and the overall Pearson correlation is depicted
in black. To guide the eye, the axis at 0, the diagonal and
local polynomial regression fitting are depicted in gray. The
histograms of the scores are plotted on the axis, separated by
color based on the original categorization. The three models
based on the Loewe Additivity principle show highest cor-
relation (center right and lower row). All comparison with
fbliss (x1, x2) show lowest correlation (first three cases). There
is a large difference between the correlation between the ad-
ditive models and the comparison of Bliss Independence by
roughly 0.3.
are both positive and negative scatter symmetrically roughly
between −0.1 and 0.1. Barely any of the computed synergy scores
for antagonistic cases are positive. Therefore, the chances of a
record being antagonistic if the synergy score is above zero are
quite low as well as the risk of categorizing a record as antagonistic
if it is synergistic.
We further looked in detail into dose combinations for which
both the fGI (x1, x2) and fmean (x1, x2) yield positive synergy
values for antagonistic cases and into dose combinations for which
the fmean (x1, x2) model results in negative synergy values for
records which are labeled as synergistic. In total we found four
dose combinations. A visualization of the observed and expected
phenotype responses based on the Explicit Mean Equation model
is shown in Supplement B.4, Fig. B.6. The respective Hill curve
parameters for the sigmoidicity s and the maximal effect y∞ of
these four records are shown in Fig. 3.6. One of these four records
is a compound combined with itself. Hence, per definition of
the Loewe Additivity, no interaction is expected. From Fig. B.6,
one can see why this record was mis-categorized: for high dose
combinations, a greater effect is found, which is not found for
the conditional runs. Probably, the dose ranges are too small to
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Figure 3.5: Cokol data: model comparison. Scatter
plot of synergy scores γ of the Cokol dataset. The scores are
computed with the lack-of-fit method. Displayed are the four
best models according to the Kendall rank correlation coeffi-
cient and ROC analysis in Section 3.2.1 and Supplement B.2.
The scores of one model are depicted on the x-axis and the
other on the y-axis. The original (continued next page)
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Figure 3.5 (previous page): categorization is given based
on color. The Pearson correlation score between the synergy
scores are depicted by color for every categorization and the
overall Pearson correlation is depicted in black. To guide
the eye, the axis at 0, the diagonal and the local polynomial
regression fitting are depicted in gray. The histograms of the
scores are plotted on the axis, separated by color based on the
original categorization. fmean (x1, x2) and fGI (x1, x2) show
highest correlation (center right), fbliss (x1, x2) shows lowest
(first three comparison cases).
show such effects. We looked at the conditional responses of the
other three dose combinations and observed that for the originally
antagonistic records (three out of four) one of the conditional
responses exhibits small maximal effects with the minimal response
y∞ being above 0.70 (see right panel of Fig. 3.6).
This leads to the computed null-reference surface to be quite
high and hence causes synergistic scores if any effects are measured
that are smaller than max (y(1)∞ , y(2)∞ ). We suspect that the dose
concentrations are not well-sampled and larger maximal doses
should have been administered.
We looked the three dose combinations (excluding the one
where the compound is combined with itself) up in the Connec-
tivity Map [108, 191], which is one of the largest repositories of
drug response studies. We could find all three combinations in
the Connectivity Map. All of these dose combinations showed
non-interactive effects on all cell lines they were tested on. The
assays found in the Connectivity Map are run on cancer cell
lines. The dose combinations investigated here are run on yeast.
Hence, a full comparison cannot be made, but results are certainly
suggestive that the compound combinations are non-interactive.
In Fig. 3.4 and Fig. 3.5, the computed scores from different
null reference models are plotted against one another. We com-
pare the implicit formulation (General Isobole Equation) to the






































Figure 3.6: Conditional dose-response parameters of
misclassified records. Maximal response y∞ (left) and slope
parameters s (right) of Hill curves. Parameters are shown for
the conditional responses of the four cases for which the lack-
of-fit method resulted for fmean (x1, x2) and fGI (x1, x2) in
a synergy score of opposite sign to its categorization from
the Cokol dataset. Different records are depicted in different
colors. The original categorization of each record is depicted
per shape. The conditional responses of one record, and hence
their Hill curve parameters, are grouped depending on size of
the Hill curve parameter s (larger or smaller).
that are based on the explicit formulation of Loewe Additiv-
ity, fmean (x1, x2) and flarge→small (x1, x2). The coloring of the
scores is based on the original categorization as antagonistic, non-
interactive or synergistic as provided by Yadav et al. [227] and
Cokol et al. [32].
In Fig. 3.4, we show the scores from the Mathews Griner
dataset. In the two panels in the upper row and the left panel in
the middle row Bliss Independence is compared to the other three
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null models that build up on the principles of Loewe Additivity. It
is obvious, that the scores based on Bliss Independence are larger
than those of Loewe Additivity and mainly above zero. This is
due to the more conservative null reference surface as derived
from Bliss Independence (see Sinzger et al. [183, Fig. 6]). The
scores from models which are based on Loewe Additivity are very
similar to each other as they scatter along the diagonal (panels in
middle right and lower row). It is difficult though to tell apart
whether a record is synergistic or antagonistic as non-interactive
records scatter largely between −0.5 and 0.5. Only records with a
computed score outside that range can be categorized as interac-
tive. For the Cokol dataset, which serves as basis for Fig. 3.5, the
scores can be better separated. Despite the scores being generally
smaller than those from the Mathews Griner data the records
can be separated more easily, when using a Loewe Additivity
based model. Additionally, we see here the similarity between
these additive models given their strong correlation (right pan-
els in middle row and both panels in lower row). Further, the
scores based on flarge→small (x1, x2) achieve higher values than
those from the other two Loewe Additivity based models. This
becomes obvious when comparing the null-reference surfaces of
those three models, as depicted in Fig. 2.4 in Chapter 2. The sur-
face spanned by flarge→small (x1, x2) spans a surface above those
surfaces spanned by Explicit Mean Equation or General Isobole
Equation. Therefore, in synergistic cases where the measured
effect is greater and hence the response in cell survival smaller the
difference from the null-reference surface to flarge→small (x1, x2)
is greater than to the other two models. We suspect the synergy
models from the Cokol dataset to be better separable due to the
experimental design of the dataset. All compounds were applied
up to their known maximal effect dose [32]. This was not the
case for the Mathews Griner dataset, where all compounds were
applied at the same fixed dose range.
All in all, the lack-of-fit method performs better for any model
when applied to the Mathews Griner dataset and mostly better for
the Cokol dataset, with the exception of the fsmall→large (x1, x2)
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and Geary model. We suggest that the lack-of-fit method should
be preferred over the parametric method due to the overall per-
formance on both datasets. When using the lack-of-fit method,
the Explicit Mean Equation model performs either second best
(Mathews Griner dataset), or best (Cokol dataset). The other
two well performing models, the explicit flarge→small (x1, x2) or
the original implicit formulation of Loewe Additivity, the General
Isobole Equation, do not perform equally well on both datasets.
To exclude any bias from these models for different datasets, the
Explicit Mean Equation should be preferred.
3.3 Discussion
The rise of high-throughput methods in recent years allows for
massive screening of compound combinations. With the increase
of data there is an urge to develop methods that allow for reli-
able filtering of promising combinations. Additionally, the recent
success of a synergy study of in vivo mice by Grüner et al. [67]
underlines the fast development of possibilities to generate bio-
logical data. Therefore, it is all the more important to develop
methods that are sound and easily applicable to high-throughput
data.
In this chapter we use two datasets of compound combinations
that come with a categorization into synergistic, non-interactive
or antagonistic for each record.
Based on the fitted conditional responses, we compute the
synergy scores of all records. We compare six models that build
on the principles of Loewe Additivity and Bliss Independence.
These six models are used with two different methods to compute
a synergy score for each record. The first method is a parametric
approach and is motivated by the Combination Index introduced
by Berenbaum [5]. The second method quantifies the lack-of-fit,
i. e. the difference in volume between the expected response assum-
ing no interaction and the measured response and is motivated
by Di Veroli et al. [41].
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We compare the computed synergy scores from both methods,
each applied with the six reference models, based on Kendall rank
correlation coefficients. Based on these correlation coefficients
we investigate the reconstruction of ranking of the records (see
Section 3.2.1). We further conduct an ROC analysis (results
shown in Supplement B.2). With this, we quantify the methods’
and models’ capacity to distinguish records from different cate-
gories given a computed synergy score. Both, the Kendall rank
correlation coefficient and the ROC analysis, show a superiority
of those models that are based on Loewe Additivity relative to
those based on Bliss Independence. From these additive models
the Explicit Mean Equation is the overall best performing model
for both datasets.
For the above comparison of the six null reference models and
the two methods, we rely on the underlying categorization of
both datasets. All performance metrics are based on how well the
predicted synergy scores agree with the underlying categorization.
The categorizations of both datasets were created very differently
from one another. On one hand, the Mathews Griner dataset was
categorized on a visual inspection, on account of which we cannot
be certain about the assumptions made that guided the decision
making process. On the other hand, the categorization of the
Cokol dataset is based on the principle of Loewe Additivity. This
leads to the natural preference of null models that are based on
Loewe Additivity over those based on Bliss Independence, which
we find back in our analysis. Irrespective of the origin of the
classification, we stress that the labels were provided to us by
independent researchers and hence were not biased in any way to
favor the Explicit Mean Equation model.
Note that we conduct the research only on combinations of
two compounds. Research on higher-order combinations is usually
performed with the principle of Bliss Independence [97, 235] as
its extension is straight-forward. The General Isobole Equation is
also easily extendable to more than two compounds (theoretical
work by Gennings and Carter [60] and an analysis of three combi-
nations can be found in [49, 206]). An extension of the explicit
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formulations of Loewe Additivity to more than two compounds
would increase the number of explicit equations (Eq. 3.5 and
Eq. 3.6) equal to the number of compounds used. Hence, all six
null-reference models can be extended to higher-order compound
combinations. The same holds for the parametric and lack-of-fit
method. It has to be kept in mind, that the number of drug
combinations grows exponentially with the number of drugs. A
full experimental design with complete set of dose combinations
is, to the best of our knowledge, only reported in the work of
Fang et al. [49] and Tosi et al. [206].
Meanwhile, it is shown in [173] that Bliss Independence main-
tains accuracy when increasing the number of compounds that
are combined with each other. Loewe Additivity, however, loses
its predictive power for an increasing number of compounds.
The comparison of the parametric method with the lack-of-fit
method shows a superiority of the lack-of-fit method. To recall,
the motivation behind the parametric approach was the statistical
advantages of such an approach. It allows to define an interval
around α = 0 in which a compound combination can be considered
additive. For the lack-of-fit method, such statistical evaluation
cannot be done directly, but could be performed on the basis of
bootstrapping.
Chou and Talalay [28] measure the interaction effect locally
for a fixed ratio of doses of both compounds that are supposed to
reach the same effect, say one unit of the first compound causes
the same effect as two units of the second compound, which results
in the dose combination of 1:2. Along this fixed ratio of doses,
they compute the left-hand side of Eq. 3.3 given the two doses x1
and x2 that are assumed to reach a fixed effect y∗ together with x∗i
being the dose of compound i that reaches the fixed effect alone.
For the fixed dose ratio, they run over all expected effects, usually
from zero to one. A geometric interpretation of that method is
depicted in [66, Fig. 7, p. 341]. The resulting values of the left-
hand side of the General Isobole Equation in Eq. 3.3 are analyzed
graphically: all computed values are plotted versus the expected
fixed effect y∗ = [0, 1]. Values higher than one exhibit synergistic
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behavior, values below one antagonism. This method allows for
results that show antagonistic behavior for, say, smaller effects, as
well as synergistic behavior for higher effects, or vice versa. That
such a behavior of switching from antagonistic behavior in one
region to synergistic behavior in another can occur was also shown
in Norberg and Wahlström [151]. With one synergy score, as used
throughout this paper, we do not provide such a measure for local
antagonism and synergism. Our main motivation in this study is
to provide a single synergy score that allows for fast filtering of
interesting candidates for more in-depth research. To extend that
idea, the standard deviation could be taken into account, as in a
t-value or Z-score. Additionally, the superior lack-of-fit method is
much faster and simpler to implement than the parametric one.
Finally, to asses how distinguishable the synergy scores γ are,
we visualize the synergy scores based on the underlying category
(Section 3.2.2). The synergy scores from the lack-of-fit method
can, based on their sign, reliably be categorized as synergistic
or antagonistic. For records categorized as non-interactive, the
computed synergy scores are positive as well as negative. For the
two datasets, we saw different extents of separation between those
γ-scores, which makes it difficult to generalize the results. All in
all, the differentiation from no interaction poses a more difficult
task as choosing the threshold is arbitrary.
During the analysis we observed higher synergy scores when
applying the Bliss Independence principle as null reference model.
This is due to the more conservative null reference surface as
derived from Bliss Independence (see exemplary comparison of
isoboles from most of the models discussed here in [183, Fig. 6]).
Due to the synergy scores being relatively high, a differentiation
between categories based on the synergy score poses a bigger
challenge. There is a strong overlap of synergy scores from all
three categories. Additionally, most of the synergy scores γ, that
are computed with the lack-of-fit method, are above zero. Different
ranges of synergy scores for both datasets make it additionally
difficult to assess synergy or antagonism for a record based on
the unique information of the synergy score.
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We want to emphasize the performance benefit of the recently
introduced Explicit Mean Equation (Chapter 2) over the implicit
formulation in form of the General Isobole Equation. On both
datasets, it is the overall best performing model when compared
to the provided categorizations. The explicit formulation of this
additive model was shown to speed up computation by a factor
of more than 250 (see Fig. A.1 in Supplement A.5). Together
with the implementation of the lack-of-fit method, which is easier
to implement and a lot faster than the parametric method, this
combination of model improvement and method can be of great
benefit for the research community.
Although the performance of models and methods are consis-
tent across the two (quite different) datasets considered in this
study, reliable comparison of different models and methods would
benefit from the availability of drug screening datasets that are
available with ground truth labeling.
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4 Bayesian Linear Mixed Model
for Motif Activity Analysis
Cell type-specific gene expression programs are mainly driven by
differential expression and binding of transcription factors (TFs).
The human genome contains ∼1, 600 TFs, which represent 8% of
all genes [110]. These proteins bind DNA in a sequence-specific
manner and typically have a 1000-fold or greater preference for
their cognate binding site as compared to other sequences [59]. By
binding to cis-regulatory regions, i. e. promoters and enhancers,
they can control the chromatin environment and the expression of
downstream target genes [110]. Cell type identity is determined
by the expression of a select number of TFs. This is evidenced
by the growing number of cell reprogramming protocols that
rely on the activation of a few TFs to reprogram the cell state,
for instance from a somatic cell to a pluripotent stem cell [114,
197]. Mis-regulation of TF expression or binding is associated
with a variety of diseases, such as developmental disorders and
cancer [114]. Hence, it is of great importance to understand the
mechanisms of gene regulation driven by TFs.
TFs bind to specific DNA sequences called sequence motifs.
These motifs are relatively short, with a length usually ranging
from six to twelve nucleotides, and flexible in the sense that several
TFs can bind to the same motif [110]. The binding sites of TFs can
be determined genome-wide using chromatin immunoprecipitation
with specific antibodies followed by high-throughput sequencing
(ChIP-seq). Although ChIP-seq studies suggest that many TF
binding events appear to be not functional, the presence of a
1This chapter is based on Simone Lederer, Tom Heskes, Simon J van
Heeringen, and Cornelis A Albers. “Investigating the effect of dependence
between conditions with Bayesian Linear Mixed Models for motif activity
analysis”. In PLOS ONE, 15 (2020). DOI: 10.1371/journal.pone.0231824.
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sequence motif is still predictive of gene expression [110]. With
a linear regression model, in which the sequence information is
used to model gene expression, one can learn the TFs that play
a major role in gene regulation [3, 127, 156, 177, 200]. Typical
approaches either use linear regression with L2-regularization
(Ridge Regression) or a combination of L1- and L2-regularization
(ElasticNet). These approaches tend to explain only a small
fraction of the variation of gene expression. However, due to
the large number of genes, the coefficients are generally highly
significant and can be interpreted as a measure of transcription
factor activity.
One of the key assumptions of a linear regression model is
the independence between samples. If samples originate from the
same cell line, tissue, or other biological source, this assumption
may be invalid. In addition, related cell types will also have
similar gene expression profiles, where the expression of many
genes will be highly correlated.
Here, we propose a Bayesian Linear Mixed Model that builds
upon the previously described Bayesian Ridge Regression [3, 200],
but allows for correlated motif activity between samples. Our
model relaxes the rigid independence assumption common to
earlier approaches.
We compare our full Bayesian Linear Mixed Model with
Bayesian Ridge Regression on simulated data, for which we con-
trol the degree of correlation between samples. We show that
the Bayesian Linear Mixed Model formulation outperforms the
Ridge Regression for data with randomly distributed noise. This
is the case especially for highly correlated data. We further show
that the Bayesian Linear Mixed Model loses its superiority over
the Ridge Regression if only a small part of the gene expression
signal can be explained by motif influence, while other influential
factors contribute largely to the gene expression. We confirm the
observations made during the simulation study on four real-world
datasets, in which a significant amount of the biological signal
cannot be uniquely explained by a linear combination of motifs.
We can explain this phenomenon mathematically and give more
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technical details regarding the computation of the model.
4.1 Methods
Here, we introduce the mathematical models that are used
throughout this paper. First, we introduce the linear model
that represents the signal of expression data YG,C as a linear
combination of motif scores and their influential weights. Second,
we present a Bayesian perspective on the model. Finally, we show
that the Ridge Regression formulation is a special case of the
newly introduced Bayesian formulation. We then outline in detail
how we simulate data, which we use to compare the complete
Bayesian perspective and the Ridge Regression model.
In the following sections we will interchangeably use sample
or condition.
4.1.1 Inference of Motif Activities
The general model used throughout this paper models gene ex-
pression yg,c in condition c as a linear function of motif scores
mt,g of motifs t = {1, . . . , T}, weighted by the motif influence ωt,c,




mt,gωt,c + noise, (4.1)
with the normalized gene expression data ȳg,c = yg,c − ȳg − ȳc,
where ȳg is the average signal over the promoter of gene g over
all conditions C and ȳc is the average signal of condition c over
all genes G. In the following, we will refer to the normalized gene
expression simply as YG,C . The term “noise” represents all signal
that cannot be explained by the model, i. e. the linear combination
of the motif scores MT,G. This can be any technical noise, motif
influence, for which the linear assumption might be too simplistic,
but also any other source that drives the gene expression yg,c and
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is not modeled. The model was originally introduced by The
Fantom Consortium and the Riken Omics Science Center [200]
and subsequently expanded by Balwierz et al. [3].
For the application of the above model to the H3K27ac dataset,
we re-use the above notation, where G represents the dimension-
ality in enhancer space (not gene space). Instead of computing
motif scores MT,G in the promoter region, we compute them in the
enhancer region and the expression signal YG,C is the H3K27ac
ChIP-seq signal.
4.1.2 Bayesian Linear Mixed Models
The main idea behind a Bayesian formulation is to include prior
knowledge about the data, called the prior. Here, we model ωt,c,
the influence of motif t ∈ {1, . . . , T} in condition c ∈ {1, . . . , C},
as a normally distributed prior with mean zero, with σ2IT being
the covariance over all motifs and VC the covariance over all
conditions:






We use the vector notation for the matrix normal distribution,
for which we make use of the Kronecker product between the
covariance matrices. Another mathematical notation of the model
isMN T,C (0T,C , σ2IT ,VC). Note that in the vectorized notation
the mean 0T,C is written in vector notation, too: vec (0T,C) = 0TC .
In this paper, we assume independence between motifs. Ex-
tending the assumption to dependence between motifs with co-
variance matrix Ψ could easily be implemented.
Combining the prior knowledge about ωT,C in Eq. 4.2 with
the model in Eq. 4.1, it follows that the expression data YG,C
conditioned upon ωT,C obeys:
vec (YG,C |ωT,C) ∼ N
(
0, σ2VC ⊗ΠG + δΣC ⊗ IG
)
, (4.3)
with ΠG = MᵀT,GMT,G, where
ᵀ is the transpose. Hence, the
covariance between genes is driven by the similarity among motif
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counts MT,G. ΣC is the covariance of noise between conditions
and δIG is the covariance matrix between genes. Thus, we assume
independence between genes in the noise term. The posterior mean
of the motif influence ωT,C , denoted ω̂T,C , given the expression
vec (YG,C) then reads:





⊗ΠG + δΣC ⊗ IG
]−1 vec (YG,C) .
This model is explained in more detail in Supplement C.1.
Special Case: Ridge Regression
Ridge Regression, also known as Tikhonov Regularization [161,
203–205], prevents over-fitting in a linear regression by using an L2-
regularization on the estimated parameters. For more details on
L2-regularization and Ridge Regression, we refer the reader to Ng
[148]. Note that in a Ridge Regression the samples are assumed
to be isotropic, i. e. independent and identically distributed. The
covariances in the model, VC and ΣC , therefore reduce to identity
matrices, which only differ in the constant with which they are
multiplied:
VC = σ
2IC , ΣC = δIC . (4.5)
With the above model we formulated a Bayesian Linear Mixed
Model to explain the motif influence on expression data YG,C
based on motif scores. The Bayesian Linear Mixed Model provides
a relaxation of the so far used assumption of independence in Ridge
Regression. It allows for modeling dependency structures between
conditions and in the noise, which can increase the power of the
model, as shown in Section 4.2. In the following, we will refer
to the model as Bayesian Linear Mixed Model when allowing for
correlation between samples and noise, i. e. the covariance matrices
VC and ΣC are not restricted except for being symmetric positive
definite matrices. We refer to the model as Ridge Regression
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when we specifically assume independence between conditions and
noise, i. e. VC = σ2IC , and ΣC = δIC ,
4.1.3 Code Availability
The project implementation (https://github.com/Sim19/
SimGEXPwMotifs) is provided in the programming language
Python [140, 155], where we make use of the packages pandas [132],
matplotlib [85], seaborn [216] and numpy [154].
4.1.4 Model Fitting
We run the optimization of Eq. 4.3 to compute Eq. 4.4 with
the Python package limix [21, 120, 121] and use the module
VarianceDecomposition(), which we use with the parameter
settings for restrictions on VC to “freeform”, which models con-
currently ΣC to be of “random” shape. These parameter settings
only restrict VC and ΣC to be positive-definite matrices, with
1
2
C × (C + 1) parameters to be estimated. With these settings,
there are no restrictions on the rank of the matrix, i. e. the degree
of correlation among samples. For the optimization start, VC
and ΣC are both set to be the estimated covariance matrix of
YᵀG,C , each divided by half. The optimization is based on the
L-BFGS algorithm to minimize the log likelihood with an L2-
regularization along the non-diagonal elements of the covariance
matrix ΣC , which is also known as isotropic Gaussian prior with
zero mean. The implementation makes use of the reduction of com-
putational complexity by using the Kronecker product notation
and its identities for the case of matrix variate data, which is highly
efficient [21, 120]. For more detailed information about Linear
Mixed Models and its implementation in limix, refer to Lippert
et al. [122]. We run Ridge Regression in the simulation study with
the Python implementation in the package sklearn.linear_-
model.RidgeCV() [159]. For the data application, we make use of
the limix.VarianceDecomposition() implementation with the
setting “freeform” for VC and “random” noise for ΣC for fitting
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the Bayesian Linear Mixed Model. For the computation of Ridge
Regression, we restrict VC and ΣC to be identity matrices. Both
computations (limix.VarianceDecomposition() with restric-
tions for VC and ΣC to identity matrix and sklearn.linear_-
model.RidgeCV()) yield the same results (see Supplemental
Fig. C.1 in Supplement C.3).
4.1.5 Visualization
For the visualizations in this article, we work with the plotting
facility from pandas and seaborn [216]. For boxplots and other
results from the simulation study, we make use of the R-ggplot2
package [219] and R-cowplot [220]. The visualization of clustered
data is done with python’s seaborn.clustermap() using the
“complete” method for the dendogram computation on Euclidean
distance.
4.1.6 Simulating Data
For the simulation study we generate data based on the model
introduced in Eq. 4.1 - Eq. 4.4, given a covariance matrix VC . The
prior weight ω̃T,C and the expression signal YG,C are generated
according to Eq. 4.2 and Eq. 4.1. The expression data YG,C
from Eq. 4.1 is then used to estimate VC and ΣC . Based on
these computations, the posterior motif influence ω̂T,C is then
computed and compared to the simulated motif influence ω̃T,C
with a Pearson correlation [158] over all conditions. We provide
the same analysis with the Spearman’s rank correlation [139] and
the mean-squared error in Supplement C.3, Fig. C.2 and Fig. C.3.
As gene set we use the 978 landmark genes from the LINCS
project [105]. In a secondary simulation we increase the size of
the gene set to 5000 genes, which originate from an analysis of the
most variational genes across all samples from the GTEx project
(Genotype Tissue Expression, https://gtexportal.org/home/).
We generate data for C = {10, 30, 50, 70, 100, 120} conditions.
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4.1.7 Covariance Types of VC
For the generation of simulated motif influence ω̃T,C (Eq. 4.2), we
need to give a covariance matrix σ2VC ⊗ IT . As the covariance
along TFs is modeled to be isotropic (independent and identically
distributed), one can generate ω̃t,C randomly T times with ω̃t,C ∼
N (0, σ2VC). For the covariance between the weights ω̃T,C in
Eq. 4.2 and hence expression data YG,C in Eq. 4.3, we consider
four types of covariance matrices for VC , according to assumptions
made about the correlation between samples: (i) Isotropic V:
same number on the diagonal, all off-diagonal elements set to zero.
Samples drawn from such a covariance matrix are independent.
This matches the implicit assumption of the Ridge Regression.
We will refer to this as “V: independent”. (ii) Full matrix V with
all positive off-diagonal elements. Samples drawn from such a
covariance matrix are positively correlated, without any specific
(block) structure. This is a clear mismatch with the assumptions
underlying Ridge Regression, and results are expected to favor
the (full) Bayesian Linear Mixed Model. We will refer to this as
“VC : correlated (no groups)”. (iii) Block structure with many
blocks, each modeling a group of biological replicates. Samples
within each block are highly correlated, with small correlation
values between the blocks. Blocks vary in size. Average block size
is two. We will refer to this as “VC : correlated (many groups)”.
(iv) Block structure similar to (iii), but now with just two blocks.
We will refer to this as “VC : correlated (two groups)”.
For the generation of the correlated covariance matrices with
groups, we provide pseudocode in Supplement C.2. An exemplary
visualization of a covariance matrix with samples that correlate
in many groups is given in Fig. 4.1A and B, left panel.
4.1.8 Noise ΣC - Unstructured and Structured
To generate the gene expression data YG,C |ω̃T,C , we compute the
signal as the product of the motif scores MT,G (explained here-
after) and their weights ω̃T,C (explained previously). Due to the
randomness in the signal that is not explained by motifs, we add
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some random noise, which is drawn from a normal distribution
with covariance δΣC ⊗ IG. We generate ΣC in two different ways:
(i) we assume no particular structure, Σ
C,random, which is a ma-
trix filled with values drawn from a standard normal distribution,
multiplied with itself. This is the Wishart distribution with C
degrees of freedom. (ii) We add the same covariance matrix VC
that is used to model the correlations between the conditions
to Σ
C,random from (i): ΣC,VC ,ρ = ΣC,random + ηρVC . The
noise matrices are then normalized by their trace. The detailed
description of the generation of the noise matrices as well as the
control of structuredness in it is given in Supplement C.2. For the
simulation study depicted in Fig. 4.1 and discussed in Section 4.2
we generate the structured noise with ρ = 0.7. A visualization of
both types of noise matrices is given in Fig. 4.1A and B, both in
the respective right panel.
Signal-to-Noise Ratio
Previous research has shown that roughly 10-20% of the signal
of gene expression can be explained by motif influence in the
promoter region [3]. We therefore generate the data in such a way,
that 20% of the signal in expression data YG,C is due to motifs,
and the rest unexplainable noise. We achieve this by adjusting
the parameter σ2 and δ. We fix δ and determine σ2 by bisection
such that it explains 0.2 of the variance coefficient (Eq. 4.1). More
details can be found in Supplement C.2.
4.1.9 Motif Scores
For the computation of the transcription factor motif scores MT,G
we use log-odds scores based on the positional frequency matrices,
which are computed with the software GimmeMotifs, v13 [17, 80].
We make use of the database gimme.vertebrate.v3.1, included
with GimmeMotifs. In general, we filter for genes that are known
to be protein coding and on chromosomes 1-22 and X. For the
GTEx dataset we assume the promoter region to be 400bp up-
stream and 100bp downstream of the Transcription Start Site of
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the given gene sets. We take the Transcription Start Site from
the GENCODE database (version 26) [53] and generate a bed file
with the promoter regions with BEDTools, v2.17.0 [165] and the
subcommand slop. For the Cacchiarelli and Toufighi dataset, we
scan for motifs in the closest accessible region, as measured using
DNase1. We downloaded the regulatory index (version 20190703),
created by integrating 733 DNase-seq datasets [136], from https:
//www.meuleman.org/project/dhsindex/. For each gene we se-
lect the DNaseI summit with the highest mean signal within 1kb
of the gene Transcription Start Site. We use 200bp centered at
the summit for motif scanning. For the H3K27ac data we use
200bp centered at the summit of the corresponding DNaseI peak,
see Bruse and Heeringen [17] for more details.
4.1.10 Cross-Validation and Permutation
In Section 4.2, we compare the performance of the Bayesian Linear
Mixed Model and of the Ridge Regression on four real-world
datasets. To assess the performance of both model assumptions,
we make use of a ten-fold cross-validation by creating ten random
subsets across the genes. Each of these ten subsets is used as
a test dataset, while the model is trained on the union of the
remaining nine subsets. As there is no knowledge about the
motif influence ω̃T,C , we compute the expression ŶG,C with the
predicted posterior motif influence ω̂T,C (Eq. 4.1) and compare
the Pearson correlation between predicted expression ŶG[test],C
on the test set and the original expression YG[test],C of the test
set.
Per cross-validation round, we additionally run 1000 permuta-
tions (without replacement) in the motif scores MT,G along the
genes.
4.1.11 Experimental Data
For the application analysis presented in Section 4.2, we make
use of four experimental datasets.
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H3K27ac ChIP-Sequencing Signal at Hematopoietic En-
hancers
We use experimental enhancer activity data from the human
hematopoietic lineage [17, 129]. This dataset is based on 193
ChIP-seq experiments in 33 hematopoietic cell types using an
antibody specific for histone H3 acetylated at Lysine 27 (H3K27ac).
The H3K27ac histone modification is deposited by the histone
acetyltransferase p300 (EP300) and is associated with enhancer
activity [37]. ChIP-seq reads were counted in 2kb regions centered
at accessible regions, log-transformed and normalized using scaling
by Z-score transformation. The peaks, or accessible regions,
represent putative enhancers. We subset the peaks to the most
variable 1000 peaks over all samples. We selected all replicates of
the cell types “monocytes” and “T-cells”, which are 23 samples in
total. Different samples of the same cell type represent different
donors.
Human Tissue Gene Expression Data (GTEx)
Second, we make use of gene expression data from human tis-
sues. The data is from the Genotype Tissue Expression (GTEx)
database [125], and is available on https://gtexportal.org/
home/. It is RNA-seq data from many different tissues. The data
was downloaded with project number SRP012682 with the R-
package R-recount, v.1.63 [33, 34, 46]. We scale the raw counts
by the total coverage of the sample (function scale_counts(),
setting “by=auc”) and keep entries with at least 5 counts. We
transform the data with the DESeq2-package, v.1.20.0 and use
the variance stabilizing transformations [1, 84, 201], implemented
in the package function vst(), with blind transformations to the
sample information.
We selected the 5,000 most variable genes over all samples of
the entire GTEx experiment. We then choose 75 random samples,
of which there are 35 different tissues from 21 different organs.
As we model the normalized expression data YG,C (see Eq. 4.1),
we subtract the mean along genes and along conditions from the
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expression data. For the analysis, we further normalize the motif
score matrix.
Time-Series Data
We additionally compare the performances of both model assump-
tions on two time-series datasets [19, 207]. Samples from different
time-series are known to be highly correlated.
Human Cellular Reprogramming RNA-seq Data
We make use of RNA-seq data for a reprogramming time-course
from human induced fibroblasts (hiF) to induced pluripotent stem
cells (hIPSC) [19]. Gene expression levels were measured at sev-
eral different time points, and human embryonic stem cells (hESC)
were included for comparison. The expression data is available at
https://www.cell.com/cms/10.1016/j.cell.2015.06.016/
attachment/97ec2bc2-5577-4d4a-966b-3cd2a63a76c2/mmc2.
xlsx. We transform the data to a log2-scale. For more details on
the data and the original analysis, refer to Cacchiarelli et al. [19].
Human Keratinocyte Differentiation Microarray Data
The microarray data of the differentiation of human primary
keratinocytes was originally generated by Janich et al. [93] and
is re-used in Toufighi et al. [207]. Gene expression levels were
measured every five hours over a time span of 45h, resulting in
ten samples. Measurements were taken in triplicates. Data is
available at the article’s website and published at https://doi.
org/10.1371/journal.pcbi.1004256.s022. The data has been
processed using background correction and quantile normalization,
and was log2-transformed [207].
4.2 Results
In this section, we apply the model that we introduced in detail
in Eq. 4.1 - Eq. 4.4, to simulated data and to four real-world
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datasets. We compare the two assumptions about the shape of
covariance, as discussed before: the novel allowance of dependence
(Bayesian Linear Mixed Model) to the restriction of independence,
that has been applied so far (Ridge Regression).
4.2.1 Simulation
To quantify the differences in the model when allowing for depen-
dence between conditions, instead of assuming independence, we
simulate data according to Eq. 4.1. We generate different datasets
for G = 978 genes, for C = {10, 30, 50, 70, 100, 120} samples, and
T = 623 motifs. We vary the degree of correlation between the
samples, expressed in the covariance matrices VC and ΣC . We
also vary the influence of these covariance matrices on the signal:
As covariance matrix VC we generate (i) an identity matrix, (ii) a
full matrix with positive off-diagonal elements (unrestricted corre-
lation between samples), (iii) a block matrix with k = 1
2
C blocks
along the diagonal, which models groups of biological replicates
and (iv) a block-structured matrix matrix with k = 2 blocks along
the diagonal, modeling k = 2 groups of biological replicates. As
noise matrix ΣC we first generate unstructured or random noise.
In a second step, we generate the data with a structured noise
matrix ΣC . For every parameter set we generate 100 replicates to
verify the robustness of the two model assumptions. We compare
the performance of the two assumptions on the shape of covariance
with a Pearson correlation score. The correlation is computed
between the simulated motif influence ω̃T,C and the estimated
posterior motif influence ω̂T,C . The higher the correlation val-
ues the better the performance of the model. In Supplemental
Fig. C.1, we confirm that the Bayesian Linear Mixed Model with
fitting independent samples and independent noise is equal to
Ridge Regression.
We summarize the simulation study visually in Fig. 4.1.
We separate the simulation study first on data generated with
unstructured noise (exemplary visualization of data in Fig. 4.1A,
Pearson correlation values in Fig. 4.1C) and second on data
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Figure 4.1: Simulation study. Data is generated over
G = 978 informative genes and T = 623 motif scores and 100
repetitions, with either unstructured noise ΣC (A,C) or struc-
tured noise ΣC (B,D). (A,B): exemplary covariance matrix
between samples, VC , and noise matrix ΣC being unstruc-
tured (A) or structured (B). Data is shown for C = 50 samples
with a covariance between conditions with k = 25 blocks, i. e.
25 sample groups, in which samples are (continued next page)
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Figure 4.1 (previous page): completely correlated. (C) and
(D): The Pearson correlation values between generated and
estimated motif-condition-weights are shown for different de-
grees of correlation between samples. The values are depicted
per method used to predict the motif-condition-weights: the
Bayesian Linear Mixed Model (BLMM, in red), which allows
for dependence between samples, and the Ridge Regression
(RIDGE, in blue), which assumes independence between sam-
ples. Data is generated with the following covariances between
samples: (i) independence between samples, VC = IC , (ii) un-
restricted correlation between samples, (iii) correlated data
with many sample groups, and (iv) highly correlated samples,
assuming samples originate from two biologically different
samples, Results are shown based on data generated with
unstructured noise ((C), see (A)), or with structured noise
((D), see (B)). (E): Exemplary comparison of Pearson correla-
tion values between simulated and predicted posterior motif
influence ω̂T,C . The data is generated with highly correlated
samples, modeling two groups of biological replicates. Corre-
sponding replicates are combined by a gray line. The data in
the left panel is generated with unstructured noise ΣC (see
(A)) and in the right panel with structured noise (see (B)).
with structured noise (exemplary data shown in Fig. 4.1B, model
performances shown in Fig. 4.1D). Summarizing, we compare the
performance of both models on the two types of data (unstructured
versus structured noise ΣC) in Fig. 4.1E. We show an example of
the model performance for data generated with a covariance matrix
VC that models all samples to originate from many blocks, on
unstructured (left) and structured noise (right). In Supplemental
Fig. C.5, we show on the example of C = 50 samples that a higher
dimensional dataset, generated with G = 5000 genes, exhibits the
same performance as for G = 978 genes.
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Unstructured Noise ΣC
Given the covariance VC , we generate a gene expression signal
YG,C according to Eq. 4.1 with random noise ΣC,random (see
Fig. 4.1A). In Fig. 4.1C, we compare the performance of the
Bayesian Linear Mixed Model, which allows for dependencies
between samples, to Ridge Regression, which assumes indepen-
dence. We depict the Pearson correlation values between es-
timated and simulated motif influence ωT,C for 100 randomly
generated datasets per boxplot. In every panel, we compare both
model assumptions, (i) dependence (in red, labeled BLMM) and
(ii) independence (in blue, labeled RIDGE). We present the re-
sults separated by the degree of correlation in VC , which was
used to generate the data. Allowing for dependencies between
conditions leads to a better prediction performance, especially for
correlated data (Fig. 4.1C, E), independent of the sample size
C. For uncorrelated data (VC = σ2IC), the allowance for depen-
dency yields a slightly better performance for small sample sizes,
C ∈ {10, 30, 50} (Fig. 4.1C, upper left panel). For higher sample
sizes, the performances are equal. In Fig. 4.1E, left panel, we show
explicitly that the Pearson correlation values that result from the
dependence assumption (BLMM, in red) are always higher than
those from the independence assumption (RIDGE, in blue). The
exemplary visualization shows the correlation between estimated
and simulated motif influence ω̃T,C that was generated with a co-
variance matrix VC with two blocks along the diagonal, i. e. k = 2
correlated groups of samples over C = 50 conditions. We run
both model assumptions on the same datasets. The correlation
values from the same datasets, depicted per model assumption,
are connected with gray lines.
Structured Noise ΣC
For the generation of the gene expression signal with structured
noise, we add the structure of correlation between conditions
to the noise (see Fig. 4.1B). This is motivated by the fact that
we can explain roughly 20% of the signal in expression data
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YG,C data by motif influence, but not the remaining 80% of the
signal. This remaining signal is often similar to the covariance
between samples. In Fig. 4.1D, we depict the Pearson correlation
values that are computed between simulated motif influence ω̃T,C
and posterior motif influence ω̂T,C . They result from applying
the dependence (BLMM, in red) and independence assumption
(RIDGE, in blue) to data that is generated with such a structured
noise at a degree of ρ = 0.7. The results are again shown for
differently correlated datasets between conditions VC , analogous
to the previous section. With that structure in the noise ΣC ,
both methods perform equally with low correlation values. As
shown in Fig. 4.1E, right panel, the Bayesian Linear Mixed Model
performs equally or slightly worse than Ridge Regression.
Indeed, when applying a degree of structure in the noise ΣC
(explained in detail in Supplemental Eq. C.17 - Supplemental
Eq. C.18 in Supplement C.2) by varying ρ between zero and one
in a step size of 0.1, there is loss of performance of the Bayesian
Linear Mixed Model for an increasing structured signal in the
noise (see Supplemental Fig. C.4). In contrast, the correlation
values resulting from Ridge Regression applied to this data with
structured noise are very similar, if not equal, to those from data
that was generated with unstructured noise (Fig. 4.1C). Both
model assumptions perform approximately equally when applied
to data with structured noise. For an exemplary visualization
we depict the correlation values per sample in Fig. 4.1E, right
panel, with lines connecting the two results from the two model
assumptions, which were applied to the same dataset. The reason
for this performance loss is the computation of the posterior motif
influence ω̂T,C (Eq. 4.4). If ΣC takes a structure that is too similar
to VC , these two terms can be summarized in the covariance of
vec (YG,C |ωT,C) in Eq. 4.3. This covariance returns as inverse in
Eq. 4.4 and therefore VC and ΣC cancel out with VC from the
motif-dependent term VC⊗MᵀT,GIT . We give more mathematical
details in the Discussion.
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4.2.2 Application
We compare the Bayesian Linear Mixed Model and the Ridge
Regression on four real-world datasets. First, we apply the method
to a ChIP-seq dataset of the histone modification H3K27ac in
the human hematopoietic lineage. This histone mark correlates
with enhancer activity [37]. We refer to this dataset as H3K27ac.
Second, we use RNA-seq gene expression data from the GTEx
consortium. It is known from RNA-seq data, that there is generally
a high contribution of “technical” noise, such as measurement
noise that is introduced purely by the experiment (laboratory [92,
180] and batch [115]) and by biological variation [77]. Hence,
we expect a significant contribution of such “technical” noise to
the signal. We refer to this RNA-seq dataset as GTEx. We
additionally compare the two model assumptions on two time-
series datasets: the Cacchiarelli dataset is an RNA-seq dataset
applied to reprogramming from fibroblasts to IPSCs. Additionally,
we analyse microarray data, which we refer to as Toufighi data,
that measures the human keratinocyte differentiation over 45
hours. For all four datasets, we compare the dependence and
independence assumption (Bayesian Linear Mixed Model and
Ridge Regression) by means of a cross-validation.
Acetylation Data H3K27ac
We split the acetylation dataset H3K27ac into two sample groups,
originating from two different cell types: (i) monocytes from the
myeloid lineage and (ii) T-cells from the lymphoid lineage. Within
these two groups the ChIP-seq signal YG,C is highly correlated as
the samples represent the same cell types from different donors.
The results from the application of the Bayesian Linear Mixed
Model and the Ridge Regression to the H3K27ac dataset are
summarized in Fig. 4.2.
To assess and compare the model performances, we run a ten-
fold cross-validation. Per run we compute the Pearson correlation
between measured and predicted ChIP-seq signal YG,C of the test
and training set. The correlation values from the cross-validation
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Figure 4.2: Data application on H3K27ac data. (A):
Pattern of H3K27ac ChIP-seq signal in putative enhancers
over two hematopoietic cell types, T cells and monocytes. (B):
Pearson correlation between training set and predicted ChIP-
seq signal on training set and between test set and predicted
test ChIP-seq signal of a ten-fold cross-validation. In gray, the
mean Pearson correlation between predicted and real signal is
shown using each method with a (continued next page)
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Figure 4.2 (previous page): 1000-fold randomization of mo-
tif scores (overprinted lines show high concordance between
methods). (C) and (D): Motif weights for 50 enhancers across
the two cell types, assuming dependence (C) or independence
(D) between the conditions. Enhancers are chosen based on
largest difference in mean H3K27ac ChIP-seq signal per tissue
group. Common motifs of Bayesian Linear Mixed Model (C)
and Ridge Regression (D) are depicted in blue, others are
depicted in yellow.
are shown in Fig. 4.2B. The performance of the test set (solid
line) is depicted to gain insight into the prediction performance
of each model, the performance of the training set (dotted line)
to check for over-fitting. We additionally depict a summary of
Pearson correlations over 1000 permutations in the motif scores
MT,G along the genes G per cross-validation (gray line). Both
model assumptions yield very similar performances and shuffling
the motif scores completely negates the models’ performances.
Hence, on the basis of cross-validation, no clear statement about
superiority of one model assumption to another can be made.
A visualization of the estimated VC and ΣC , depicted in Sup-
plemental Fig. C.6 - Supplemental Fig. C.9, emphasizes again
the great difference between the two models and their model fits.
While for Ridge Regression both matrices are identity matrices
with a scaling factor, both covariance matrices from the more
flexible Bayesian Linear Mixed Model exhibit strong correlation
structures (Supplemental Fig. C.8 and Supplemental Fig. C.9).
These two latter matrices are very similar. Clustering the co-
variance matrices yields two clearly separated blocks along the
diagonal, showing a strong correlation among the samples within
the cell types, and independence, or even a slight anti-correlation,
between the two cell types. This pattern follows the partitioning
of the samples into biological replicates for the two different cell
types.
Looking in more detail into the importance of the posterior
motif influence ω̂T,C , we compare the motifs by ranks. They are
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ordered based on the difference of the motif’s mean influence onto















with Cmonocytes + CT-cells = C. They are sorted in decreasing
order, i. e. the higher the mean difference, the higher the rank of
a motif, where rank 1 is the most important motif and rank 623
the least important. For Fig. 4.2C and D, we choose the top 50
ranking motifs, respectively. We color motifs that are shared for
both methods in blue and different motifs in yellow. All in all,
40 motifs are shared among the 50 chosen. The posterior motif
influences, depicted in Fig. 4.2C and D, clearly separate the motif
influences based on the underlying cell types for both models.
Despite the clear differences in model estimates, the performances
in predictive power are very similar. We hypothesize that the
similarity of the performances results from the similarity between
estimated covariance matrix VC and noise ΣC in the Bayesian
Linear Mixed Model, which leads to canceling out the covariance
structure in the posterior. We elaborate on this phenomenon in
the discussion.
RNA-seq Data GTEx
We further compare the performance of both model assumptions
on a human tissue-specific RNA-seq dataset from GTEx. In
comparison to the H3K27ac dataset discussed in the previous
section, RNA-seq is known to exhibit more “technical” noise,
i. e. noise that is added to the signal purely by conducting the
experiment. Hence, the expected noise structure should be better
separable from the motif signal.
For the G = 5000 most variable genes across the entire GTEx
dataset, we apply the Bayesian Linear Mixed Model and the Ridge
Regression on C = 75 randomly chosen samples. Among those,
there are several biological replicates, resulting in 35 different
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tissue types across 21 organs. The results of the GTEx dataset
are summarized in Fig. 4.3.
Analogous to the analysis on the H3K27ac dataset, we conduct
a ten-fold cross-validation together with a 1000 permutations
over the motif scores MT,G per cross-validation. The Pearson
correlation values of the cross-validation of the expression data
YG,C (colored lines) are very similar for both model assumptions
(see Fig. 4.3A) on the test (solid line) and on the training (dotted
lines) dataset. Again, shuffling the motif scores along the genes
negates the models’ performances. The Pearson correlation of
all motif scores between the two model assumptions per tissue is
high with the median at 0.83, the first quantile at 0.79 and the
third quantile at 0.90 (see Fig. 4.3B). In Fig. 4.3C we highlight
examples of high (left) and low (remaining four panels on the right,
same replicate) Pearson correlation values between the estimated
motif weights from the two models (colored accordingly).
When we compare the estimated covariance matrices, there
are strong differences in VC and ΣC (Supplemental Fig. C.11 -
Supplemental Fig. C.14). Independent of the model assumptions,
there is a difference of 104 in order of magnitude of the signal
assigned to the covariance between condition and the estimated
noise.
We compute the inter-quantile range of the posterior motif
influences of all T = 623 motifs per tissue to investigate the
posterior motif influence ω̂T,C in more detail. We summarize the
posterior motif influences over tissues with replicates with the
median. We then filter those motifs that lie outside the range of
2.5 times the inter-quantile range above and below the median.
Combining the two sets from Bayesian Linear Mixed Model and
Ridge Regression results in 56 motifs, of which 50 are in the
intersection of the two sets.
The clustering of posterior motif influence ω̂T,C results in
comparable clusters (Supplemental Fig. C.10), with the clustering
on tissues from Ridge Regression being seemingly better due to a
clearer clustering of replicates.
The overall correlation between the posterior motif influence
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Figure 4.3: Data application on GTEx data. (A): Pear-
son correlation values between training set and predicted gene
expression of training set and between the test set of the gene
expression data and the predicted gene expression of ten-fold
cross-validation for Bayesian Linear Mixed Model (BLMM,
in red) and Ridge Regression (RIDGE, in blue). In gray, the
mean Pearson correlation between predicted and real signal
using both methods (overprinted lines show high concordance)
with a 1000-fold randomization of motif scores is shown. (B):
Pearson correlation of estimated motif scores on the basis of
the Ridge Regression and the Bayesian Linear Mixed Model.
Per correlation value, all motif scores are taken per replicate.
Examples shown in (C) are colored according to respective
color. (C): Exemplary scatter plots of tissue replicates, on
which the Pearson correlation for the posterior motif influence
ω̂T,C is high or low between the two methods, Bayesian Linear
Mixed Model and Ridge Regression, as colored in (B). The
values along the x-axis result from the Bayesian Linear Mixed
Model, assuming dependence between samples, and on the
y-axis from assuming independence (Ridge Regression). The
diagonal is shown in gray and the overall trend of the data is
shown with its 95% confidence interval.

























































Quantiles of all motif activities on sample BLMM RIDGE
B
Figure 4.4: IQR-study on GTEx motif-weight. (A):
Pearson correlation values between the predicted posterior
motif influence ω̂T,C from the Bayesian Linear Mixed Model
and the Ridge Regression of 56 selected motif values over
all tissues. (B): extreme cases of different motif scores per
method. Each box shows the predicted motif scores per sample,
separated by model assumptions used to predict the scores
(dependence, denoted BLMM, colored in red, and indepdence
between samples, named RIDGE, colored in blue). Per sample,
the first, second and third quantile (as in a boxplot) of the
overall motif activity of all motifs on that sample are depicted
in gray.
ω̂T,C per tissue of both methods is very high (median ≥ 0.95,
Fig. 4.4A), which underlines the strong similarity between the two
models (see Supplemental Fig. C.15 for the five highest correlated
motifs across all tissues and Supplemental Fig. C.16 for the five
lowest correlated motifs). The assumption of dependence between
samples (BLMM) results in higher variation of posterior motif
influences (see Supplemental Fig. C.17). Among the 56 chosen
motifs, there are a few cases, where one model assumption yields a
weight value of around zero and the other is significantly different
from zero (see Fig. 4.4B). Out of those four examples, we found
evidence that the TFs are known to play a major role in the
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descriptive tissue: FOXO1, FOXO3 and FOXO4 in liver [202],
RUNX1-3 in blood [153, 164, 185] and in B-cell lymphocytes [70].
We found no explicit relevance for YY1 in skin fibroblasts. The
YY1 TF is known to be involved in the repression and activation
of a diverse number of promoters [11, 147, 194]. It is relatively
highly expressed in skin cells and fibroblasts, which we find from
gene expression profiles from the Protein Atlas [210], data avail-
able from v18.1proteinatlas.org. This could be biologically
relevant, but no specific function is known. Hence, despite sim-
ilar performances we find evidence of motif influences found by
the Bayesian Linear Mixed Model, but not by Ridge Regression.
The same holds vice-versa for EBV-transformed lymphocytes, for
which Ridge Regression predicts an influence of the motif to which
the TFs RUNX1, RUNX2, RUNX3 bind, whilst the Bayesian
Linear Mixed Model does not. This finding is concordant with the
observation that the Epstein-Barr virus (EBV) TF EBNA-2 in-
duces RUNX3 expression in EBV-transformed lymphocytes [187].
Time-Series Datasets
As a final test of the Bayesian Linear Mixed Model we analyze two
time-series datasets. Due to the nature of temporal expression
data, we expect significant correlation of gene expression levels
between subsequent time-points. We made use of two different
time-series experiments: (i) reprogramming of fibroblasts to in-
duced pluripotent stem cells (iPSCs) [19] and (ii) differentiation
of keratinocytes [207] (see Section 4.1 for details). We analyze
these datasets analogous to the previous benchmarks. We run
a ten-fold cross-validation with 1000 permutations per fold to
compare both model assumptions on each dataset. We summarize
the most important results from the analysis in Fig. 4.5, where we
capture the Pearson correlation between expression data from the
ten-fold cross-validation study (Fig. 4.5A), as well as the Pearson
correlation values between the two posterior motif influences ω̂T,C
over all conditions (Fig. 4.5B), which result from the two methods
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Cacchiarelli Toufighi
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Correlation between BLMM and RIDGE
per motif over all conditions
B
Figure 4.5: Data application on time-series datasets.
(A): Pearson correlation between training set and predicted
expression signal on training set and between test set and
predicted test expression signal of a ten-fold cross-validation.
In gray, the mean Pearson correlation between predicted and
real signal using Bayesian Linear Mixed Model (results for
Ridge Regression are almost identical) with a 1000-fold ran-
domization of motif scores is shown. (B): Pearson correlation
values per condition between the predicted motif weights ω̂T,C
assuming (i) dependence and (ii) independence between the
conditions.
assuming (i) dependence as well as (ii) independence per time
series.
We show the estimated covariance matrices VC and ΣC for
both model assumptions for the Cacchiarelli and Toufighi dataset
in Supplemental Fig. C.19 - Supplemental Fig. C.22 and Supple-
mental Fig. C.25 - Supplemental Fig. C.28, respectively. Analo-
gous to the previous two datasets, the covariance matrices from
the Bayesian Linear Mixed Model show a correlation pattern of
the data. Again, the values estimated for the noise matrix ΣC
are larger by a factor of 104 and more for both methods.
We depict scatter plots of the estimated motif weights ω̂T,C
between the Bayesian Linear Mixed Model and Ridge Regres-
sion, separated by time frame, in Supplemental Fig. C.23 and
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Supplemental Fig. C.29.
Fig. 4.5A shows the Pearson correlation between real and
predicted expression levels for both the Cacchiarelli and Toufighi
dataset. The correlation values average to 0.2 across the folds for
the test dataset (ranging both from 0.1 to 0.3) and 0.6 for the train-
ing dataset. Both models show a similar degree of (over)fitting
to the training data, and equal performance in predicting the
test data. As expected, shuffling the motif scores (gray line) com-
pletely negates the model performance. Overall, we see that there
is no significant difference between the two methods based on the
cross-validation analysis. This recapitulates the findings from the
previous benchmarks.
In Fig. 4.5B, we depict the Pearson correlation values between
the motif scores from both methods over all conditions (depicted
in Supplemental Fig. C.18 and Supplemental Fig. C.24 in detail).
We only show the correlation values for the union of the 50 most
variable motifs for both methods. The motifs that are in the com-
mon subset for both methods are colored in black. The remaining
motifs are colored based on the method, for which they were found
to be among the 50 most variable. There are 42 motifs shared
among the 50 most variable motif scores across conditions for the
Cacchiarelli dataset. The motif scores for the Cacchiarelli dataset
are highly correlated with a median correlation value at 0.97 and
the first and third quantile at 0.95 and 0.99, respectively. The
correlation values rank from 0.83 to 0.998. Hence, both methods
perform equally well on the Cacchiarelli dataset and produce very
similar results. The motif scores of the Toufighi dataset are also
highly correlated with a median correlation at 0.84, and the first
and third quantile at 0.77 and 0.90, respectively. The estimated
motif influences are more different between the two models for
these data, as compared to the Cacchiarelli dataset. One of the
reasons could be the nature of the data, as microrarray data gener-
ally contains more technical noise and has a lower dynamic range
as compared to RNA-seq data. While the predicted motif activity
scores are different, qualitative evaluation of the identified motifs
shows no clear advantage of either method (see Supplemental
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Fig. C.29). Motifs for TFs that are known to be differentially
expressed in keratinocyte differentiation show very similar score
for both methods. For instance, TP63 is important for epidermal
commitment and is downregulated during differentation, which
is recapitulated by the predicted score of both methods. Simi-
larly, both Ridge Regression and Bayesian Linear Mixed Model
identify the JUN motif. The AP1 TFs that are known to bind to
this motif are well-studied regulators of epidermal keratinocyte
differentiation [45].
In summary, we can not find a clear advantage of Bayesian
Linear Mixed Model as compared to Ridge Regression on the
basis of these time-series datasets.
4.3 Discussion
In this work we introduce a novel extension of Ridge Regression
for motif activity analysis. The Bayesian Linear Mixed Model
can leverage the sample covariation structure to more accurately
determine motif activities. Through extensive simulation bench-
marks, we observe a clear superiority of the Bayesian Linear
Mixed Model over Ridge Regression when the entire signal can
be explained by motif influence and no, or less, comparable struc-
ture between samples can be found in the noise. However, with
the simulation study, we observe a decrease in performance for
the Bayesian Linear Mixed Model for an increasingly structured
signal in the noise (see Supplemental Fig. C.4). When applying
the two model assumptions to four real-world datasets, we see no
favorable performance on the basis of a cross-validation. Only
a more detailed investigation of motif importance reveals some
differences, which are a lot stronger for the GTEx and Cacchiarelli
RNA-seq datasets, as more “technical” noise is present than in
the acetylation dataset. The origin of noise in our model has
two different sources: the “technical” noise, which includes noise
introduced (i) in the lab (different technicians, different days of
experiment conducted, pipeting error, different kits, etc.), (ii) by
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the machine (batch effect, sequencing, lane-to-lane variability,
etc.), and (iii) through biological variability due to gene expres-
sion being a stochastic process [47]. The other source of noise
originates from the model that explains the expression signal
uniquely as a linear combination of motif scores. Other sources
that contribute to the signal are not modeled here, hence end up
in the noise. And it is this large contribution of noise to the signal
that is no “technical” noise that causes the loss of performance of
the dependence assumption in the covariance. Mathematically,
VC cancels out of the computation of the posterior (Eq. 4.4) if
the covariance between conditions VC and the noise term ΣC are
comparable. This is the reason why the Bayesian Linear Mixed
Model does not perform better than the Ridge Regression in this
case. If the noise takes a form similar to the correlation between
conditions, say:
ΣC = γVC , (4.7)






σ2VC ⊗ΠG + δγVC
⊗ IG
]−1 vec (YG,C) ,





σ2IC ⊗ΠG + δγIC
⊗ IG
]−1 vec (YG,C) .
Hence, the correlation structure between samples plays no role
in the determination of posterior motif influence ω̂T,C . One can
therefore conclude, that the entire formulation of the Bayesian
Linear Mixed Model we proposed is equivalent to Ridge Regres-
sion if VC and ΣC are the same up to a scaling factor. Hence,
the Bayesian Linear Mixed Model is only to favor over Ridge
Regression if there is less noise from the signal than from the
“technical” noise in the data.
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4.4 Conclusion
In this research paper we extended a known framework to model
motif influence on gene expression signal, which was originally
introduced by Balwierz et al. [3] and The Fantom Consortium
and the Riken Omics Science Center [200]. While the previous
formulation assumes independence between samples, our Bayesian
formulation provides the possibility to relax this assumption and
allows to model correlation between samples and hence to better
control the breakdown of measured signal into different sources.
There are many applications in the field of molecular biology,
where Ridge Regression has proved to be successful. The limix
package itself was mainly developed to investigate the influence
of SNPs on phenotype prediction [21, 54, 168]. With an increase
of computational power and better implementations that reduce
the computational complexity, this Bayesian formulation allows
for a more flexible separation of source influences onto the signal.
We first ran a simulation study on the basis of which we
showed a significant improvement of the Bayesian Linear Mixed
Model as compared to Ridge Regression for data with independent
noise. For noise that is dependent on the signal, the Bayesian
Linear Mixed Model quickly loses its predictive power and has
a similar performance to Ridge Regression. We further com-
pared the two model assumptions on four real-world datasets:
H3K27ac, RNA-seq and microarray data. Across all four datasets,
we observed the same phenomenon as in the simulation study:
no distinct superiority of the Bayesian Linear Mixed Model over
Ridge Regression.
Practically, our findings indicate that the theoretical superior
performance of the Bayesian Linear Mixed Model do not translate
to noticeable improvements on motif activity estimation on real-
world data. For expression data, we confirm the findings of
earlier work, which demonstrated that at most 10-20% of gene
expression levels can be explained by transcription factor motifs
near the gene promoter. Crucially, the remaining 80-90% of the
variation is not independent noise. This expression variation
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contains, for instance, the regulatory effect of distal enhancers,
RNA degradation rates and many other biological parameters
that are not captured by our relatively simple model. This results
in a similar covariance structure over samples in the expression
modeled by the motifs and the signal that ends up in the noise
term of the model. As we explain mathematically above, this
means that the effect of the correlation structure will be canceled
out. Even in the case of H3K27ac ChIP-seq data, where ∼40% of
the signal can be explained by transcription factor motifs, we do
not see a clear benefit of the Bayesian Linear Mixed Model over
Ridge Regression.
In conclusion, with the current model formulation we observe
that the Bayesian Linear Mixed Model does not gain predictive
power over Ridge Regression using real-world data. However,
this might potentially change if the formulation of the model’s
covariates is further improved. For instance, this could include
incorporation of motifs at enhancer regions, chromatin interaction
maps determined by chromosome conformation capture techniques
such as Hi-C [118] and ChIP-seq assays measuring the chromatin
environment.
Finally, while we showed here one specific application, we
believe that these types of models can be more generally useful
to model biological systems. The advancements made in faster
implementations together with mathematical reformulations, as
done by Casale et al. [21] and Lippert et al. [120], allow for the
usage of more complex models, such as the Bayesian Linear Mixed
Model over simple Ridge Regression. In concert with the increase
in computational power, such increase of mathematical complexity
becomes more feasible to work with and no longer represents a
practical constraint as it used to.
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5 Investigating Compound Inter-
action from Gene Expression to
Phenotype
Drug combinations have a wide range of clinical applications
and are used in treatment of many diseases, including cancer,
metabolic disorders, asthma, and AIDS. The clinical benefits of
combination therapies are threefold:
1. Combinations may achieve the same effect at a lower dose
than single agents, potentially decreasing toxicity.
2. Combination treatments may prevent or delay the develop-
ment of drug resistance.
3. In cancer, combinations may also address tumor heterogene-
ity or patient-to-patient genomic variability [26, 143].
Despite the obvious benefits of combination therapies, much
is still unknown as to what the underlying mechanisms are. More-
over, many combinations are context specific, relying on unique
target expression or resistance mechanisms [213]. A drug combi-
nation discovery dataset must therefore address the two following
questions: (i) does a drug combination exhibit an interaction ef-
fect, and if so, (ii) what are the underlying molecular causes [99]?
As to the first question, we recently provided a mathematical
formulation of restrictions to the Loewe Additivity [112], which
is one of the most widely used principles to determine the ex-
pected response of two compounds without an interaction effect.
1This chapter is based on work conducted in collaboration with Tjeerd MH
Dijkstra and Nicholas J Lyons from the Broad Institute of MIT and Harvard.
It reflects the current status of the project which we hope to continue in the
near future.
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We suggested a new mathematical formulation of the Loewe Ad-
ditivity principle which provides a better fit to non-interactive
drug combination screens, and is computationally less complex
than others. In a second publication [111] we compared different
synergy scores, and showed that a synergy score computed as
the volume between the expected and measured response per-
forms better than a parameter-dependent model that captures the
changes in effect. We further showed that the above mentioned
model formulation introduced in Lederer, Dijkstra, and Heskes
[112] performs better in measuring an interaction effect than other
formulations and models.
As to the second question, several models aiming to explain
the molecular mechanisms underlying drug interactions have been
proposed [32]: the parallel pathway inhibition model explains a
synergistic effect between two drugs when they target parallel
pathways responsible for the same phenotype. Another explana-
tion for synergy, the bioavailability model [236], posits increased
availability of one drug caused by another one, for example when
drug one opens a cell wall channel to facilitate entry of the other
drug into the cell, or blocks a transporter that removes the other
drug. An explanation for antagonism is provided by the com-
petitive binding model where both compounds bind the same
site on a protein. Another explanation for antagonism is the
metabolic imbalance model [12, 225] where one drug reduces the
metabolic activity of the cell such that the other drug acts less
effectively. Note that these models are probably simplifications
in that synergy could be explained by multiple molecular inter-
actions, e. g. one compound both increasing bioavailibility of the
other and targeting a parallel pathway. While these models have
been around for decades, there has not been a large-scale effort
to quantify how often (combinations of) these models provide
an explanation for observed synergy or antagonism. Our dataset
aims to fill this gap. In detail, support for the parallel pathway
model is found when transcript abundances on different pathways
covary with the phenotype. Support for the bioavailability model
can be found when transcripts related to cell wall channels or
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transporters are increased. Extra support for the bioavailability
model can be obtained by time-delaying the addition of one of
the compounds relative to the other one in the mixture. First
adding the compound that increases the bioavailability and then
the effector compound should result in the same amount of syn-
ergy as when adding both synchronously. Reversing the order
should decrease synergy. Support for the competitive binding
model could be observed when the transcript abundance of the
targeted protein covaries with the phenotype. Lastly, support for
the metabolic imbalance model would come when the abundance
of many transcripts related to metabolism is reduced. As for the
bioavailability model, extra support can obtained by adding the
compounds asynchronously.
Measuring drug combinations in vitro is costly and labor in-
tensive due to the quadratic growth of number of measurements
with the number of doses. For a drug pair many measurements
are necessary: both compounds individually as reference, and in
combination at several concentrations. Measuring two compounds,
each at six concentrations, and in combination, results in 36 mea-
surements, including controls but without considering replicates
for statistical rigor. Testing a set of ten compounds in pairs of
two results in 9 ∗ 10/2 = 45 unique combinations. Increasing the
amount of candidate compounds to 100 results in 4950 pairs to
be tested [217]. While there have been several recent attempts to
reduce this quadratic dependence [88, 128] each attempt makes
specific assumptions. We want to avoid additional assumptions
as much as possible for our benchmark dataset. Lastly, and often
ignored in practice, optimal dose ranges need to be determined
for each compound and disease model [111, 137]. For best results,
two steps are needed, a first optimal dose-finding step with a
large range of doses and each compound tested individually and
a second step with compound combinations at the optimal dose
ranges.
Given the labor and cost of screening compound interactions,
prediction of synergistic compound pairs has become a popular
topic in recent years. Predictions are made from molecular and
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chemical information of the individual compounds, the disease and
known interactions from other compound pairs [4, 134]. Simple
methods like summing up differentially expressed genes from cell
death related pathways [229] proved to be the most successful in
the first DREAM challenge on predicting synergy from molecular
data [4]. Yet, it has been shown that correlated gene expression
profiles are more predictive of synergistic events [42]. More sophis-
ticated approaches have been developed to dive deeper into the
understanding of molecular events that lead to synergy: One class
of prediction algorithms exploits the network topology of drug-
target-disease interactions, using information of the drug targets
and their chemical description [25, 26, 169]. These networks are
then combined with disease-related genes and specific signaling
pathways. Li et al. [117] provide a review about the general
concept of network types and an overview of useful databases.
Deep learning has also found its application in predicting synergy
from molecular information [226]. A common validation of the
predicted synergistic compound pairs consists of finding evidence
from the literature for the highest ranked predictions [25, 237].
After labeling the dataset, which is usually done manually by the
researchers themselves (e. g. [227]), one can report Area Under the
Curve (AUC) values: Chen et al. [25] report an AUC of 0.9054.
In Chen et al. [25], the proposed method is not compared to other
methods, which is justified by the overhead of implementation
and the lack of additional data on which other methods rely [25].
Lastly, comparisons have been made to methods outside of the
field of synergy, such as Zitnik, Agrawal, and Leskovec [237], who
compared their method to other multi-relation link prediction
methods, achieving an AUC of 0.872.
In this study, we aim at generating a benchmark dataset that
contains both the phenotype and the molecular response to drug
combinations that are known to have an interactive effect in killing
cancer cells. We use common human cancer cell lines and readily
accessible drugs. This allows for the inclusion of a wide range of
additional data sources such as pathway information, drug-target
interaction, protein-protein interaction and drug side-effects. We
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determine (i) the physiological response (confluence of well by
viable cells from microscopy) as well as (ii) the molecular response
(gene expression from the L1000 assay [191], explained below).
Both experimental setups are identical to the maximal extent
possible and are run in the same facility, conducted with the same
batch of cells and the same chemical compounds, as well as dose
ranges. This prevents artifacts that are commonly observed when
running experiments in different facilities, on different batches of
cells, and by different lab staff [149]. To the best of our knowledge,
we would be the first ones to collect both phenotype and molecu-
lar response data on the same experimental platform with a full
design matrix. The gene expression data at hand coupled with
the available pathway information will allow us to reason about
the origin of synergistic events. In summary, determining synergy
on the basis of the phenotype response yields a global picture of
the effect while investigating the molecular response in combina-
tion with additional information, such as pathway information
or protein-protein interaction, uncovers the underlying causes.
Combining both allows linking molecular changes to physiological
ones, which leads to a better understanding of the mechanisms of
synergy in killing cancerous cells.
5.1 Methods
5.1.1 Experimental Setup
We run the experiment on two well-studied human cancer cell lines
from different organs: (i) the breast cancer cell line MCF7 (female
patient), (ii) the lung cancer cell line A549 (male patient). We
also used the skin carcinoma cell line A375 (female patient) in the
first iteration of the pilot experiment, but as this cell line did not
perform well, we dropped it for the second iteration. All three cell
lines are part of the Touchstone dataset (clue.io, [191]), which
contains perturbational profiles across 2429 compound treatments
at multiple doses.
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Based on a literature research, we selected 15 compounds that
are known to have an interactive effect with at least one other
compound in the set on at least one of the two cell lines or a
closely related cell line, e.g. MDA-MB-23 and MDA-MB-46 are
related to MCF7 (see Fig. 5.1 and Supplemental Table. D.1). Note
that we have one compound pair (sulforaphane and oxaliplatin)
that is known to be interactive on a colorectal cell line [95],
which we do not investigate in detail. We included the pair
nonetheless due to the combination of a plant-derived substance
(sulforaphane) with a chemotherapeutic agent (oxaliplatin) and
their shown synergy by sulforaphane sensitizing cancerous cells
to the effect of oxaliplatin, and would like to investigate the
genetic response in greater detail. In the first iteration of the
pilot experiment we also used compounds acetazolamide, cisplatin,
elacridar, gemcitabine, Ko 143, taxol, vemurafenib and vincristine
but we dropped these for the second iteration as they did not
perform well. We added compounds bortezomib, itraconazole
and vorinostat as we expected these to show interactive effects
with other selected compounds, see Fig. 5.1 and Supplemental
Table. D.1.
We run the experiments on 384 well plates with an identical
design, cell lines, compounds, and concentrations for the molecular
(L1000) and the phenotype readout (CellTiter-Glo® and later
Incucyte®).
Gene Expression Assay The L1000 platform has proven to
be a powerful tool for gene expression based hypothesis gener-
ation and small molecule screening [191]. The assay has been
used extensively to investigate the transcriptional signatures of
small molecule and genetic perturbations, but there is not yet a
well-validated experimental workflow for studying compounds in
combination.
The L1000 assay uses ligation-mediated amplification, and
quantifies transcript abundance of 978 landmark genes by fluores-
cence with a Luminex FlexMap 3D flow cytometer [191]. The raw

























Figure 5.1: Overview of known interactions. Com-
pounds used in the second pilot study, with known interactions.
The direction of interaction is given in colors, the cell line,
on which the compound pairs are known to be interactive, is
depicted as line-type.
data to the next level. The levels are visualized in Subramanian
et al. [191, Fig. 2C]. The raw fluorescence intensity and bead
identity as detected by the Luminex scanner are stored as level
1 - raw (LXB) data. As each analyte bead is coupled to two
genes (see Subramanian et al. [191] for details), the composite
signal is deconvolved into two values (level 2 - deconvolute (GEX)).
Next, the data is rescaled based on the expression of 80 genes
that are found to be invariant across a baseline dataset. Next,
the data is quantile normalized, yielding normalized expression
values of the 978 landmark genes. Based on a linear prediction
with provided weights, the expression of the remaining 12,328
genes reported by the L1000 assay is computed. At this stage,
the data is referred to as level 3 - normalization (NORM). In the
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third processing step, yielding the level 4 - differential expression
(ZSPC) data, the robust z-score is used across all samples of
a plate for a relative gene expression signal. Lastly, the gene
expression signal is summarized over its three replicates, weighted
by their pairwise Spearman rank correlation, resulting in level 5 -
replicate-consensus signatures (MODZ) data.
As a summary value over the gene expression signal, a Tran-
scriptional Activity Score (TAS) is computed that takes into
consideration the number of differentially expressed genes (level 4
data), weighted by replicate reproducibility, which is determined
as the 75th quantile of the Spearman correlations computed be-
tween all pairwise combinations (of level 4 data).
Cell Viability Assays We used CellTiter-Glo® for the first
pilot experiment but switched to image-based quantification of
cell density in the second pilot. In a CellTiter-Glo® experiment
the ATP level in a cell lysate is measured. The ATP level is
proportional to the number of living cells as ATP is rapidly
degraded after cell death [149]. However, when drugs alter the
cell size or the ATP metabolism, the relationship between the
number of cells and the ATP level changes, which leads to a poor
correlation between CellTiter-Glo® and direct cell counts [78,
149, 176, 184]. Given these drawbacks, which were exacerbated
due to an insufficient number of cells in our first pilot experiment,
we decided to switch to direct counting of cells. Image based
quantification of cell count also has the advantage that the assay
is non-destructive, meaning one can observe a time series of
response to compounds, allowing both growth inhibition and cell
death to be observed. We used the commercial Incucyte® system
which has performed well in independent benchmarks [64, 72, 149].
In detail, the Incucyte® system reports confluence, which is the
fraction of the well that is covered by cells. The initial value
depends on plating density and subsequently can increase or
decrease over time, dependent on whether cells grow or die. We
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sampled confluence for 96 hours with 45 minutes between samples
for a total time series of length 129.
5.1.2 Experimental Design
The study is designed in two parts: a single compound dose-
finding part (pilot study) and a two-compound interaction part
(combination study). Because we found issues (detailed below) in
the first execution of the pilot study, we repeated this part with
four changes: (i) we only used two cell lines and (ii) we switched
the cell viability read-out from CellTiter-Glo® to Incucyte®,
(iii) we reduced the number of compounds from 20 to 15 and
(iv) we seeded each well of a 384 well plate with at least 3,000
cells, and (v) we changed the plate design by making sure all
experiments of one compound are plated on the same plate, which
reduced the number of concentrations from twelve to eleven.
Pilot Study In the first iteration of the pilot experiment,
we used twelve concentrations decreasing from 50µM in a
two-fold serial dilution: {50, 25, 12.5, 6.2, 3.1, 1.6, 0.78, 0.39, 0.20,
0.10, 0.05, 0.02}µM. In total, we measure gene expression and
phenotype response each on three cell lines, exposed to 20 com-
pounds at 12 different concentrations, with three repetitions each,
including 24 controls per plate, and one control plate for every
cell line and experiment resulting in:
2(assays)× 3(cell lines)×
[20(compounds)× 12(concentrations)
× 3(replicates) + 24(controls)] +
3 ∗ 384(control plates for every cell line) = 6, 912
experiments, distributed over 18 well plates with 384 wells. The
twelve concentrations were distributed across two (384 well) plates:
(i) one plate for the six lower concentrations, (ii) one plate for
the six higher concentrations. Per plate, all six concentrations
of a compound were applied in consecutive order over the rows.
Concentrations were repeated three times on the same plate,
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Figure 5.2: Plate layout of first iteration of the pilot
phase. Plate design is identical for all three cell lines. Controls
are shown in gray, compounds in color. For simplicity, only
four compounds are shown (in different non-gray colors). In
every compound block, each row is exposed to a different
compound. The concentration range is shown as a block with
increasing concentration (shown with an arrow). The low
and high concentration plates have the same design, one for
the lower from 0.02µM to 0.78125µM and one for the higher
compound concentrations, from 1.5625µM to 50µM .
distributed over rows and columns. Control measurements were
placed in the first two rows for the first six columns, as well as in
the last two rows on the last six columns (see Fig. 5.2).
Due to plate effects exacerbated by the above study design
(see Results), we refined the design for the second iteration (see
Fig. 5.3): we ran all concentrations of a compound on a single
plate. To be able to better detect column (and row) effects we also
changed the layout of the controls, ensuring they were included on
the first and last well of each row. A downside of the new design
is that we could only fit 11 doses on one plate so we dropped the
lowest concentration of 0.02µM. We felt that this is a small price
to pay for the benefits of fewer plate effects and better positioning
of controls. Lastly, as we reduced the number of compounds from
20 in the first iteration to 15 in the second, we ran one plate with
10 and one with only 5 compounds.
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Figure 5.3: Plate layout of second iteration of the
pilot phase. Plate design is identical for both cell lines.
Controls are shown in gray, compounds color. For simplicity,
only blocks of compounds are shown (in different non-gray
colors). Due to an error in programming the dispensing robot,
the green compound in the first row ended up shifted up and
to the right. In every compound block, each row is exposed
to a different compound. The concentration range is shown
as a block with increasing concentration (indicated with an
arrow). Every compound is applied with three repetitions of
11 concentrations, ranging from 0.04µM to 50µM.
The switch from a CellTiter-Glo® to an Incucyte® assay is
motivated by responses that were weaker than anticipated (see
Results).
112 Chapter 5. Synergy from Gene Expression to Phenotype

















Figure 5.4: Plate layout for the combination experi-
ment. Controls are shown in gray, compounds in color Each
concentration combination is shown as a block with increasing
concentrations along the two axes of the block (shown with an
arrow). For simplicity, only the mono-therapeutic concentra-
tions of each compound are shown in color. The white space
in between the combination block is filled with concentration
combinations of both drugs along the concentration increase
shown on the axes. As an additional positive control, every
compound is also applied individually at twelve concentrations
(only once). Every compound is applied with six concentra-
tions in the combination at the optimal concentration range
determined in the pilot phase. Two compound combinations
are applied per plate, with three repetitions.
5.1.3 Combination Design
Once the optimal dose range is determined per compound and cell
line, we plan to run a combination screen: In three repetitions, we
apply a matrix-design along six concentrations for every compound.
The choice of six concentrations is pragmatic, optimizing the
experimental setup on the 384 well plate (see Fig. 5.4).
Despite the benefits of a reduced response-matrix design [88,
128], we refrain from adopting such a reduced design. Such
reduced designs have been proposed based only the phenotype
and we use the same design also for the transcriptional response.
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As we focus on finding causal relations, we think it is important to
work with a more complete picture - and to allow for verification
of reduced designs.
5.2 Results
5.2.1 Plate Effects in the First Pilot Study
In both assays of the first pilot study (L1000 and CellTiter-Glo®),
we found strong intra and inter plate effects. In Supplement D.2,
we present the plate effects in greater detail, we present the plate
effects in greater detail and how to correct for them.
5.2.2 Improved Data Quality in the Second Pi-
lot Study
We repeated the pilot phase with two main differences (i) a
different plate design, plating each compound on one plate only
(see Fig. 5.3) and (ii) by determining the phenotype response from
cell confluence using the Incucyte® system. Minor differences
were that we (i) dropped the A375 cell line, (ii) reduced the
number of compounds from 20 to 15, (iii) reduced the number
of concentrations from twelve to eleven due to a different plate
design, and (iv) made sure that we plated at least 3,000 cells per
well.
We cannot find systemic plate effects and see an overall im-
provement of the quality of data (see Fig. 5.5, Fig. 5.6). In Fig. 5.6,
we compare the overall variation between the CellTiter-Glo® and
Incucyte® assays on compounds and cell-lines tested in both
pilot phases. We compute the median absolute deviation for each
cell-line, compound, and concentration, and normalized them by
the median response. We compare these values between both
experiments with a one-sided Wilcoxon signed-rank test. The
p-values are displayed in Fig. 5.6 and show a clear improvement
of variance reduction from the first pilot phase to the second. We























































































Figure 5.5: Improved data quality for Incucyte®
data. Percent confluence from raw Incucyte® data after
t = 72h, colored by row on the plate. The four exemplary
compounds were applied to the A549 cell line.
also see an overall improvement of the L1000 experiment (see
Fig. 5.7).
5.2.3 Determining Dose Range in the Second
Pilot Study
Optimal Experimental Design In the dose-finding study, we
run mono-therapeutic experiments on the phenotype and molec-
ular response to determine the optimal concentration range for
each compound and cell line. The dose range is of great impor-
tance as it strongly affects the estimation of the dose-response
curve of a compound [111, 149], which determines crucial re-
sponse metrics, such as the maximal effect or the EC50. An














































Figure 5.6: Reduction of variation from first to second
pilot study in phenotype data. P-values of a one-sided
Wilcoxon signed-rank test, comparing the overall variation
between the CellTiter-Glo® and Incucyte® experiment for
compounds and cell-lines that were run in both experiments.
The overall variation is computed as the median absolute
deviation (MAD) per cell-line, compound and dose, normalized
by the median.
to maximal effect (y∞) for the phenotype data as well as for
the genetic effect from the genetic response. There are several
methods to optimize dose designs for estimating mono-therapeutic
dose response curves [86, 87, 100], as well as drug combination
therapy in phase I clinical trials [228]. Here, we refrain from
applying these methods. As an alternative to optimal design one
could sample symmetrically around the EC50 value, for example
EC10,EC20,EC50,EC80,EC90 with an extra dose one dilution
step smaller than EC10 and a dose one dilution step before EC90.
This is motivated by the point-symmetry in EC50 of dose effect
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Figure 5.7: Improved data quality for L1000 data.
TAS score of both pilot phase L1000 experiments (shown in
different colors). The four exemplary compounds were applied
to the MCF7 cell line.
curves in the log-scale, when modeled with the four-parametric
Hill curve [65, 81]. Both approaches, the optimal dose design, as
well as picking values around the EC50 value, aim at optimizing
the concentrations for one type of measurement, namely the phe-
notype response. While this can be supported to a certain degree
by the argument of some null reference models, such as the Loewe
Additivity relying on the mono-therapeutic responses, we must
not forget that here, we aim at comparing the genetic response
with the phenotype response. Therefore, we picked concentrations
at a quasi equidistant grid pattern in the log2-space within the
range of concentrations for which could observe an effect in both
types of measurement. This allows us to compare the effects of
both data sources.
We determined the optimal dose range for each compound
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Figure 5.8: Dose range. TAS score of L1000 data on the
left y-axis (blue) and confluence percentage of the median
Incucyte® data after t = 72h on the right y-axis (red). De-
termined dose range per compound and cell-line is shown in
orange for five compounds on cell-lines A549 and MCF7.
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and cell line after visual inspection of the mean and standard
deviation of the raw Incucyte® together with the TAS score
of the L1000 data. We chose the dose ranges such that they
capture the TAS scores τ ≥ 0.2, analogously to Subramanian
et al. [191], who use it as threshold for transcriptional activity,
and a decrease in phenotype effect (see Fig. 5.8). For extreme
cases such as the compound docetaxel, where the applied dose
range is too high to observe a decrease in confluence percentage
with increasing concentrations, we decided for a much smaller
dose range than originally applied. On the other side, we also
decided to increase the dose range to 100µM for compounds
such as erlotinib, as no apparent plateau effect has set in at the
maximum concentration of 50µM . In Supplemental Table. D.2 we
depict the chosen concentrations for each compound and cell-line.
5.3 Future Work
Lukačišin and Bollenbach [126] performed a controlled growth
experiment, so-called “isogrowth” profiling on the yeast Saccha-
romyces cerevesiae. They showed that the first three Principal
Components (PCs) from a Principal Component Analysis (PCA)
applied to the gene expression along the isobole have a clear bio-
logical interpretation. The first two components account for the
global gene expression response to growth inhibition, independent
of the drug ratio, and the interpolation of gene expression between
the two individual drugs. As these first two components account
for a large fraction of variance explained, the response of genes in
yeast to a drug combination can be predicted from the responses
to the drugs individually. In the third component, Lukačišin
and Bollenbach [126] identified “emergent” gene expression, where
genes were higher or lower expressed than at an individual drug
alone. We can run the same analysis by accounting for the growth
rate in our cell lines [31, 71, 72]. Then we will verify whether
the biological interpretation of the three first PCs on the gene
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expression of growth inhibitors in yeast also holds for our human
cell lines.
In a second analysis, we will extend the PCA along the isobole
in Lukačišin and Bollenbach [126] to a tensor decomposition across
the full dose-response matrix. This extends the two-dimensional
PCA analysis to a higher-dimensional analysis, taking into ac-
count the full response surface, as well as dose-dependent effects.
Tensor decomposition has attracted great interest in recent years
in Machine Learning and molecular biology [101, 104, 167, 196].
In particular, it has been applied to time series data [44]. Here,
we have analogous data, but instead of a progressing time-line, we
have an increase in dose concentration. Taguchi [195] applied a
tensor decomposition to the L1000 Touchstone dataset [195, Chap-
ter 7.3], on the basis of which he identified genes with significant
dose-dependency. Julkunen et al. [94] applied a similar approach
using tensors and higher order factorization machines [10]. In their
study, they use the NCI-ALMANAC dataset that is generated
by the National Cancer Institute (NCI) and comprises more than
three million drug combination measurements over different cell
lines and tissues [82]. Our planned approach is different from that
of Julkunen et al. [94] in at least two ways: we can include gene
expression for all compounds combinations from the L1000 assay,
and we do not only determine synergy based on Bliss Indepen-
dence. We are convinced that applying a tensor decomposition to
our drug combination data will shed light on the complex interplay
of gene expression and phenotype in dose-response assays.
In a third analysis, we plan to connect the drug target to the
disease proteins to validate several methods that were recently
introduced [23, 26, 69, 117]. With known requirements on the
drugs’ target-disease interaction for therapeutic effect, namely
that both compounds target the disease, but at different neigh-
borhoods [26], we will reassemble the Broad’s connectivity score
τ [191] and activity score TAS to a new synergy score, predicting
synergistic drug combinations.
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5.4 Discussion
In a reproducibility study on dose-response assays, Niepel et al.
[149] showed that the biggest variability occurred when compar-
ing cell viability measured with an image-based approach to cell
viability measured with CellTiter-Glo® resulting in partly dif-
ferent maximal effects and dose-response curves. This variability
between techniques has also been shown in previous studies, e. g.
Haibe-Kains et al. [73] and Kepp et al. [99]. For some compounds,
the differences are caused by variability of the ATP levels in
lysates rather than differences in viability. A temporal effect of
drug administration was also shown to play a major role in the
observed differences. For human cell lines, it is standard to mea-
sure cell viability after 72h of compound exposure, whereas for
the L1000 it is standard to measure after 24h of exposure. Recent
advances which consider the cell’s reproduction rate can account
for different exposure times [31, 71, 72]. With the switch of assay
from CellTiter-Glo® to Incucyte® we can align phenotype and
gene expression after 24h as well as obtain the phenotype response
after 72h (for comparison with data from the literature). Other
sources of variability, such as edge and other spatial plate effects,
can be taken care of by randomization or statistical and visual
analyses [15, 107, 131], but, as mentioned above, we would not
have discovered the plate effects if we had randomized the plate
design. Therefore, also for the planned combination study, we
refrain from randomizing.
Overall, it needs to be kept in mind that there is a “sub-
stantial inconsistency” between phenotype readouts that measure
drug sensitivity, whereas gene expression profiles are significantly
more correlated [73, 144, 174]. To understand the underlying
causes of synergistic effects it is crucial to have an experimental
pipeline that allows for correlating the phenotype response to the
molecular read-out. By switching from ATP-based assay to direct
cell-counting, we believe to erase a major source of variability,
that might have led to confounding results and finding wrong
correlations. Nonetheless, we are aware of the challenges to build
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a causal relationship between the molecular and phenotype re-
sponse, which is already a major challenge in single compound
assays. By generating a dataset that is FAIR (findable, acces-
sible, inter-operable and reusable), we contribute to the recent
community efforts for reproducible results.2
Still today, we only partly understand the complexity of human
cancer [56, 142]. Using in vitro cell lines certainly hinders further
understanding of the disease because (i) there is evidence that
synergy discovered in vitro does not necessarily translate to in
vivo models, and vice versa [56], and, (ii) for known complex
cases, only individualized therapies seem to work [213]. While
there have been advancements towards personalized medicine by
constructing a landscape of patient derived tumor cells [103, 113],
it is crucial to investigate in detail how synergistic events arise
and use that knowledge for their prediction. Only then we can
translate that knowledge to the diverse landscape of human tumor
biology and to in vivo models.
2The data used for the two pilot studies is available at clue.io/data/NLT.
The code implementation will be made fully accessible once the study is
concluded. The current version of the code used for the two pilot studies can




Throughout this thesis we have defined and quantified synergy
between pairs of compounds, reviewed its history, and analyzed
synergistic effects on different levels.
To do so, we first looked at the definition of an interaction ef-
fect, which we did in two steps: in Chapter 2, we investigated what
to expect in case of a non-interactive effect between compounds.
We extensively turned over every stone related to the theory of
Loewe Additivity, a methodology introduced in the first half of the
last century. Loewe Additivity is based on two assumptions: (i)
dose equivalence and (ii) a sham combination. Dose equivalence
is the assumption that interchanging two compounds with one
another yields the same effect. The sham experiment assumption
is that in an experiment where one compound is combined with
itself no interaction is expected. We provided a mathematical
framework for this methodology. We showed limitations that were
commented on in the literature, but were neither provided in a
mathematical formulation nor communicated in greater detail.
We formulated the limitations mathematically and defined them
as Loewe Additivity Consistency Condition (LACC). The major
limitation is that both compounds have to be proportional in
their dose, otherwise interchanging compounds yields different
effects, violating the assumption of dose equivalence. Additionally,
one cannot replace one compound with the other if one com-
pound reaches an effect that is greater than the maximal effect
of the other. For the latter, we provided a pragmatic solution
for this inconsistency of the model. Based on the mathematical
formulation derived from the two basic assumptions of Loewe
Additivity, we introduced a new mathematical formulation of the
Loewe Additivity, the Explicit Mean Equation. It is an explicit
formulation of a non-interactive effect which is directly computed
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from the concentrations of the two compounds given their con-
ditional dose-response curves. In contrast, the General Isobole
Equation, the most common variant of Loewe Additivity, is an
implicit formulation based on which the expected effect can only
be computed with greater effort. Both formulations, the explicit
and the implicit one, are equivalent if the LACC is fulfilled. The
benefit of the Explicit Mean Equation is two-fold: (i) it better
fits to two real datasets and (ii) its computation is more effi-
cient resulting in significantly shorter computation times. This
is advantageous when applying the model to high-throughput
data. Having provided a framework for computing the effect of a
compound combination if no interaction is expected, we moved
on to examine how to best determine an interaction effect. In
Chapter 3, we compared two methods to quantify synergy building
on various models of non-interaction, all based on one of the two
main synergy principles: Loewe Additivity or Bliss Independence.
We showed that computing synergy as the integral difference
between expected non-interactive and measured effect is to be
preferred over a parametric approach. Furthermore, we showed
that taking the Explicit Mean Equation as null reference model is
to be preferred as it performs well for two different datasets. In
summary, we have looked at the effect of a combined treatment of
two compounds by investigating the changes in phenotype - the
effect on the cell “surface”.
Second, we completely changed perspective and investigated
the underlying mechanisms within a cell. In Chapter 4 we moved
from the global viewpoint on cell survival or cell growth towards
the genetic interplay within cells. To better understand a cell’s
response to perturbations we investigated the dynamics between
genes and their products. Molecular biology has attracted much
interest in the past decades. Major advances in deciphering
the human DNA, the development of new ways to measure the
transcriptional response, and a continuous drop in prices of high-
throughput measurements over the recent years allow us to observe
and uncover the mechanisms of an organism on its most funda-
mental level, the molecular one. About 10% of all proteins in
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humans regulate gene expression by binding to a specific DNA
sequence, called motifs, in the genes’ proximity. A common ap-
proach to determine the influence of these so-called TFs on gene
expression is to model gene expression as a linear combination
of its motifs in the promoter region. The fitted weights are then
used to relate the motif to their binding TFs. This results in
the identification of TFs that are most influential on the gene
activation or repression. In Chapter 4 we experimented with
loosening an important assumption made in the process: indepen-
dence between biological samples. This assumption is not met
when the samples are replicates or similar in condition. With
the formulation of a Bayesian Linear Mixed Model we provided a
mathematical framework that breaks open the rigid independence
assumption between samples. While we found that loosening the
independence assumption improves the performance on simulated
data, we could not observe an improvement on real world data.
Third, we pursued the idea to combine the insights from the
underlying mechanisms on the molecular level to the global ef-
fects observed in the phenotype response. This would allow us
to fully understand the complicated interplay between compound
interaction from a molecular to a phenotype level. We developed
an experiment to measure gene expression and phenotype anal-
ogously in a full matrix design. Such an experiment has only
recently become feasible due to technological advancements and
cost reduction of large-scale experiments in molecular biology.
In the previous chapters we have seen that technicalities can
have a strong influence on the overall outcome of a combination:
throughout Chapter 2 and Chapter 3 we stressed the importance
of well sampled dose-ranges. In Chapter 5 we described in detail
the experimental design that led us to determine the optimal dose
range. We further described the technical obstacles that we had
to overcome and which led to a repetition of the pilot experiment.
These lessons learned were integrated into the experiment. Next
to the technicalities, we provide an extensive overview of the
current state of research on synergy, both on the molecular and
the phenotype level. Having completed the pilot phase of the
126 Chapter 6. Conclusion
study, we determined dose ranges for all compounds within which
both molecular and phenotype effect could be observed. While
we have worked out the technical framework for the experiment,
the main experiment of combinations of compounds as well as
the development of a robust tool for the detection of a synergistic
effect still have to be realized.
All in all, we have defined synergy for phenotype data, provided
a more flexible modeling approach for gene regulatory networks,
and presented our ideas on how to combine both types of data
for a better understanding of the complicated interplay between
synergistic compounds. With that, we have drawn a complete
picture on drug-drug interaction models - from gene expression
to phenotype.
6.1 Future Work
While we investigated the principle of synergy in great detail on
the basis of the phenotype response, we barely touched the idea
to follow synergy on the molecular level. While the idea presented
in Chapter 5 is to develop a predictive synergy score from the
individual gene expression profiles, the idea of synergy on the
molecular level can also be followed independent of the project
idea presented in Chapter 5: In Chapter 4 we investigated the
influence of TFs on gene expression, and this line of research
can be extended to include synergistic interactions between TFs.
We explain the gene activity with a linear combination of motif
influences in the promoter region only. Yet, it is known that
combinatorial binding between TFs can have synergistic effects on
the transcriptional response in the enhancer region [188]. The re-
search presented in Chapter 4 can be extended from the promoter
region to also take into account the enhancer region. Addition-
ally, the Bayesian Linear Mixed Model can be modified to take
into account possible interactions between the binding TFs. The
idea of transcriptional synergy has already found a successful
application in the identification of TFs that act synergistically
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to determine cell subpopulation identities in single-cell RNA-Seq
data [152]. Hence, the extension of the linear combination of TFs
and the identification of synergistic combinations of TFs promises
potential to the understanding of molecular mechanisms.
Above, we discussed synergistic events on the molecular level.
Moving to synergistic effects on the phenotype data that are
predicted with molecular events, we arrive at the idea presented
in Chapter 5. While the idea of bridging the molecular to the
phenotype response is described in Chapter 5, the data collection
and analysis still have to be performed. A major challenge in
this research field, and seen throughout this thesis, is the lack of
drug combination datasets with ground truth labeling [211]. In
the past decades, we have witnessed an impressive growth of data
availability in molecular biology which led to huge improvements
in understanding genetic dynamics and interplay. At the same
time, we observe a huge interest in the development of statistical
machine learning methods that find their application increasingly
in the field of biology. This is due to the increased availability of
data from different molecular processes as well as the challenge
that lies in their integration. In Chapter 5 in particular we
have seen that it becomes increasingly difficult to re-engineer
and translate results from synergy studies from one experimental
setup to another. This is mainly due to the overhead of data
integration as well as the difference in experimental setups. With
the generation of a benchmark dataset with (i) a full matrix design
on (ii) the phenotype as well as (iii) the molecular response, we
are certain to pave the way for bringing together various research
approaches and allow for a direct comparison of methods. It
consequently presents the opportunity to combine methods from
both perspectives: the global one in form of the phenotype data,
and the molecular one on the basis of gene expression.
But setting aside our efforts to generate a benchmark dataset,
there are more difficulties that arise when going from basic research
to application in patients.
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6.2 Other Challenges to Overcome
Given the nature of synergy studies, it is an enormous challenge
to translate results from in vitro studies to in vivo.
The full matrix design, where the compounds are combined
in different concentrations, as used throughout this thesis, is
unfeasible in patients. The determination of the optimal dose
combination remains challenging due to cell-to-cell and patient-
to-patient variability [192]. Successes of compound combination
treatment in a patient do not necessarily result from the com-
bination treatment, but can be due to a disease sensitivity to
one of the compounds. In such a case, the drug action would be
independent of the combination [20, 157, 160].
Nonetheless, the successes of synergy studies heavily rely on
the successes of in vitro studies. The disadvantage of those studies
lies in the simple set-up of the experiment: most media, in which
cell lines grow, do not mimic physiological conditions and have
an influence on the metabolism and phenotype response. It was
therefore suggested to either use a complex culture medium [212]
or primary tissue assays which are comprised of multiple cell
types [236]. An additional challenge that arises in the process of
translating insights from an in vitro study to an in vivo setup is
a possible loss of efficacy: the effects of known in vitro synergies
may be too small to show an effect in the human body [20, 133].
Interactions with other drugs might result in adverse drug effects,
an increase in toxicity, or a decrease of drug effectiveness [192].
The field therefore remains extremely challenging and consists
of many more obstacles to overcome before the successes of possible
interactive combinations can be effectively brought to the patient.
Nonetheless, we should keep in mind the opportunities that
come with research on compound combinations: complex dis-
eases such as cancer are most often treated with a compound
combination as shown with e. g. breast cancer therapy where a
combination of doxorubicin and cyclophosphamide is later fol-
lowed by paclitaxel [150], or in leukemias and Hodgkin lymphoma,
where combination chemotherapy has greatly increased survival
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rates. An example is the treatment of Hodgkin’s disease with
the combination of the chemotherapy medications doxorubicin,
bleomycin, vinblastine, and dacarbazine [233].
Another major opportunity lies in the repurposing of already
approved compounds. This saves time and costs for the approval
process: Viagra (sildenafil) was initially intended to treat hy-
pertension and angina pectoris. Today, it is well known for the
treatment of erectile dysfunction [13]. Even in the contemporary
practice of medicine we are constantly on the lookout for approved
drugs that can be used for a different treatment: in the beginning
of the pandemic of Sars-Cov-2 in 2020, the anti-malaria drug
chloroquine as well as the antiviral drug remdisivir have been
tested extensively for their allegedly positive effect against the
viral infection [215]. Even though these two drugs were not shown
to be effective treatments for patients with the Corona Virus
Disease, the pandemic highlights the importance for quick and
reliable screening methods to find approved drugs that serve as
possible candidates for treatments of diseases different from the
ones they were originally developed for.
With the successes of current combination treatments for com-
plex diseases and recognizing the importance of drug repurposing,
we should embrace the opportunities that arise with the increasing
data availability and technical improvements. We should use them
to align current knowledge from different research fields to bring
synergistic effects to the field of synergy.
Each one sees a piece of the world,
together we see the whole.
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A Supplement to Chapter 2
A.1 Loewe Additivity Consistency Con-
dition
Theorem 1. If and only if a dose and its equivalent are pro-
portional to each other (Eq. 2.9 and 2.10) the Loewe Additivity
Consistency Condition in Eq. 2.8 holds.
Proof. For notational convenience we define g ≡ f−11 ◦ f2 thus
g−1 = f−12 ◦f1 The function g maps dose x2 to its effect-equivalent
dose x1. The LACC can now be written as:
x1 + g (x2) = g
(
g−1 (x1) + x2
)
. (A.1)
“ =⇒ ” We first provide a proof for the LACC to hold if the
equivalent doses are proportional, meaning
xequiv1 (x2) = g (x2) = cx2, (A.2)
and thus




















= x1 + cx2.
“ ⇐= ” Proving the theorem in the other direction, we assume
that the LACC holds. Starting from the statement in Eq. A.1
we define the function h (x1, x2) as the difference of these two
equations:
h (x1, x2) = x1 + g(x2)− g(g−1(x1) + x2)
!
= 0 ∀x1, x2. (A.4)
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= g′ (x2)− g′
(
g−1 (x1) + x2
) !
= 0. (A.5)
To further exclude that the inverse of g on x1 is always equal to











= 0 ∀x1, x2,
(A.6)
from which one can deduct that g′′ (g−1 (x1) + x2) has to be zero
for all x1, x2. This implies that g (x2) is linear in x2. Thus:
g′(x2) = constant ⇒ g(x2) = c0 + cx2
and since g(0) = 0, one obtains c0 = 0. Substituting this result in
Eq. 2.4, one gets:
xequiv1 (x2) = g(x2) = cx2, (A.7)
which shows equivalent doses to be proportional.
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A.2 General Isobole Equation under
LACC
Corollary 2. If the Loewe Additivity Consistency Condition in
Eq. 2.8 holds, (1) fGI (x1, x2) = f2→1 (x1, x2) = f1→2 (x1, x2) and
(2) the isoboles are parallel.
Proof. (1) Assume a response level denoted by y∗, then the doses
of compounds 1 and 2 that cause this effect by themselves are given
by f−11 (y∗) and f
−1
2 (y
∗) being related by concentration scaling,
i.e. f−11 (y∗) = cf
−1
2 (y
∗) (Eq. 2.9 and 2.10). The isobole for effect
y∗ is given by
y∗ = f1(x1 + cx2)






which leads to the linear isobole equation depicted in Eq. 2.3,









(2) For a given y∗, this linear isobole equation gives the contour
lines of the response surface. Since the two concentrations x∗1
and x∗2 are related by linear scaling (x∗1 = x
equiv
1 (x2) = cx
∗
2, see
Eq. 2.9), the isoboles for different effect levels y∗ are parallel. This
becomes clear by replacing x∗2 with its equivalent cx∗1 in the linear













⇔ x2 = cx∗1 − cx1 = c (x∗1 − x1) ,
where x∗1 = f
−1
1 (y
∗). Therefore, x2 is linearly dependent with
a fixed slope parameter c > 0. This results in an isobole with
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slope −c for any effect y∗ that is reached by x∗1, and therefore the
isoboles are parallel.
A.3. Consistency Condition for Hill Curve 135
A.3 Consistency Condition for Hill
Curve
Corollary 3. If the Loewe Additivity Consistency Condition in
Eq. 2.8 holds with f1 and f2 taking the form of two Hill curves,
then the slopes and effect ranges y0 and y∞ of the Hill curves
must be the same. Further, the proportionality factor c takes the
form of a fraction of the EC50 value of the drug to be expressed
in terms of the other divided by the EC50 value of this other drug,




For the Loewe Additivity Consistency Condition,
xequiv1 (x2) = f
−1
1 (f2 (x2)) = cx2, (A.9)
to be fulfilled when using the Hill curve for fj, j ∈ {1, 2}, which
is of the form
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=























Hence, in order for xequiv1 (x2) to be constant y∞,1 = y∞,2,
which gives:
xequiv1 (x2) =





























which is constant if s2/s1 = 1⇔ s1 = s2.
The Loewe Additivity Consistency Condition is therefore ful-
filled for the Hill curves in the same ranges, y∞,1 = y∞,2 and
y0,1 = y0,2 and with the same slope s1 = s2.
A.4. Violation of the Loewe Additivity Consistency Condition137
A.4 Violation of the Loewe Additivity
Consistency Condition
When the LACC applies, the General Isobole Equation,
fGI (x1, x2), and both explicit solutions, f2→1(x1, x2) and
f1→2(x1, x2), are equivalent. When the LACC fails, one may won-
der how to combine the two explicit solutions such that they are
still close to the solution of the General Isobole Equation Eq. 2.3.
Since the solution of the General Isobole Equation Eq. 2.3 is
symmetric, it makes sense to take the (weighted) mean of the two
solutions f2→1(x1, x2) and f1→2(x1, x2). Therefore, we define
(A.12)fmean (x1, x2) = β(x1, x2)f2→1(x1, x2)
+ [1− β(x1, x2)]f1→2(x1, x2) ,
with β(x1, x2) a weighting function. We wonder how to choose
β(x1, x2) such that fmean (x1, x2) ≈ fGI (x1, x2) under mild vio-
lations of the LACC.
In case the LACC holds, we have
x
equiv






i. e., the equivalent doses are proportional to the original doses. To
study mild violations of LACC, which we will refer to as LACC-ε,
we add a small quadratic term, i. e., consider
x
equiv





















1 (x2)) = x2 +O(ε2)
where we take ε to be small so that we can ignore all second and
higher order terms in ε. Note the different dependence on c in
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the two quadratic terms. These are necessary for the consistency
condition to hold. Our goal is now to find β(x1, x2) such that
under LACC-ε we still have fmean (x1, x2) = fGI (x1, x2), or,
to put it differently, such that fmean (x1, x2) still satisfies the
General Isobole Equation.
Theorem 2. Under LACC-ε, the simple arithmetic mean
fmean (x1, x2) with β(x1, x2) = 1/2 satisfies the General Isobole
Equation.
Proof. As an intermediate step, we note that we can rewrite f2
into f1 and vice versa through
f2(x2 + x
equiv
2 (x1)) = f1(x
equiv





1 (x2)) = f2(x
equiv






1 (x2 + x
equiv
2 (x1)) =
= cx2 + cx
equiv




= cx2 + x1 − ε
x21
c
+ εcx22 + 2εx1x2 + ε
x21
c
= x1 + x
equiv





































where, here and in the following, we ignore second and higher
order terms in ε.
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For fmean (x1, x2) to satisfy the General Isobole Equation, we
need
x1
f−11 (fmean (x1, x2))
+
x2
f−12 (fmean (x1, x2))
= 1 .
Luckily, using the above expressions, we have two ways to rewrite
fmean (x1, x2): in terms of f1,
fmean (x1, x2)
= β(x1, x2)f1(x1 + x
equiv
1 (x2))
+[1− β(x1, x2)]f1(x1 + x
equiv





1 (x2) + 2ε[1− β(x1, x2)]x1x2
)
,
and in terms of f2,
fmean (x1, x2)
= β(x1, x2)f2(x2 + x
equiv
2 (x1)− 2εx1x2/c)
+[1− β(x1, x2)]f2(x2 + x
equiv
2 (x1))
= f2(x2 + x
equiv
2 (x1)− 2εβ(x1, x2)x1x2/c) ,
where the last step follows from the observation that, again keeping
track of just the first order terms in ε,
βf(x+ ε) + (1− β)f(x)
= βf(x) + βεf ′(x) + (1− β)f(x)
= f(x) + βεf ′(x) = f(x+ βε) . (A.13)
140 Appendix A. Supplement to Chapter 2
Plugging these two formulations at the obvious places in the
General Isobole Equation, we obtain
1 =
x1
f−11 (fmean (x1, x2))
+
x2










1 (x2)− 2εβ(x1, x2)x1x2/c
=
x1
x1 + cx2 + εcx22 + 2ε[1− β(x1, x2)]x1x2
+
cx2
cx2 + x1 − εx21/c− 2εβ(x1, x2)x1x2
.
Further expansion in ε yields















So, for the first order term in ε to cancel, we must have
0 = −cx1x2 − 2[1− β(x1, x2)] + cx1x2 + 2β(x1, x2)
= −2 + 4β(x1, x2) ,
with solution β(x1, x2) = 1/2: simple equal weighting.
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A.5 Benchmark Test on Generated
Data from Yonetani
To show the speed advantage of the explicit formulation derived
from the Loewe Additivity principle, we conducted a benchmark-
ing test. We compare the computation time of the null reference
models GI (Eq. 2.3), f2→1 (x1, x2) (Eq. 3.5), f1→2 (x1, x2) (Eq. 3.6),
and Explicit Mean Equation (Eq. 2.13). For this, we use the
dataset from Yonetani and Theorell [231] which is known to be
non-interactive [30]. We fit the conditional parameters as de-
scribed in Supplement B.1. For the benchmarking test, we made
use of the microbenchmark package [135]. It runs each calculation
per default 100 times. A visualization of the runtime is depicted in
Fig. A.1 The explicit formulations are clearly faster in computing


































Figure A.1: Benchmark study. Elapsed computation
times on a log-scale for the four models fGI (x1, x2) (Eq. 2.3),
the explicit formulation (Eq. 3.5 and Eq. 3.6), and its mean
formulation fmean (x1, x2) (Eq. 2.13).
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A.6 Geometric Mean Model
Analogously to the weighted mean, we take the geometric mean
of the two explicit models f2→1 (x1, x2) and f1→2 (x1, x2) depicted
in Eq. 3.5 and 3.6
fgeometric (x1, x2) =
√
f2→1f1→2. (A.14)
In parallel to the Explicit Mean Equation, the geometric mean
is the least sensitive to a violation of the LACC with an equal
weighting of both formulations f2→1 and f1→2: Assume the Ex-
plicit Geometric Mean Equation model with weights β(x1, x2):




Obviously, under LACC we have fgeometric (x1, x2) =
fmean (x1, x2) = fGI (x1, x2) for any choice of β(x1, x2).
Theorem 2. Under LACC-ε, the (weighted) geometric mean
fgeometric (x1, x2) equals the arithmetic mean fmean (x1, x2) with
the same β(x1, x2).
Proof. Following the exact same line of reasoning as in the proof
of Theorem 2 up to Eq. A.13 in Supplement A.4, again ignoring
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fgeom.mean(x1,x2) with s1 ≠ s2, y∞,1 ≠ y∞,2
Figure A.2: Response surface of fgeometric (x1, x2).
Contour lines of the fgeometric (x1, x2) model for three dif-
ferent scenarios, where the LACC is violated: from left to
right: the slopes are different, s1 6= s2, here depicted with
s1 = 1, s2 = 2, y∞ = 0, or the maximal effect values differ,
y∞,1 = y∞,2, here shown with s = 1, y∞,1 = 0.3, y∞,2 = 0 or
both are different, here shown with s1 = 1, s2 = 2, y∞,1 =
0.3, y∞,2 = 0. The remaining two parameters of the Hill curve
are set equally for all figures to y0 = 1 and e = 1 are equal.
= f1(x1 + x
equiv
1 (x2) + 2ε[1− β(x1, x2)]x1x2)
= fmean (x1, x2) ,
where we applied the reasoning of (A.13) to the term in the
exponent.
This then gives the following corollary:
Corollary 4. Under LACC-ε, the simple geometric mean
fgeometric (x1, x2) with β(x1, x2) = 1/2 satisfies the General
Isobole Equation.
Analogously to Fig. 2.4D, the Explicit Geometric Mean Equa-
tion model takes different shapes for the different violations of
LACC, as depicted in Fig. 2.3. They are depicted in Fig. A.2
We compute the mean-squared error values of each non-
interactive record and compare them with the mean-squared errors
of the fGI (x1, x2) model. The scatter plots for the two datasets
are depicted in Fig. A.3. A Wilcoxon signed-rank on both error
value sets for the fGI (x1, x2) and the fgeometric (x1, x2) model,











































































































Figure A.3: Quality of fit. Mean-squared error between the
measured and the expected responses of the fgeometric (x1, x2)
and fGI (x1, x2) model. To better qualify the differences in
mean-squared error, the diagonal is depicted. The distribu-
tion of the models’ mean-squared error is given in histograms
plotted on the axes.
with the alternative hypothesis being that the errors of fGI (x1, x2)
are larger, give the following p-values: for the Mathews Griner
dataset: 6.38× 10−6 and for Cokol 7.26× 10−4.
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B.1 Data Cleaning, Fitting of Hill
Curve and Parameter Estimation
for Implicit Models
First, we normalize all records by the measured response at zero
dose concentration from both compounds, y0. Second, we conduct
an outlier analysis of the normalized responses by fitting a spline
surface and deleting outliers to discard them. Third, we fit the
conditional responses of the cleaned data to Hill curves. Fourth,
we explain how to calculate the implicit response values of the
fGI (x1, x2) model.
We fit a general additive model (GAM) to the normalized raw
data using thin plate splines [222], not transforming the doses
in any way. The surfaces of those fitted thin plate splines span
the checkerboards of every record and data points with too large
absolute residual values are rejected. For fitting the splines we
use method gam() of the mgcv package [221], defining the smooth
terms within the gam formula with the method s() We set the
dimension of the basis, that is used to represent the smooth term
to k = 30 fixed knots.
The threshold to reject data points is at three times (Chapter 2)
or five times (chsynergy the inter-quantile range of all residuals of
a given record. Every data point with an absolute residual above
that threshold is discarded. With three times the inter-quantile
range, we exclude the following: For the Mathews Griner data,
this leads to 125 records out of the 466 where a mean of 1.59
outliers were excluded per record. A maximum of 6 outliers was
detected once. Similarly, we excluded 4.21 data points for the
Cokol data on 150 of the total 200 records with a maximum of
13 data points. With a threshold of five times the inter-quantile
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range, we are exclude the following: For the Mathews Griner data,
this leads to 18 records out of the 466 (less than 4%) where a mean
of 1.28 outliers were excluded per record with an overall of 23
data points excluded, which is less than one percent of the overall
data. A maximum of 6 outliers was detected once. Similarly, we
excluded on average 2.48 data points for the Cokol data on 52 of
the total 200 (≤ 25%) records with a maximum of 13 data points
and an overall of 129 data points excluded, which is about 1% of
all data points.
To fit the two conditional responses of a record to two Hill
functions of the form of Eq. 2.1 we use the drc package [170].
Unlike other synergy analyses such as [227], the response at zero
concentration y0 is not fixed to 1 but merely constrained to be
the same for both response curves. The other Hill parameters,
y∞, s and e are fitted for both compounds individually. In case
the asymptote parameter y∞ is below zero for any of the two
Hill curves, the conditional response of that compound is refitted
to a two-parameter model with y∞ set to zero and y0 kept from
the fitting of both compounds together. This is the case for 43
records of the Mathews Griner dataset and 125 records of the
Cokol dataset. We exclude records for which any of the Hill curve
parameters slope or EC50 are negative (s < 0, e < 0). This is the
case for 187 records for the Mathews Griner dataset (133 records
with negative slope s, 88 records with negative EC50 value e, out
of which there are 34 records with negative slope and negative
EC50 value), which is roughly 40% of all records. More details
follow below.
B.1.1 Sensitivity of Model Performance to
Inter-Quantile Range
For the two chapters Chapter 2 and Chapter 3, we cleaned the
data to three times the inter-quantile range and to five times the
inter-quantile range, respectively. With this smaller inter-quantile
range we removed in the Mathews Griner dataset in total 199
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data points instead of 23, and in the Cokol dataset 623 instead of
129.
The different results of the Wilcoxon signed-rank test, as
applied in Chapter 2 on the definition of null-reference models,
are displayed in Table B.1.
3 · IQR 5 · IQR
pMathews Griner 1.18× 10−5 9.73× 10−7
pCokol 5.47× 10−3 4.68× 10−2
Table B.1: p-values of Wilcoxon signed-rank test of the
mean-squared error values from fitting fGI (x1, x2) and
fmean (x1, x2) to the non-interactive records of the Mathews
Griner and Cokol datasets, respectively.
The performance of the synergy study on the Mathews Griner
dataset for the lack-of-fit method slightly decreased, whereas the
overall performance for the Cokol dataset increased.
As a note, approximately the same number of records were
excluded for the analysis due to two issues: i) negative slopes
of at least one of the conditional dose response curves, or ii)
the root-finder for the fCI (x1, x2|α) model not converging (no
convergence after 1000 iterations). These issues are independent
from data cleaning with three or five times the inter-quantile
range (see Supplement B.3, Table B.13 - Table B.16).
B.1.2 Handling Records with Negative Slope s
or EC50 Values e
Roughly 40% (187) of all records of the Mathews Griner dataset
were excluded in the study because of a negative slope or EC50
parameter. This is due to a suboptimal choice of doses. We
observed two types of sub-optimality: first, the maximal dose can
be too small to induce a significant change in response. Due to
the noise in measurements, negative slope and EC50 parameters
are fitted. This is the case for 34 records. A second type of
sub-optimality is observed when the maximal effect is already





































































Figure B.1: Sensitivity of quality of fit to IQR. Scat-
ter plot of mean-squared error values of the Mathews Griner
(upper row) and the Cokol dataset (lower row), comparing the
results for cleaning data with three times the inter-quantile
range (on x-axis) and five times the inter-quantile range (on
y-axis). The mean-squared error values are computed be-
tween the compute null-reference models fGI (x1, x2) (left)
and fmean (x1, x2) (right) for all records that are originally
categorized as non-interactive. Outliers for either model are
colored in the same color for both models.
reached for the second dose (the first dose is always zero). This is
the case for the remaining 153 records.
Although we could not fit two reasonable Hill curves to these
records, we can still use both methods, lack-of-fit and parametric,
to quantify synergy. They both only require two mathematically
well-defined conditional response curves. Here, we define a con-
ditional response for cases with negative slope or negative EC50
parameter according to Table B.2.
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Figure B.2: Sensitivity of synergy to IQR on the basis
of Kendall rank correlation coefficient. Scatter plot of
Kendall rank correlation coefficient for both datasets, Mathews
Griner (left) and Cokol (right), comparing the performance of
the lack-of-fit method for different data-cleaning thresholds.
The Kendall rank correlation coefficient values resulting from
the cleaned data with three times the inter-quantile range are
plotted on the x-axis and those from the data cleaned with a
threshold of five times inter-quantile range are plotted on the
y-axis. Each model is depicted in a different colour. To guide
the eye, the diagonal is plotted.
With the above definition for conditional response curves, we
investigated the 187 previously excluded records in detail. We
computed the lack-of-fit synergy values γ for those 187 records
and for the entire dataset of 466 records. For two of these records,
the fGI (x1, x2) model did not converge. The Kendall rank corre-
lation coefficient values are given in Supplement B.3, Table B.17.















































Figure B.3: Sensitivity of synergy to IQR on the ba-
sis of AUC values. Scatter plot of ROC analysis for both
datasets, Mathews Griner (left) and Cokol (right), compar-
ing the performance of the lack-of-fit method for different
data-cleaning thresholds. The AUC values resulting from the
cleaned data with three times the inter-quantile range are
plotted on the x-axis and those from the data cleaned with
a five times inter-quantile range are plotted on the y-axis.
AUC values from different models are shown in different colors.
AUC values comparing the different categories are depicted in
different shapes, where the naming of the shape represents the
category that is compared to the remaining two. To guide the
eye, the diagonal is plotted. The more a datapoint is above
the diagonal, the better the performance of the data cleaned
with a threshold of five times the inter-quantile range, and
vice versa.
The inclusion of those datasets results in lower Kendall rank corre-
lation coefficients relative to the original analysis. The coefficients
decrease by roughly 0.05 when averaged over all models.
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s e y(x)
< 0 < 0 y0 ∀ x
< 0 > 0 y∞ for x 6= 0
> 0 < 0 y∞ for x 6= 0
Table B.2: Response curves for cases where the Hill model
fit leads to negative slope or negative EC50 values.
Parameter Estimation for Implicit Models
The fGI (x1, x2) model is an implicit model for the response y.
Therefore, a root finder is used to find a response ŷi for a given
parameter set Θ = {y0, y∞,j, ej, sj}, and concentrations xi,1 xi,2.
For finding such a root the standard implementation of a root
finder in the R stats package, uniroot() [166], is used which
uses the Brent-Dekker-van Wijngaarden algorithm [163, Chapter
9]. As convergence criterion we used 1.22× 10−4 with a maximum
of 103 iterations.
To ensure the existence of the inverse values of the Hill curve at
a given response y, f−1 (y), the responses are limited to the range
for which the Hill curve is defined, [y0, y∞]. Responses outside this
range are set to the closest range limits, i.e. if y > y0 ⇒ y = y0
and if y < y∞ ⇒ y = y∞.
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B.2 ROC Analysis
In high-throughput synergy studies, one generally screens for
promising candidates that exhibit a synergistic or antagonistic
effect. Those promising candidates are then investigated in more
detail with genetic assays and other techniques. To determine
how well the underlying null reference models result in distin-
guishable synergy scores, we conduct an ROC analysis (receiver
operating characteristic), comparing the estimated synergy scores
with the class categorization that is given for both datasets. A
standard ROC analysis applies to binary classification, where
cases are compared to controls. In this study, we have three
classes: synergistic, antagonistic and non-interactive. We there-
fore compare each class to the combination of the other two, e.g.
synergistic as cases versus the antagonistic and non-interactive
combined as control. Typically, in ROC analyses, the cases rank
higher than the controls. When treating the class antagonistic as
case compared to the control synergistic and non-interactive we
change all signs of the synergy scores. Therefore, the ranking of
synergy scores is reversed and antagonistic synergy scores rank
higher. Problems arise when comparing non-interactive cases to
the control synergistic and antagonistic as their values should lie
between the two control classes. Therefore, the absolute value
of the estimated synergy scores is taken, which allows a ranking
where the synergy scores of the non-interactive records should
rank lower than the other synergy scores. Additionally, we can
again multiply all synergy scores with minus one to revert the
order of scores such that the cases rank higher.
The AUC values (area under the curve) are reported in Ta-
ble B.5 - Table B.8 in Supplement B.3. For completeness, and
based on the critique of Saito and Rehmsmeier [175] to use PRC-
AUC (precision/recall area under the curve) values for imbalanced
datasets, the PRC-AUC values are also computed and can be
found in Table B.9 - Table B.12 in Supplement B.3.
Analogously to the previous section, we depict the AUC values
for both datasets in scatter plots (Fig. B.4) with AUC values
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based on the parametric approach depicted on the x-axis and






















































Figure B.4: ROC analysis. Scatter plot of AUC values
for both datasets, Mathews Griner (left) and Cokol (right).
The AUC values resulting from the parametric approach are
plotted on the x-axis and those from the lack-of-fit approache
are plotted on the y-axis. Each model is depicted in a different
color. The three different comparisons, of one case versus
the remaining two, are depicted in different shapes. To guide
the eye, the diagonal is plotted. If a data point is above the
diagonal, the AUC value from the lack-of-fit method is higher
than that from the parametric method, and vice versa. Except
for the non-interactive comparison of the Bliss Independence
model, the synergy scores γ from the lack-of-fit method always
result in higher AUC values than those computed based on
the synergy scores α from the parametric method.
The underlying null reference models are shown by color. The
different comparisons, such as synergistic versus non-interactive
and antagonistic, are depicted by shape of the plot symbol.
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From Fig. B.4, the dominance of the lack-of-fit approach over
the parametric one is as apparent for the Mathews Griner dataset
as from Fig. 3.2. With regard to the comparison of the different
cases, visualized in shape, the AUC values from the comparison
of the synergistic cases to the non-interactive and antagonistic
controls, score the highest values around 0.9. The comparison of
the non-interactive cases to the interactive ones score the lowest.
As the overall highest AUC scores result from the lack-of-fit
method, we have a closer look at those for both datasets (Table B.6
and Table B.8 in Supplement B.3). For the antagonistic case,
the values range around 0.80 for the Mathews Griner dataset
and around 0.85 for the Cokol dataset. AUC values of the non-
interactive case range around 0.75 for both datasets. The AUC
values for the synergistic case for both datasets range around a
value of 0.90 with one outlier of 0.75 for the Bliss Independence
model on the Mathews Griner dataset.
Overall, the lack-of-fit outperforms the parametric method on
the Mathews Griner dataset. For the lack-of-fit method, both
the flarge→small (x1, x2) and Explicit Mean Equation perform
best on the Mathews Griner dataset for synergistic cases, and a
clear dominance of flarge→small (x1, x2) over the Explicit Mean
Equation for antagonistic and non-interactive cases. On the second
dataset, the Cokol dataset, Explicit Mean Equation performs
overall best for both methods.
We attribute the differences in performances of methods and
models on the two datasets to the differences in the experimental
design for these datasets. For the Cokol dataset, all compounds
were applied up to their maximal effect dose. In the Mathews
Griner dataset, all compounds were applied with the same fixed
dose range.
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model lack-of-fit parametric
fGI (x1, x2) 0.52 0.23
flarge→small (x1, x2) 0.54 0.32
fsmall→large (x1, x2) 0.48 0.19
fmean (x1, x2) 0.53 0.10
fgeary (x1, x2) 0.47 0.30
fbliss (x1, x2) 0.36 0.22
Table B.3: Kendall rank correlation coefficient of Mathews
Griner dataset.
model lack-of-fit parametric
fGI (x1, x2) 0.62 0.12
flarge→small (x1, x2) 0.61 0.50
fsmall→large (x1, x2) 0.50 0.57
fmean (x1, x2) 0.67 0.64
fgeary (x1, x2) 0.56 0.58
fbliss (x1, x2) 0.56 0.16
Table B.4: Kendall rank correlation coefficient of Cokol
dataset.
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synergistic non-interactive antagonistic
fGI (x1, x2) 0.67 0.63 0.62
flarge→small (x1, x2) 0.73 0.68 0.72
fsmall→large (x1, x2) 0.68 0.53 0.53
fmean (x1, x2) 0.62 0.68 0.46
fgeary (x1, x2) 0.70 0.57 0.60
fbliss (x1, x2) 0.66 0.45 0.62
Table B.5: AUC analysis of parametric method applied to
Mathews Griner dataset.
synergistic non-interactive antagonistic
fGI (x1, x2) 0.88 0.77 0.81
flarge→small (x1, x2) 0.89 0.78 0.84
fsmall→large (x1, x2) 0.86 0.68 0.78
fmean (x1, x2) 0.89 0.75 0.82
fgeary (x1, x2) 0.85 0.69 0.78
fbliss (x1, x2) 0.75 0.60 0.76
Table B.6: AUC analysis on lack-of-fit method applied to
Mathews Griner dataset.
synergistic non-interactive antagonistic
fGI (x1, x2) 0.62 0.62 0.55
flarge→small (x1, x2) 0.80 0.64 0.84
fsmall→large (x1, x2) 0.86 0.64 0.89
fmean (x1, x2) 0.89 0.74 0.93
fgeary (x1, x2) 0.80 0.74 0.89
fbliss (x1, x2) 0.62 0.55 0.59
Table B.7: AUC analysis on parametric method applied to
Cokol dataset.
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synergistic non-interactive antagonistic
fGI (x1, x2) 0.93 0.78 0.88
flarge→small (x1, x2) 0.94 0.63 0.86
fsmall→large (x1, x2) 0.83 0.66 0.83
fmean (x1, x2) 0.95 0.80 0.91
fgeary (x1, x2) 0.88 0.71 0.86
fbliss (x1, x2) 0.86 0.43 0.87
Table B.8: AUC analysis on lack-of-fit method applied to
Cokol dataset.
synergistic non-interactive antagonistic
fGI (x1, x2) 0.39 0.69 0.35
flarge→small (x1, x2) 0.62 0.73 0.32
fsmall→large (x1, x2) 0.52 0.58 0.13
fmean (x1, x2) 0.56 0.74 0.18
fgeary (x1, x2) 0.61 0.61 0.15
fbliss (x1, x2) 0.39 0.55 0.17
Table B.9: PRC-AUC analysis on parametric method applied
to Mathews Griner dataset.
synergistic non-interactive antagonistic
fGI (x1, x2) 0.78 0.75 0.48
flarge→small (x1, x2) 0.80 0.74 0.55
fsmall→large (x1, x2) 0.72 0.69 0.33
fmean (x1, x2) 0.78 0.76 0.42
fgeary (x1, x2) 0.71 0.70 0.35
fbliss (x1, x2) 0.52 0.64 0.39
Table B.10: PRC-AUC analysis on lack-of-fit method applied
to Mathews Griner dataset.
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synergistic non-interactive antagonistic
fGI (x1, x2) 0.30 0.57 0.51
flarge→small (x1, x2) 0.56 0.56 0.65
fsmall→large (x1, x2) 0.62 0.52 0.83
fmean (x1, x2) 0.71 0.55 0.89
fgeary (x1, x2) 0.60 0.58 0.82
fbliss (x1, x2) 0.30 0.45 0.50
Table B.11: PRC-AUC analysis on parametric method ap-
plied to Cokol dataset.
synergistic non-interactive antagonistic
fGI (x1, x2) 0.84 0.65 0.83
flarge→small (x1, x2) 0.87 0.46 0.72
fsmall→large (x1, x2) 0.63 0.56 0.72
fmean (x1, x2) 0.87 0.66 0.86
fgeary (x1, x2) 0.75 0.60 0.77
fbliss (x1, x2) 0.76 0.35 0.70
Table B.12: PRC-AUC analysis on lack-of-fit method applied
to Cokol dataset.
synergistic antagonistic non-interactive total
parametric 19 15 48 82
lack-of-fit 34 59 93 186
both 19 16 49 84
Table B.13: Number of excluded records from parametric
and lack-of-fit method applied to the Mathews Griner dataset
with a threshold of three times the inter-quantile range.
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synergistic antagonistic non-interactive total
parametric 21 16 49 86
lack-of-fit 36 58 91 185
both 21 16 49 86
Table B.14: Number of excluded records from the parametric
and lack-of-fit method applied to the Mathews Griner dataset
with cleaned data of a threshold of five times the inter-quantile
range.
synergistic antagonistic non-interactive total
parametric 6 4 6 16
lack-of-fit 7 5 7 19
both 6 4 6 16
Table B.15: Number of excluded records from parametric and
lack-of-fit method applied to the Cokol dataset with cleaned
data of a threshold of three times the inter-quantile range.
synergistic antagonistic non-interactive total
parametric 3 2 4 9
lack-of-fit 3 3 4 10
both 3 2 4 9
Table B.16: Number of excluded records from parametric
and lack-of-fit method applied to Cokol dataset with cleaned
data of a threshold of five times the inter-quantile range.
subset of entire set of original analysis on
model 185 records 464 records 279 records
fGI (x1, x2) 0.37 0.47 0.52
flarge→small (x1, x2) 0.34 0.43 0.54
fsmall→large (x1, x2) 0.42 0.46 0.48
fmean (x1, x2) 0.37 0.43 0.53
fgeary (x1, x2) 0.35 0.39 0.47
fbliss (x1, x2) 0.27 0.34 0.36
Table B.17: Kendall rank correlation coefficients with re-
computed conditional response curves according to Table B.2
on 185 records with negative slope or EC50 value (left) and
on entire dataset with 464 records (right).
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B.4 Supplemental Figures
Figure B.5: Defining antagonism. Description of the analysis
steps of the lack-of-fit method for the compound pair FEN and
DYC from the Cokol dataset. This compound pair is categorized as
antagonistic according to [32]. The raw response data of the record
is depicted in (B). The response data normalized by the read at
zero dose concentration (lower left). In (B) the degree of relative
cell growth is colored from high to low values in red to blue. Step
1: compute Hill curves for conditional responses: Based on the raw
reads of the single dose responses (lower and left outer edges) fit a
Hill curve to the conditional responses. The fitted Hill curves shown
in (A) and (D) with original raw data shown as points. Step 2:
compute expected non-interactive response for all six models: not
shown. Step 3: compute difference between measured data (C) and
expected data from all six null reference models: shown in (C). The
direction of difference is shown by color (red for negative and blue
for positive, green for zero). The larger the degree of difference, the
larger the bullet, and vice versa. Step 4: compute integral γ over
the differences: Over all those bullets, we then compute the integral,
which gives the synergy score γ. For every model, the synergy score
γ is depicted in the title of each matrix in (C).


































































































































































































Figure B.6: Misclassified records. Raw responses (left)
and expected responses from the Explicit Mean Equation
model (right) of the four records from the Cokol dataset,
for which the General Isobole Equation and Explicit Mean
Equation gave synergy scores of opposite sign to the orignal
categorization. More details on some parameters of the Hill
curves can be found in Fig. 3.6.
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C.1 Bayesian Linear Mixed Models





mt,gωt,c + noise, (C.1)
where we model the normalized gene expression signal ȳg,c =
yg,c − ȳg − ȳc as a linear combination of the motif scores MT,G,
which are each, dependent on the sample c and the TF t, weighted
with ωT,C . The term ‘noise‘ represents all signal that cannot be
explained by the model, i. e. the linear combination of the motif
scores MT,G. This can be any technical noise, motif influence
for which the linear assumption might be too simplistic, but
also any other source that drives the gene expression yg,c and
is not modeled. The model was originally introduced by The
Fantom Consortium and the Riken Omics Science Center [200]
and subsequently expanded by Balwierz et al. [3].
The main idea behind a Bayesian approach is to include some
prior knowledge into the data, called the prior. Here, we model ωt,c,
the influence of motif t ∈ {1, . . . , T} in condition c ∈ {1, . . . , C},
as a normal distributed prior with mean zero. Its marginal distri-
butions are
ωC ∼ N (0,VC) , (C.2)







with σ2IT being the covariance over all motifs. Hence, we assume
independence between motifs. Assuming dependence between
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motifs with covariance Ψ can easily be implemented in the model.
Making use of the vectorization representation of multivariate
normal distribution, we can write the multivariate Normal distri-
bution of ωT,C as follows:
vec (ωT,C) ∼ N
(
0, σ2VC ⊗ IT
)
. (C.4)
Analogously, we can rewrite Supplemental Eq. C.1 in matrix-
vector notation:
vec (YG,C) ∼ N
(
MᵀT,GωT,C , δΣC ⊗ IG
)
, (C.5)
with ΣC being the covariance conditions and δIG covariance over
genes. In the following, we use Bayes’ rule on marginal and
conditional Gaussians (see Bishop [8, Chapter 2.3, p. 93]). We
first list the general formulas here, which we copy from Bishop
[8]: The marginal distribution of x and conditional distribution











Translating that notation into our own notation, we get the
following equivalences:
x ≡ vec (ωT,C) ¯ ≡ 0 Λ−1 ≡ σ2VC ⊗ IT (C.8)
y ≡ vec (YG,C) A ≡MᵀT,G b ≡ 0 L
−1 ≡ δΣC ⊗ IG. (C.9)
In our own notation, and following Supplemental Eq. C.7, the
distribution of YG,C given ωT,C can be rewritten as:
vec (YG,C |ωT,C) ∼ N
(
0, σ2VC ⊗ΠG + δΣC ⊗ IG
)
, (C.10)
where ΠG = MᵀT,GMT,G.
Going back to the general formula from Bishop [8], the
marginal distribution of y and conditional distribution of x given
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y are computed according to the following:
p(y) = N
(

















Hence, based on Supplemental Eq. C.11 and Supplemental
Eq. C.12, the posterior distribution of ωT,C given YG,C is then










2VC ⊗ΠG + δΣC ⊗ IG. (C.15)
For the reformulation, we used the Woodbury matrix identity [223].
For the computation of the posterior values of ωT,C , with notation
ω̂T,C , it suffices to compute the mean of Supplemental Eq. C.14:





⊗ΠG + δΣC ⊗ IG
]−1 vec (YG,C)
As the covariance matrix is assumed to be the sum of Kronecker
products, the runtime complexity is reduced to O (G3 + C3) in
a O (G2 + C2) space instead of O (G3C3) runtime and a memory
requirement of O (G2C2) [122].
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C.2 Simulating Data
For the simulation study we generate data based on the model
introduced in Eq. 4.1-Eq. 4.4, given a covariance matrix VC . The
prior weight ω̃T,C and YG,C are generated according to Eq. 4.2
and Eq. 4.1. The expression data YG,C from Eq. 4.1 is then
used to estimate VC and ΣC . Based on these computations,
the posterior motif influence ω̂T,C is then computed and com-
pared to the simulated motif influence ω̃T,C with a Pearson cor-
relation [158] over all conditions. As gene set we use the 978
landmark genes from the LINCS project [105]. In a secondary
simulation we increase the size of the gene set to 5000 genes,
which originate from an analysis of the most variational genes
across all samples from the GTEx project (Genotype Tissue Ex-
pression, https://gtexportal.org/home/). We generate data
for C = {10, 30, 50, 70, 100, 120} conditions.
C.2.1 Covariance Types of VC
For the generation of simulated motif influence ω̃T,C (Eq. 4.2), a
covariance matrix σ2VC⊗IT needs to be given. As the covariance
along TFs is modeled to be independent, one can generate ω̃t,C
randomly T times with ω̃t,C ∼ N (0, σ2VC). In the following,
four covariance types are explained that we generate as VC to
serve as covariance for the generated ωT,C in Eq. 4.2 and hence
expression data YG,C in Eq. 4.3. All covariance matrices are then
normalized by their trace. Below, we explain how σ2 is generated.
Independence
For independent conditions, we simply set VC to an identity
matrix: VC = σ2IC . We refer to these as independent, but in
reality they are even isotropic, as the covariance between samples
is assumed to be identical.
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Unrestricted Correlation
A random (uniform) C × C matrix RC is generated and added
with an identity matrix. This is then multiplied with itself: VC =
σ2 (IC + RC) (IC + RC)
ᵀ
Correlation - High Correlation and 50% Correlation
We assume correlation between samples to allow for replicates and
similarities between cell-lines. Hence, we would expect that those
samples cluster in blocks when applying a clustering algorithm to
the data (see Supplemental Fig. C.8 or Supplemental Fig. C.13
as examples). Therefore, we generate these block matrices with
k blocks of ones. Samples within are block are then completely
correlated and completely independent from samples outside that
block. The size of the blocks is minimally one and randomly de-
termined. The sum of all block sizes is C. These blocks are lined
up along the diagonal. The non-block elements are set to −0.01.
The procedure is written in pseudo-code in Supplement C.2.3.
For an example of a k = 1
2
C covariance matrix, see Fig. 4.1A and
B, left panel. For the analysis, we generate highly correlated co-
variance matrices with two blocks, i.e. k = 2, and 50% correlated




C.2.2 Noise ΣC - Unstructured and Structured
To generate the gene expression data YG,C |ωT,C , we compute the
signal as the product of the motif scores MT,G (explained hereafter)
and ωT,C (explained previously). Due to the randomness in the
signal that is not explained by motifs, we add some random
noise which is drawn from a normal distribution with covariance
δΣC ⊗ IG. We generate ΣC in two different ways: (i) assuming
no particular structure, Σ
C,random, which is a matrix filled with
values drawn from a standard normal distribution, multiplied with
itself, or (ii) adding structure that is similar to VC : ΣC,VC ,ρ =
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Σ
C,random + ηρVC . The noise matrices are then normalized by
their trace.
Unstructured Noise ΣC
In a first step, we randomly generate a covariance matrix, anal-
ogously to the random covariance matrix VC : by taking the
product of a randomly drawn matrix, we assure its symmetry and
positive definiteness. A visualization is given in Fig. 4.1A, right
panel.
Structured Noise ΣC
To the unstructured noise matrix ΣC , explained in the previous
paragraph, we add a structure that is similar to VC :
ΣC,VC ,ρ = ηρVC + ΣC,random, (C.17)
where ηρ depends on ρ ∈ [0, 1], the degree of structure in the
noise. If ρ = 0, the noise is unstructured, and a fraction ρ of








tr(VC) for ρ ∈ (0, 1)
(C.18)
ΣC,VC ,ρ = ηρVC + ΣC,random (C.19)
We therefore control the degree of structure in the noise. A
visualization of such a structured noise matrix is given in Fig. 4.1B,
right panel. As any model is just a simplification of reality, we
cannot explain the entire signal expressed in the expression data
YG,C . This is especially the case as we model the signal uniquely
as a linear product of artificially computed motif scores. Hence,
there will always be signal in the data that cannot be explained by
motifs. We therefore add to the random environmental or technical
noise signal that explains the relationship between conditions.
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Signal-to-Noise Ratio
From previous research [3], it has been shown that roughly 10−
20% of the signal of gene expression can be explained by motif
influence in the promoter region. We therefore generate the data
in such a way, that 20% of the signal in expression data YG,C
is due to motifs, and the rest unexplainable noise. We achieve
this by adjusting the parameter σ2 and δ. The latter is fixed by
the rough percentage wished to be expressed by the noise, 1− β,
which we set to β = 0.2. For scaling reasons, it is divided with





with ‖·‖2= σmax (·) as the matrix 2-norm which is equivalent to
σmax (·), the maximal singular value. σ2 is determined by bisection,
such that it explains 0.2 of the variance coefficient (Eq. 4.1). As





tr (VC) tr (ΠG)
. (C.21)
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C.2.3 Pseudocode for the Generation of Lower
Rank Block Matrices
Algorithm 1 Generation of correlated covariance matrices
1: function generateBlocksizes( C, k ) . generate k blocksizes
that sum up to C
2: num_blocks← k
3: blocksizes← initialize vector of length num_blocks
4: for block_i in (num_blocks− 1) do
5: lenght_blocks← sum( blocksizes )
6: leftover-space← C − length_blocks + 1
7: blocksize_i← random integer between 1 and leftover-space
8: blocksizes[i]← blocksize_i
9: blocksizes[num_blocks]← C − block-lengths + 1
10: return blocksizes
11: procedure Block matrix of dimension C with k blocks
of size blocksizes
12: matrix ← initialize matrix of dimension C
13: block_i_start← 1
14: block_i_end← 0
15: blocksizes← generateBlocksizes(C, k)
16: for blocksize_i in blocksizes do
17: block_i_end← block_i_end + blocksize_i
18: matrix[block_i_start : block_i_end, block_i_start :
block_i_end]←
19: matrix of ones of size blocksize_i . place matrix of
ones onto diagonal
20: block_i_start← block_i_end
21: for all elements in matrix that are zero do
22: fill with 1e−2 . fill all off-diagonal elements
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Figure C.1: Ridge Regression is a special case of
Bayesian Linear Mixed Model, limiting the estimated
covariance and noise to be independent. Data was gen-
erated over G = 978 informative genes and T = 623 motif
scores and 100 repetitions, with structured ΣC . The results for
Bayesian Linear Mixed Model and Ridge Regression (RIDGE,
in blue) are equal when Bayesian Linear Mixed Model is lim-
ited to VC = σ2IC and ΣC = δIC (BLMM_id, in red). The
Pearson correlation values are computed between the generated
and predicted posterior motif influence ω̂T,C , and separated
by method used to compute them. Data is generated with (i)
independent samples, VC = IC , (ii) unrestricted correlation
between samples, (iii) 50% correlated data, where the samples
cluster in many (k = 12C) sample groups, (iv) highly correlated
data, by generating a covariance matrix with k = 2 completely
correlated sample groups, with C the number of conditions.
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Figure C.2: Simulation Study with Spearman’s rank
correlation values. Results of simulation study analogously
presented as in Fig. 4.1 with Spearman’s rank correlation
values.
C.3. Supplemental Figures 173
A B
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Figure C.3: Simulation Study with mean-squared er-
ror values. Results of simulation study analoguously pre-
sented as in Fig. 4.1 with mean-squared error values.
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correlated (two groups)


















Figure C.4: Models’ performance interchange supe-
riority for data generated with increasing structured-
ness in noise. Data was generated over G = 978 informative
genes, T = 623 motif scores, 100 repetitions, and with a co-
variance matrix “VC : highly correlated (two groups)”. ΣC is
generated with increasing degree of structuredness (x-axis).
Model performance of Bayesian Linear Mixed Model (BLMM,
in red) and Ridge Regression (RIDGE, in blue) are shown on
the bases of the Pearson correlation values between generated
and predicted motif-condition-weights.
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Figure C.5: Simulation study on G = 5000 genes. We
compare the model assumptions of Bayesian Linear Mixed
Model (BLMM, depicted in red) and Ridge Regression (LIMIX,
in blue) on datasets generated with C = 50 samples, and
G = 5000 genes. On the x-axis we show data that is generated
with unstructured noise (degree of structuredness=0) and with
structured noise with ρ = 0.7. On the y-axis, we depict the
Pearson correlation values between generated and predicted
motif-condition weights. In each panel, the data was gener-
ated with different assumptions on the degree of correlation
between samples: (i) independence (VC = IC (upper left),
(ii) unrestricted correlation (upper right), (iii) correlated with
many sample groupgs (lower left), and (iv) highly correlated
with two sample groups) (lower right). There is no difference
in performance when increasing the dimensionality of genes.
The Bayesian Linear Mixed Model has predictive power over
Ridge Regression when the data is correlated, uniquely for
unstructured noise. For structured noise (ρ = 0.7), there is no
gain in performance, despite the bigger size of the dataset.






























































































































Figure C.6: H3K27ac: VC for Ridge Regression. Esti-
mated correlation between conditions VC assuming indepen-
dence between the conditions for the H3K27ac dataset.






























































































































Figure C.7: H3K27ac: ΣC for Ridge Regression. Esti-
mated noise ΣC assuming independence between the condi-
tions for the H3K27ac dataset.






























































































































Figure C.8: H3K27ac: VC for Bayesian Linear Mixed
Model. Estimated correlation between conditions VC as-
suming dependence between the conditions for the H3K27ac
dataset.






























































































































Figure C.9: H3K27ac: ΣC for Bayesian Linear Mixed
Model. Estimated noise ΣC assuming dependence between
the conditions for the H3K27ac dataset.
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Figure C.10: GTEx: clustermaps of motif-condition-
weight matrix. Weights for the motif-condition-weights of
those 56 common motifs, that are outside of 2.5 times the
inter-quantile range for all motifs over a tissue. The weights
are computed assuming dependence (A) or independence (B)
between the conditions.
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Figure C.11: GTEx: VC for Ridge Regression. Esti-
mated correlation between conditions VC assuming indepen-
dence between the conditions for the GTEx dataset. Note that
only a subset of samples are labeled.
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Figure C.12: GTEx: ΣC for Ridge Regression. Esti-
mated noise ΣC assuming independence between the condi-
tions for the GTEx dataset. Note that only a subset of samples
are labeled.
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Figure C.13: GTEx: VC for Bayesian Linear Mixed
Model. Estimated correlation between conditions VC assum-
ing dependence between the conditions for the GTEx dataset.
Note that only a subset of samples are labeled.
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Figure C.14: GTEx: ΣC for Bayesian Linear Mixed
Model. Estimated noise ΣC assuming dependence between
the conditions for the GTEx dataset. Note that only a subset
of samples are labeled.
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Figure C.15: GTEx: Most similar motif scores be-
tween methods. Motif values for the five highest correlated
motif scores over all tissues.
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Figure C.16: GTEx: Least similar motif scores be-
tween methods. Motif values for the five lowest correlated
motif scores over all tissues.
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Figure C.17: GTEx: High variation between repli-
cates. Variation of all chosen 56 motif scores on exemplary
tissue EBV - cellline.
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Figure C.18: Cacchiarelli: clustermaps of motif-
condition-weight matrix. Motif weights for the 50 most
variable weights across conditions assuming dependence (A)
or independence (B) between the conditions. Common motifs
of Bayesian Linear Mixed Model (A) and Ridge Regression
(B) are depicted in blue, others are depicted in yellow.
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Figure C.19: Cacchiarelli: VC for Ridge Regression.
Estimated correlation between conditions VC assuming inde-
pendence between the conditions for the Cacchiarelli dataset.
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Figure C.20: Cacchiarelli: ΣC for Ridge Regression.
Estimated noise ΣC assuming independence between the con-
ditions for the Cacchiarelli dataset.



















































































































t = 2d, DOX+
t = 5d, DOX+
hIPSC-T
t = 24d, DOX+, TRA+
t = 20d, DOX+, TRA+
t = 24d, DOX-, TRA+
t = 14d, DOX+, SSEA3+
t = 10d, DOX+, SSEA3+






Figure C.21: Cacchiarelli: VC for Bayesian Linear
Mixed Model. Estimated correlation between conditions
VC assuming dependence between the conditions for the Cac-
chiarelli dataset.



















































































































t = 24d, DOX-, TRA+
t = 14d, DOX+, SSEA3+
t = 24d, DOX+, TRA+
t = 20d, DOX+, TRA+
hiF-T
t = 10d, DOX+, SSEA3+
t = 8d, DOX+
t = 2d, DOX+







Figure C.22: Cacchiarelli: ΣC for Bayesian Linear
Mixed Model. Estimated noise ΣC assuming dependence
between the conditions for the Cacchiarelli dataset.
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Figure C.23: Cacchiarelli: Scatterplot of estimated
motif weights ωT,C . Scatterplot of posterior motif weights
ωT,C of Bayesian Linear Mixed Model vs. Ridge Regression,
depicted per time series.




































































































































































































































Figure C.24: Toufighi: clustermaps of motif-
condition-weight matrix. Motif weights for the 50 most
variable weights across conditions assuming dependence (A)
or independence (B) between the conditions. Common motifs
of Bayesian Linear Mixed Model (A) and Ridge Regression
(B) are depicted in blue, others are depicted in yellow.
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Figure C.25: Toufighi: VC for Ridge Regression. Esti-
mated correlation between conditions VC assuming indepen-
dence between the conditions for the Toufighi dataset.
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Figure C.26: Toufighi: ΣC for Ridge Regression. Esti-
mated noise ΣC assuming independence between the condi-
tions for the Toufighi dataset.
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Figure C.27: Toufighi: VC for Bayesian Linear Mixed
Model. Estimated correlation between conditions VC as-
suming dependence between the conditions for the Toufighi
dataset.
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Figure C.28: Toufighi: ΣC for Bayesian Linear Mixed
Model. Estimated noise ΣC assuming dependence between
the conditions for the Toufighi dataset.
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Figure C.29: Toufighi: Scatterplot of estimated motif
weights ωT,C . Scatterplot of posterior motif weights ωT,C of
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D.1 Supplemental Tables
Compound 1 Compound 2 Known interaction (cell line) Ref.
afatinib everolimus MCF7 (breast) [193]
bortezomib clarithromycin MDA-MB-23, MDA-MB-468 (breast) [106]
vorinostat MDA-MB-23, MDA-MB-468 (breast) [106]
clarithromycin vorinostat MDA-MB-23, MDA-MB-468 (breast) [106]
docetaxel gemcitabine (metastatic breast cancer) [40]
gefinitib (non-small-cell lung cancer) [181]
erlotinib sorfenib MCF7 (breast) [193]
tamoxifen MCF7 (breast) [193]
rosiglitazone MCF7 (breast) [193]
cisplatin MCF7 (breast) [193]
everolimus gefinitib MCF7 (breast) [193]
gefitinib rosiglitazone A549 (lung) [193]
tamoxifen MCF7 (breast) [193]
itraconazole pemetrexed (non-small-cell lung cancer) [172]
oxaliplatin sulphoraphane Caco-2 (colorectal) [95]
sorafenib tamoxifen MCF7 (breast) [193]
Table D.1: Overview of compounds used in pilot study, with
known interactions, and cell lines on which they are known
to be interactive. Compound pairs are ordered alphabeti-
cally. Compound names written in green mark synergistic, in
red antagonistic interactions. As interactions are both ways,
combinations are displayed only once.
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compound concentrations in µM
compound cell-line x0 x1 x2 x3 x4 x5 x6
afatinib MCF7 0 0.5 1 2 3 5 10
afatinib A549 0 0.5 1 2 3 5 10
bortezomib MCF7 0 0.005 0.01 0.02 0.05 0.1 0.2
bortezomib A549 0 0.02 0.05 0.1 0.2 0.5 1
clarithromycin MCF7 0 10 20 50 100 200 500
clarithromycin A549 0 10 20 50 100 200 500
docetaxel MCF7 0 0.00625 0.0125 0.025 0.05 0.1 0.2
docetaxel A549 0 0.00625 0.0125 0.025 0.05 0.1 0.2
erlotinib MCF7 0 5 10 20 50 100 200
erlotinib A549 0 5 10 20 50 100 200
everolimus MCF7 0 5 10 15 20 30 50
everolimus A549 0 5 10 15 20 30 50
gefitinib MCF7 0 5 10 15 20 30 50
gefitinib A549 0 5 10 15 20 30 50
itraconazole MCF7 0 5 10 20 50 100 200
itraconazole A549 0 1 2 5 10 20 50
oxaliplatin MCF7 0 2 5 10 20 50 100
oxaliplatin A549 0 2 5 10 20 50 100
pemetrexed MCF7 0 0.05 0.1 0.2 0.5 1 2
pemetrexed A549 0 0.05 0.1 0.2 0.5 1 2
rosiglitazone MCF7 0 2 5 10 20 50 100
rosiglitazone A549 0 2 5 10 20 50 100
sorafenib MCF7 0 2 5 8 12 20 50
sorafenib A549 0 2 5 8 12 20 50
sulforaphane MCF7 0 7.5 10 15 20 30 50
sulforaphane A549 0 7.5 10 15 20 30 50
tamoxifen MCF7 0 2 5 8 12 20 30
tamoxifen A549 0 2 5 8 12 20 30
vorinostat MCF7 0 0.2 0.5 1 2 5 10
vorinostat A549 0 0.2 0.5 1 2 5 10
Table D.2: Chosen concentrations for each compound and
cell-line for the drug combination experiment.
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D.2 Correction of Plate Effects in the
First Pilot Study
D.2.1 Intra Plate Effects
Each compound is applied in an increasing concentration in a
consecutive order across columns, with three replicates distributed
over different rows and columns. For the CellTiter-Glo® data,
we found a strong row effect on most of the plates, which is
consistent across all three plates of a cell line, i. e. the low and
high concentration plate and the control plate. We found that if
the response of a compound was consistently higher in one row
then the same ordering was found for the other two plates of the
cell line (Fig. D.1, upper row). We speculate that this row effect
is caused by cell plating effects as cells were dispensed row-by-row.
We correct for the row effect by normalizing the compound’s
readout per row by its median value and multiply by the overall













where ycomp,platei,j is the original (raw) response in row i, col-










the median response of the compound
on the whole plate. Fig. D.1 depicts the original (raw) response
ycomp,platei,j and the corrected (row normalized) one ŷ
comp,plate
i,j for an
exemplary compound and cell-line, Taxol on A375. The normal-
ization significantly reduced the differences between repetitions
(see curves of a different color in Fig. D.1 and Fig. D.4). For the
L1000 data, we only found weak row-effects, for which we do not
correct.
It is recommended to randomize the plate layout in order to



































































Figure D.1: Correcting for intra plate effects of
CellTiter-Glo® data. Row effect per plate on the ex-
ample of Taxol on the A375 cell line across all three plates.
Top: raw CellTiter-Glo® signal, bottom: row-normalized
CellTiter-Glo® signal. The colors denote different replicates.
The control data are from the corresponding well locations
on the control plate. As no compounds were applied data is
plotted against order of application (by the dispensing robot).
reduce the variation introduced by artefacts Niepel et al. [149].
These can be edge effects, that arise from evaporation at the
edge of the plate, or non-uniform cell growth, usually caused
by differences in temperature [18, 36]. We could not find any
evidence for edge effects, which we verified by comparing the
response from edge wells with the response in central wells for
the control plates that had no compounds applied (results not
shown). The same analysis also revealed no such edge effects for
the other (non control) plates (results not shown). However, had
we randomized the layout, it would have been more difficult to


































































































































Figure D.2: Correction of inter plate effect of
CellTiter-Glo® data. Discontinuities between plates of
row-normalized CellTiter-Glo® response across the lower con-
centration and higher concentration plates for Taxol across the
three cell lines (A375, A549, MCF7). Colors denote different
repetitions. Top: row-normalized CellTiter-Glo® response.
Bottom: plate- and row-normalized CellTiter-Glo® response.
discover and correct for the plating effects. Thus, in the design of
the second iteration of the pilot experiment, we decided to keep
compounds in single rows of a plate.
D.2.2 Inter Plate Effects
Furthermore, for both CellTiter-Glo® and L1000, we found
discontinuities in response curves between plates, see the top
row of Fig. D.2. To correct the CellTiter-Glo® data for these
discontinuities, we divide by the median signal of “untreated”
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Figure D.3: Combining both plates for the computa-
tion of the TAS score reduces the inter plate effect
observed in L1000 data. TAS score of L1000 signal across
the low and high concentration plates (highlighted in different
colors) for a few selected compounds shown for the MCF7
cell line. Top: uncorrected TAS score. Bottom: TAS score
recomputed by combining low and high concentration plates
from level 3.
cells of a plate (indicated gray in Fig. 5.2) from each of the
readouts of the entire plate. As one can see in (Fig. D.2) this plate
normalization reduces the discontinuities, especially for MCF7
in this case (for compound Taxol). In Fig. D.4, we visualize the
median absolute deviance (MAD) of the response for each cell
line and compound. In order to compare the MAD’s at different
stages, divide them by the median signal.
As detailed in Section 5.1, we summarize the L1000 response
in the Transcriptional Activity Score (TAS). To correct for discon-
tinuities in TAS score across L1000 plates, we apply a different
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approach: As the data processing steps of the L1000 data are per-
formed per plate, we recompute level 3 to level 5 data combining
both the low and high concentration plates of the same cell line.
From the recomputed level 5 data, we recompute the TAS score.
As shown in Fig. D.3, this combination of both plates corrects for
most of the plate discontinuity effect. In Fig. D.4, we visualize
the median absolute deviance (MAD) across the TAS score for
each cell line and compound and divide the MADs by the median
signal. We show the overall distribution of the summarized values
per cell line and compound before and after correcting for the
inter-plate effects for the TAS score on the right-hand side. On
top, we display the p-values of a one-sided Wilcoxon signed-rank
test, with the alternative hypothesis of a lesser variance of the
group to the right.








































































































Figure D.4: Effect of normalization on overall vari-
ability in CellTiter-Glo® and L1000 data. Median ab-
solute deviance, normalized by median for comparison between
the different stages of normalization. Normalization of the
CellTiter-Glo® data is shown in (A) and of the TAS score of
the L1000 data (B), after row normalization (CellTiter-Glo®
only) and plate normalization (CellTiter-Glo® and L1000).
Summary of MAD/median is computed per cell-line and com-
pound and visualized separated by cell-line. The variance
summary for each step of normalization is connected by gray
lines. The p-values of a one-sided paired Wilcoxon signed-rank
test are displayed above the compared groups.
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In this thesis, we investigate the interaction effects of drug com-
bination therapies. Combinations of drugs are promising for
complex diseases such as cancer, cardiovascular and respiratory
diseases, HIV infections, and type II diabetes. These diseases are
complex as genetic aberrations do not only affect single molecular
targets but often have multi-factorial causality. Another challenge
arises of a quickly developed resistance against the drugs. To cir-
cumvent these problems, one uses a combination of drug therapies.
The main motivation behind applying such combinations is (i) to
increase the effectiveness of a therapy, (ii) to reduce toxicity, i. e.
side effects, and (iii) to delay the development of drug resistance.
If a combination of drugs fulfills either of these three criteria one
speaks of synergy or a synergistic effect between the compounds.
In order to detect a synergistic event, one first needs to define
an expected non-interactive effect, a so-called null-reference model.
Here, we dive into the mathematical definitions of synergy that
arose over the past century and show their applicability to two
real-world datasets. In a first step, we focus on the definition of
null models and investigate in detail the Loewe Additivity prin-
ciple. We formulate the so-called Loewe Additivity Consistency
Condition (LACC) and derive explicit and implicit null reference
models and show that they are equivalent if the LACC holds.
Of these two formulations, the implicit formulation is the well-
known General Isobole Equation, whereas the explicit one, the
Explicit Mean Equation, is novel. We compare the measurements
of the non-interactive cases of both datasets to the theoretical
null reference models in terms of bias and mean squared error.
We demonstrate that the explicit formulation of the null reference
model leads to smaller mean squared errors than the implicit one
and is also much faster to compute.
In a second step, we continue with the quantification of synergy.
We compare two different methods for the computation of synergy
on the basis of six null reference models, which are based on either
the Loewe Additivity or Bliss Independence. We demonstrate that
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the most promising way to compute a synergy score is based on
determining the volume of the area spanned between the expected
and measured response with the Explicit Mean Equation as null-
reference model.
Next, we take a step away from compound combinations
and phenotype measurements. Instead, we dive into the area
of molecular biology to dig deeper into the molecular biological
processes within the cells and investigate the mechanisms that
drive gene expression. We investigate gene regulatory networks,
where we explore modeling methods to model motif influence
on gene expression profiles. We compare the effect of loosening
mathematical assumptions of samples being independent and
allow for correlation instead. While there is an apparent gain of
this more flexible model on simulated data, the gain is negligible
when applied to real world data.
Last, we combine our understanding of synergy models and
biological processes on the molecular level. We outline a novel
study of drug combinations on the basis of gene expression profiles
and phenotype measurements to derive causal effects from gene
regulatory changes to the phenotype response.
This creates a somewhat complete picture of the effect of a
compound combination - from gene expression to phenotype.
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Samenvatting
In dit proefschrift onderzoeken we de interactie van medicijn-
combinaties. Geneesmiddelcombinaties worden voornamelijk ge-
bruikt bij complexere ziekten zoals kanker, hart- en vaatziekten
en aandoeningen van de luchtwegen, hiv-infecties en diabetes type
2. Deze ziekten vormen een therapeutische uitdaging omdat de
genetische afwijkingen die de ziekten veroorzaken niet alleen indi-
viduele moleculaire doelwitten beïnvloeden, maar vaak gebaseerd
zijn op een multifactoriële causaliteit. Deze ziekten zijn ook
moeilijk te behandelen omdat de aangetaste cellen snel resistentie
tegen geneesmiddelen kunnen ontwikkelen. Om deze problemen te
omzeilen, wordt een combinatie van medicijnen gebruikt. De be-
langrijkste motivatie voor het gebruik van dergelijke combinaties
ligt in (i) het vergroten van de effectiviteit van een therapie, (ii)
het verminderen van toxiciteit, d.w.z. bijwerkingen, en (iii) het
vertragen van het ontstaan van geneesmiddelresistentie. Als een
medicijncombinatie aan een van deze drie criteria voldoet, spreekt
men van synergie of synergetisch effect tussen de medicijnen.
Om een synergetische gebeurtenis te herkennen, moet eerst
worden gedefinieerd welk effect men zou verwachten in het
geval van een niet-interactieve reactie. Dit verwachte effect
wordt beschreven met een zogenaamd nulreferentiemodel. In
een eerste stap van dit werk duiken we in de wiskundige definities
van synergie van de afgelopen eeuw en tonen we hun toepas-
baarheid op twee echte datasets. Eerst concentreren we ons op
de definitie van nulreferentiemodellen en onderzoeken het Loewe-
additiviteitsprincipe in detail. Wij formuleren de zogenaamde con-
sistentievoorwaarde voor het Loewe Additiviteitsprincipe (Loewe
Additivity Consistency Condition, afgekort LACC) en leiden ex-
pliciet en impliciet geformuleerde nulreferentiemodellen af. Verder
laten we zien dat al deze modellen gelijkwaardig zijn als aan
de LACC wordt voldaan. Van deze twee formuleringen is de
impliciete formulering de bekende algemene isoboolvergelijking
(General Isobole Equation), terwijl de expliciete, de Explicit Mean
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Equation, een nieuwe bijdrage is. We vergelijken deze nulrefer-
entiemodellen door hun kwaliteit van de fitting te berekenen
voor metingen van medicijncombinaties die geen interactief effect
hebben. Deze metingen zijn afkomstig van de twee bovenge-
noemde datasets. Aan de hand van een kleinere bias en een
kleinere gemiddelde kwadratische fout laten we zien dat de expli-
ciete formulering van het nulreferentiemodel, de Explicit Mean
Equation, de gegevens beter modelleert dan de eerder bekende
impliciete formulering. Bovendien heeft de expliciete formule het
voordeel dat deze aanzienlijk sneller kan worden berekend.
In een tweede stap gaan we verder met het kwantificeren van
synergieën. We vergelijken twee verschillende methoden voor het
berekenen van synergieën met behulp van zes nulreferentiemod-
ellen, inclusief formuleringen van het Loewe-additiviteitsprincipe
en de Bliss onafhankelijkheid. We laten zien dat de meest veel-
belovende manier om synergiescores te berekenen bestaat uit
het bepalen van het volume dat tussen de twee gebieden van de
verwachte en de gemeten waarden ligt. Het nieuwe expliciete
model, de Explicit Mean Equation, blijkt wederom het beste
nulreferentiemodel.
In de volgende stap gaan we weg van het vorige onderwerp en
in plaats daarvan duiken in het gebied van de moleculaire biologie,
en richten onze aandacht op de moleculair biologische processen
die plaatsvinden in een cel. Hier onderzoeken we mechanismen
die veranderingen in genexpressie veroorzaken. Met behulp van
genregulatienetwerken vergelijken we methoden die de invloed van
motieven op genexpressieprofielen modelleert. We vergelijken het
effect dat ontstaat door het loslaten van wiskundige aannames,
namelijk de aanname dat biologische samples onafhankelijk van
elkaar zijn versus de aanname dat ze gecorreleerd kunnen zijn.
We laten zien dat het voordeel van zo’n flexibeler model, hoewel
duidelijk zichtbaar in gesimuleerde data, verwaarloosbaar is wan-
neer het wordt toegepast op echte data.
In het laatste deel van het proefschrift slaan we een brug
tussen synergiemodellen en biologische processen op moleculair
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niveau. We presenteren een studieontwerp om medicijncombi-
naties te bestuderen op basis van genexpressie en een uiteindelijk
fenotypisch effect. Het doel van de studie is om causale effecten af
te leiden van genetische regulatoire veranderingen op de fenotypes.
Dit geeft ons een compleet beeld van het effect van medicijn-




In dieser Arbeit untersuchen wir die Wechselwirkung von Medika-
mentenkombinationen. Arzneimittelkombinationen finden ihre
Anwendung vorallmen in komplexeren Krankheiten wie Krebs,
Herz-Kreislauf- und Atemwegserkrankungen, HIV-Infektionen und
Diabetes Typ 2. Diese Krankheiten stellen eine therapeutis-
che Herausforderung dar, da genetische Aberrationen, die die
Krankheiten verursachen, nicht nur Auswirkungen auf einzelne
molekulare Ziele haben, sondern oft einer multifaktoriellen Kausal-
ität zugrund liegen. Diese Krankheiten sind insofern auch
schwierig zu behandeln, da die betroffenen Zellen schnell Medika-
mentenresistenzen entwickeln können. Um diese Probleme zu
umgehen verwendet man eine Kombination von Arzneimitteln.
Die Hauptmotivation für die Anwendung solcher Kombinationen
besteht aus (i) der Erhöhung der Wirksamkeit einer Therapie,
(ii) der Verringerung der Toxizität, d.h. Nebenwirkungen, und
(iii) einem Verzögern der Entstehung der Arzneimittelresistenzen.
Wenn eine Medikamentenkombination eines dieser drei Kriterien
erfüllt, spricht man von Synergie oder synergistischem Effekt
zwischen den Arzneimitteln.
Um ein synergistisches Ereignis zu erkennen, muss zunächst
definiert werden, welchen Effekt man im Falle einer nicht stat-
tfindenden Wechselreaktion erwarten würde. Dieser erwartete Ef-
fekt wird mit einem sogenannten Nullreferenzmodell beschrieben.
In einem ersten Schritt dieser Arbeit tauchen wir ein in die
mathematischen Definitionen von Synergie aus dem vergangenen
Jahrhundert und zeigen ihre Anwendbarkeit auf zwei realen
Datensätzen. Zuerst konzentrieren wir uns auf die Definition
von Nullreferenzmodellen und untersuchen detailliert das Loewe-
Additivitätsprinzip. Wir formulieren die sogenannte Konsistenzbe-
dingung für das Loewe Additivitätsprinzip (Loewe Additivity
Consistency Condition, kurz LACC) und leiten explizit und im-
plizit formulierte Nullreferenzmodelle ab. Desweiteren zeigen wir,
dass alle diese Modelle äquivalent sind wenn die LACC erfüllt ist.
Von diesen beiden Formulierungen ist die implizite Formulierung
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die bekannte Allgemeneine Isobolengleichung (General Isobole
Equation), wohingegen die explizite, die Explicit Mean Equation,
ein neuer Beitrag ist. Wir vergleichen diese Nullreferenzmodelle
indem wir deren Anpassungsgüte zu Messungen von Medika-
mentenkombinationen berechnen, die keinen interaktiven Effekt
haben. Diese Messungen stammen aus den beiden oben genannten
Datensätzen. Anhand eines kleineren Bias und eines kleineren
mittleren quadratischen Fehlers zeigen wir, dass die explizite For-
mulierung des Nullreferenzmodells, die Explicit Mean Equation,
besser die Daten modelliert als die bisherig bekannte implizite
Formulierung. Desweiteren hat die explizite Formel den Vorteil
signifikant schneller berechnet werden zu können.
In einem zweiten Schritt gehen wir über zu der Quantifizierung
von Synergie. Wir vergleichen zwei verschiedene Methoden zur
Berechnung von Synergien anhand von sechs Nullreferenzmodellen,
einschließlich Formulierungen des Loewe Additivitätsprinzips und
der Unabhängigkeit von Bliss. Wir zeigen, dass der vielver-
sprechendste Weg zur Berechnung eines Synergie-Scores darin
besteht das Volumen zu bestimmen, welches zwischen den beiden
Flächen der erwarteten und der gemessenen Werte liegt. Als
bestes Nullreferenzmodell eignet sich auch hier wieder das neue
explizite Model, die Explicit Mean Equation.
Im nachfolgendem Schritt entfernen wir uns vom bisherigen
Thema und tauchen stattdessen ein in den Bereich der Moleku-
larbiologie, genauer in die molekularbiologischen Prozesse, die
innerhalb einer Zelle stattfinden. Hier untersuchen wir Mechanis-
men die Veränderungen in Genexpression hervorrufen. Anhand
von Genregulationsnetzwerken vergleichen wir Methoden, die den
Einfluss von Motifen auf Genexpressionsprofilen modellieren. Wir
vergleichen den Effekt, der durch Lockerungen mathematischer
Annahmen entsteht, nämlich der Annahme, dass biologische Sam-
pels unabhängig voneinander sind im Vergleich zu der Annahme,
dass sie korreliert sein können. Wir zeigen, dass der Vorteil
eines solchen flexibleren Modells in simulierten Daten zwar klar
erkennbar ist, aber vernachlässigbar ist, wenn es auf Echtdaten
angewendet wird.
249
Im letzten Teil der Arbeit schlagen wir eine Brücke von Syn-
ergiemodellen zu biologischen Prozessen auf der molekularen
Ebene. Wir stellen einen Studienplan zur Untersuchung von
Medikamentenkombinationen anhand von Genexpression und
eines finalen phänotypischen Effekts vor. Ziel der Studie ist
es kausale Effekte aus genregulatorischen Veränderungen auf den
Phänotypen abzuleiten.
Dadurch erhalten wir ein vollständiges Bild der Wirkung von
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